



McMaster University

Curriculum vitae
Holger J. Schünemann

Full name

Schünemann, Holger Jens

Current Home Address**Current Position and Appointments**

Chair, Department of Health Research Methods, Evidence, and Impact
Michael Gent Chair in Healthcare Research (endowed)
Professor of Clinical Epidemiology and of Medicine, McMaster University
Visiting Professor, University at Freiburg, Germany
Director, Cochrane Canada and McMaster GRADE centre
Co-chair, GRADE Working Group
Board of Trustees (Directors), Guideline International Network

Work Address**Other Personal Data**

Citizenship German, US American (dual)
Languages German, English, Italian
Licenses New York State Medical License # 217732
Unrestricted License to Practice Medicine, Germany (Approbation)
Italian License (Medico e Chirurgo), Italy, #54512
Canadian Medical License #91933 (College of Physicians and Surgeons of Ontario)

Educational Background

M.D. Hannover Medical School, Germany, 1993
Dr. med. (Doctor medicinae) Hannover Medical School, Germany, 1994,
*Respiration and Exercise Physiology; Dissertation title:
Untersuchungen zur Kinetik des pulmonalen CO₂-Austauschs und*

zum Einfluß des Laktats auf das oxylabile CO₂ (German) – Pulmonary CO₂ Kinetics and oxylabile CO₂

M.Sc. (*Epidemiology*) University at Buffalo, State University of New York, USA, 1997; *Thesis title: Oxidative Stress and Pulmonary Function*

Ph.D. (*Epidemiology and Community Health*) University at Buffalo, State University of New York, USA, 2000; *Dissertation title: The relation of serum levels of antioxidant vitamins with pulmonary function in a sample from the general population*

Training and certification

Medical Residency (Internal and Pulmonary Medicine), Enrolled from 1994 – 1997, Department of Medicine, Medical School of Hannover, Germany (part of this education spent as postdoctoral research fellow at SUNY Buffalo)

Postdoctoral Fellowship (Molecular and Cellular Biology of the Lung), 1994 – 1996, Department of Medicine, SUNY Buffalo

Medical Residency (Combined Residency in Internal Medicine and General Preventive Medicine), 1997 – 2000, Departments of Medicine and Social & Preventive Medicine, University Medical Residents Services, University at Buffalo, USA

Certification in Public Health and General Preventive Medicine (Diplomat ABPM certificate #51939), American Board of Preventive Medicine, 2001 - 11

Certification (Specialty Exam) in Internal Medicine (Diplomat ABIM certificate #196126), American Board of Internal Medicine, 2002 - 12

Certified, Internal Medicine, Italian Minister of Health, Rome, Italy, 2005 -

Fellow, Royal College of Physicians and Surgeons of Canada (ID# 740874)

Professional Organizations

Member, American Thoracic Society (ATS)

Fellow, FCCP, American College of Chest Physicians (ACCP)

Fellow, FACP, American College of Physicians (ACP)

Intellectual Properties

1. Chronic Respiratory Questionnaire (CRQ) – Self-administered Standardized. © 2003 McMaster University, Gordon Guyatt & Holger Schünemann.
2. Decision Aid for COPD patients considering inhaled steroid therapy. © 2006, Elie A. Akl & Holger Schünemann. (www.predictonline.com/copd)
3. Guide-O-Game©: an educational game to teach clinical practice guidelines. © 2007, Elie A. Akl & Holger Schünemann.
4. GRADEpro (GRADEprofiler): a software application. © 2007 Jan Brozek, Andrew Oxman, Holger Schünemann. (<http://www.cc-ims.net/gradepro>)

Employment History

1991 – 1992 Research Exchange Student (during medical school),
Department of Medicine, University at Buffalo, New York, USA

- 1994 – 1996 Resident**, (Internal and Pulmonary Medicine), Department of Medicine, Pulmonary Division, Hannover Medical School, Germany (in part as a postdoctoral fellow, University at Buffalo)
- 1994 – 1996 Postdoctoral Fellow**, Lung Biology Research Program, Department of Medicine, Pulmonary and Critical Care Division, State University of New York at Buffalo, USA, Hannover Medical School, Germany and German Research Foundation (Deutsche Forschungsgemeinschaft)
- 1996 – 2001 Research Assistant Professor** of Social and Preventive Medicine, Department of Social and Preventive Medicine, University at Buffalo, New York, USA
- 1997 – 2000 Medical Resident** (Combined Residency in Internal Medicine and General Preventive Medicine), Departments of Medicine and Social & Preventive Medicine, University Medical Residents Services, University at Buffalo, USA
- 2000 – 2001 Research Assistant Professor of Medicine**, Division of General Internal Medicine, Department of Medicine, University at Buffalo, USA
- 2001 – 2004 Assistant Professor of Medicine** (tenure track), Division of General Internal Medicine & Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University at Buffalo, USA
- 2001 – 2004 Assistant Professor (adjunct)**, Department of Social and Preventive Medicine, University at Buffalo, New York, USA
- 2001 – 2004 Assistant Professor (part time)**, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
- 2004 – 2010 Associate Professor (tenured – on leave in Italy 2005 to 2008 with clinical work in Buffalo)**, Department of Medicine, Division of General Internal Medicine, University at Buffalo, NY, USA.
- 2004 – 2008 Associate Professor (part-time)**, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
- 2005 – 2008 Chief**, Clinical Research Development and Information Translation/INFORMA Unit, Department of Epidemiology, Italian National Cancer Institute “Regina Elena”, Rome, Italy
- 2006 - 2008 Chair (ad interim)**, Department of Epidemiology, Italian National Cancer Institute “Regina Elena”, Rome, Italy
- 2008 Professor, full (part time)**, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
- 2009 – Professor (joint)**, Department of Medicine, McMaster University, Hamilton, Ontario, Canada

- 2009 – Professor (tenured) and Chair**, Department of Clinical Epidemiology and Biostatistics, Michael Gent Chair in Healthcare Research, McMaster University, Hamilton, Ontario, Canada

Adjunct positions

- 2004 – 2010 Associate Professor (adjunct)**, Department of Social and Preventive Medicine & Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo, NY, USA
- 2010 – Professor (adjunct)**, Department of Medicine, Division of General Internal Medicine, University at Buffalo, NY, USA.
- 2010 – Research Professor (adjunct)**, Department of Social and Preventive Medicine, University at Buffalo, NY, USA.
- 2010 – Professor (visiting)**, Institute of Medical Biostatistics and Informatics, University of Freiburg, Germany.

Clinical Positions

- 2000 – 2003 Attending physician**, In-patient and outpatient service, General Internal Medicine, ECMC
- 2003 – 2008 Attending physician**, In-patient Service, General Internal Medicine, ECMC, 2 - 4 x 2 week blocks/year (with supervision of usually three medical residents and two students on team)
- 2009 – Attending physician**, In-patient Service, General Internal Medicine, St. Joseph's Hospital, McMaster University, 3 - 4 x 2 week blocks/year (with supervisory function)

Scholarly and Professional Activities

Journal Editor Positions

Guest Editor, *Chest* - Quick Reference Guide for the Sixth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy, 2001

Documents Editor (inaugural), American Thoracic Society, (*American Journal of Respiratory and Critical Care Medicine*, *Proceedings of the American Thoracic Society/PATS*, and *American Journal Respiratory of Cellular and Molecular Biology*), July 2005 – 2010

Regional Editor (Europe - methodology), *Journal of Experimental and Clinical Cancer Research*, June 2007 –

Editor in chief: Health and Quality of Life Outcomes (BMC Journal), September 2007 –

Co-Editor in Chief, Rare Disease and Orphan Drugs (An International Journal of Public Health), October 2013 -

Journal Editorial Boards and Advisory Board

Associate Editor, ACP Journal Club (ACP), 2003 –

Associate Editor, Evidence Based Medicine (BMJ publication), 2003 -
Associate Guest Editor/Advisory Group Member, Biomedcentral Trials, September 2005 -
Senior Editor, Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines, 2004 - 2008
International Advisory Board, *Polish Archives of Internal Medicine* (Polish title: *Polskie Archiwum Medycyny Wewnętrznej*), 2007 -
Associate Editor (for guidelines), *Journal of Infection in Developing Countries*, 2007 –
Associate Editor, *Epidemiologic Research International*, 2009 - 2010
International Advisory Board, *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen*, 2009 – 2015
Editorial Board Member, *Recenti Progressi in Medicina*, 2015 -

Other Administrative and Professional Activities

Committee Membership, Service and Peer Review Activity

Professional Societies

Co-chair/senior editor: Seventh American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy, Tucson, Arizona, 2003
Invited member, ACCP Task force on integrating cost analysis in guideline development, 2004 – 2005
Invited member, ACCP Task force on grading the quality of evidence in guidelines, 2004 – 2005
Member, American Thoracic Society, Program Review Sub-committee, 2005 - 2010
Member, American Thoracic Society, Education Sub-committee, 2005 - 2008
Member, American Thoracic Society, Publications Committee, 2005 - 2010
Chair (inaugural), American Thoracic Society Documents Development and Implementation Committee, 2005 – 2009
Co-chair: Eighth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy,
Member, American Thoracic Society Documents Development and Implementation Committee, 2009 – 2011
Co-chair (Methodology): Ninth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy, 2008 -
ACP Representative to the Steering Committee for the International Guideline Development in Chronic Respiratory Disease, 2009 – 2011
Member, ACP, Clinical Practice Guidelines Committee (now called Clinical Practice Guidelines committee), 2010 – 2015
Member (Participant) Medical Review Panel for the Canada Gairdner International awards committee, (review of nominees and recommendations for award) 2009 – 2013

Investigator, Research Investigator for the Allergy, Genes and Environmental Network (AllerGen), 2010 –

Member, ad hoc Department of Medicine and the Partners Evaluation Committee on Senior Appointments, Harvard Medical School, 2012.

University Services (McMaster University)

Member, Community Medicine Residency Program, Department of Health Research Methods, Evidence, and Impact, 2009 –

Member, Council of the M.G. DeGroot School of Medicine, 2009 -

Member, Faculty Executive Committee, 2009 -

Member, Faculty of Health Sciences Research Council Ad Hoc Committee, 2009-

Member, Search Committee, Vice President, Academic, FHS, 2010

Member, Search Committee, Associate Dean Global Health, 2010

Member, Finance Committee, FHS, 2010

Member, Selection Committee, Associate Dean, FHS, 2011

Member, Selection Committee, DeGroot Fellowship Awards, FHS, 2011

Member, Selection Committee, Program Director and Associate Program Director of the Master of Health Science Education Graduate Program, FHS, 2011

Member, Selection Committee - HRM, Assistant Dean Re-appointment, FHS, 2011

Member, Selection Committee, Chair in Health Equity, CHEPA, 2011- 2013

Member, Selection Committee, Director, Pain Institute, Michael G DeGroot School of Medicine, 2011- 2012

Member, Selection Committee, Chair, Department of Oncology, FHS, 2012.

Member, Selection Committee, Chair, Department of Medicine, FHS, 2012

Member, Selection Committee for the Director, eHealth Graduate Program, 2013 - 2014

Member, Selection Committee, The Cisco Chair in Bio-Health Informatics, 2013 - 2014

Member, external review team for the PHRI (Population Health Research Institute), 2013

Member, Commercialization Accelerator Committee, FHS, 2013 -

Member, Hamilton Academic Health Sciences Organization (HAHSO), 2013 –

Member, Selection Committee, Chair, Department of Oncology, 2017.

Member, Selection Committee, Associate Dean of Research, 2017.

Co-chair, Selection Committee, Assistant Dean, HRM, Faculty of Health Sciences . 2017

University Services (University at Buffalo)

Member, Population-Based Medicine Curriculum Committee, 2000 - 2005

Member, Evidence Based Medicine Curriculum, 2000 - 2005

Member, New Curriculum Committee, Foundation Module, 2000

Member, Lung and Respiration Section, 2000 - 2003

Faculty, Residents Research Scholarly Exchange Day, 2001
Member, Planning Committee, Evidence-Based Health Care: Teaching for Tomorrow, 2001
Student Preceptor, Generalist Scholar Program, 2001
Preceptor, Foundation Module, SPM, First Year Medical Students, 2001
QI/EBM Award Committee, 2002 - 2005
Faculty, EBM residents and fellows' master session, 2002
Faculty, Residents Research Scholarly Exchange Day, 2002
Member, Graduate Faculty, 2002 - 2003
Member, Senior Graduate Faculty, 2003 –
Faculty, Chief Resident Conferences, 2003 – 2005
Member, Strategic Planning Committee for the Center for Research and Its Implementation, University at Buffalo, 2007

Cochrane Collaboration

Co-chair, Cochrane Applicability and Recommendations Methods Group, 2005 –
Member, Cochrane Consumers and Communication Review Group, 2002 -
Member, Cochrane Health-Related Quality of Life Methods Group, 2003 –
Member, Co-Eds Methods Training Group, 2008 –
Member, Thomas Chalmers Award Committee, 2009
Member, Methods Advisory Board, 2010 –
Member, Methods Executive Board, 2010 –
Member, MARS Methods Application and Review Standards, 2010 –
Member, Cochrane Collaborations Steering Group, 2013 –

World Health Organization

Member of SURE Secretariat (chair Andrew Oxman) to Advisory Committee for Human Research (chair Judith Whitworth), July 2005
Chair, WHO AVIAN FLU Rapid Advisory Panel Guidelines, March 28 – 30, 2006
External Advisor (on site at Geneva) for establishing a guidelines review committee, Geneva, November-December 2006
Advisor and facilitator, WHO Tuberculosis Treatment Panel Guidelines Meeting, Paris, October 22nd -23rd, 2008
Advisor, WHO Radiation Injury Management Guideline, Geneva, March 2009 (participated via TC)
Member, WHO Primary Prevention of Asthma and COPD panel, April 7 & 8, 2009
Member, WHO Panel on Guidelines for Treatment of Tuberculosis Fourth Edition, 2009
Chair, WHO Guidelines for the Programmatic Management of Drug Resistant Tuberculosis Third Edition, 2009 –
Co-chair, WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses, 2009
Chair, WHO AVIAN FLU Rapid Advisory Panel Guidelines, June 22 - 24, 2009

Co-Chair, WHO Guidelines Cryotherapy of uterine neoplasia, 2009 –

Co-Chair, WHO Guidelines WHO Guidelines for intensified case finding and isoniazid preventive therapy for people living with HIV, 2010

Member, WHO Expert Advisory Panel on Clinical Practice Guidelines and Clinical Research Methods and Ethics, April 2009 – April 2013

Chair, WHO Expert Panel, Use of Interferon- γ Release Assays (IGRAs) in TB control in low and middle-income settings, July 20 & 21, 2010

Chair, WHO Expert Panel, use of commercial serological tests for the diagnosis of TB, July 22, 2010

Co-Director, WHO Collaborating Centre for Evidence-Informed Policy , 2010
Member, WHO Global Advisory Committee on Health Research (ACHR), January 2011 –

Member, WHO Expert Panel on consultation for development of a standard guideline on clinical management of influenza virus infection, Geneva June 8 – 9, 2011.

CHAIR and Presenter, WHO Expert Panel on Development of WHO policy for introduction of new TB Drugs. Geneva, June 8 – 10, 2011.

Various other WHO guideline committees since 2011 including chair of guideline committees on treatment of multi-drug resistant tuberculosis (bedaquiline and delamanide) and sexually transmitted infections

Institute for Quality and Efficiency in Health Care (IQWiG), Germany

Member of the Scientific Advisory Board (Wissenschaftlicher Beirat), June 2007 - 2015

Other International Service

Member (co-chair since 2009), GRADE Working Group (www.gradeworkinggroup.org and heigrade.mcmaster.ca), 2000 -

Consultant, Clinical Expert Group Meeting, *Outcomes in COPD*, Boehringer-Ingelheim, 2001

Consultant, medycyna praktyczna, Polish Antithrombotic Guidelines, 2002

Consultant, Multi-Centre Study in German-speaking Europe to culturally adapt and validate the Chronic Respiratory Questionnaire, Principal Investigator: M. Puhan, Horten Center, University of Zurich, Zurich, Switzerland, 2002

Member, International Advisory Board, Polish EBM Institute, Krakow, Poland, 2002 –

Member, Clinical Significance Group (Chair, Jeff Sloan, PhD, Mayo Clinic: group of 30 international quality-of-life researchers), 2002 – 2005

Consultant, Amgen, Inc., Health-Related Quality of Life in COPD, 2003 – 2004

Consultant, Pfizer, Inc., Patient-Reported Outcomes, 2003

Consultant/Co-Investigator, MoliSani Study, Italy, 2003 –

GOLD Guidelines in COPD, Invited Expert Panel Member on Symptoms and Quality of Life Subcommittee, 2004

Evidence Based Medicine Consultant, UpToDate, Inc., 2002 –

Member, Steering-Committee, AstraZeneca Study SH-NEG-0006 “GERD Feeling Thermometer”, 2002 – 2005

International Advisory Committee, Center for Educational Research and Its Implementation, University at Buffalo, 2007

European Food Safety Authority, Expert Panel on Systematic Review, invited, 2008 – 2009

Chair, Evidence Based Medicine and Guideline Committee, World Allergy Organization, 2008 –

Center for Disease Control and Prevention (CDC), Member Evidence Based Care Working Group to the Advisory Committee for Immunization Practice (ACIP), 2009 – 2010

Member of the Clinical Practice Guideline Committee

Member, American College of Physicians. Philadelphia. 2010 -

Guidelines subcommittee meeting, American College of Rheumatology, November 12, 2010

Member, AGREE A3 - meeting, Toronto, February 8, 2010

Member, Secretary's Advisory Committee on Heritable Disorders in Newborns and Children's (SACHDNC) Evidence Evaluation Methods Workgroup, Bethesda, Maryland, April 13, 2011.

Member, Guidelines International Network (G.I.N.) North American Steering Committee, 2011 -

Member, Guidelines International Network (G.I.N.) Scientific Planning Meeting 2012 Committee, 2011 –

Member, Guidelines International Network (G.I.N.) Education committee, 2011 –

Member, Decision Determinants Subcommittee, Ontario Health Technology Assessment Committee, 2012 – 2014

Member, Guidelines International Network (G.I.N.) Conference Committee, 2013 -

Elected Member, Guidelines International Network (G.I.N) Board of Trustees, 2012 – (reelected in 2015)

Member, Scientific Advisory Committee, European Network for Cancer Research in Children and Adolescents, 2013 –

Member, Planning Committee of the Evidence-based Guidelines Affecting Policy, Practice and Stakeholders (EGAPPS), 2013 – 2014

Vice-Chair, Methods, American Society of Hematology, Venous Thrombosis Guideline Coordination Panel (GCP), 2014 –

Member, Center for Disease Control and Prevention (CDC), GRADE Advisory Panel for the Advisory Committee for Immunization Practice (ACIP), 2015 -

Grant and Personnel Committees

Grant Review

Ad hoc Grant Reviewer, American Lung Association, New York Section, 2001

Ad hoc Grant Reviewer, Canadian Institute of Health (CIHR), January 2002

Ad Hoc, Grant Reviewer, The Netherlands Organization for Health Research and Development (ZonMw), July 2005

Ad Hoc, Grant Reviewer, Swiss National Science Foundation, December 2005

Ad Hoc Member, NIH (National Institutes of Health) Study Section ZRG 1, HOP-N 90S, “Health of the Population (HOP) Integrated Review Group”, NIH, Washington, 2004 June and November, 2005 February

Ad Hoc Member, NIH (National Institutes of Health) Study Section ZRG 1, HOP-D 02 M, “Pulmonary Epidemiology”, November 2005 and July 2006

Member National Review Board, Italian Agency for the evaluation of pharmacological agents (AIFA) – Italian Ministry of Health, March 19 – 21, 2007

Member National Review Board, Italian Agency for the evaluation of pharmacological agents (AIFA) – Italian Ministry of Health, March 31 – April 1, 2008

Member National Review Board, Italian Agency for the evaluation of pharmacological agents (AIFA) – Italian Ministry of Health, March 31 – April 1, 2009

Chair, German Ministry of Health Review Panel, “Studies on the Refinement of Methods and Instruments in Health Care Research”, Berlin, Germany. December 2-3, 2010.

Chair, German Ministry of Health Review Panel, “Structural development in health care research”, Berlin, Germany (September 17, 2015 and March 10/11, 2016)

Journal Referee

American Journal of Medicine; American Journal of Epidemiology; Journal of the American College of Nutrition; American Journal of Respiratory and Critical Care Medicine; Cancer Epidemiology, Biomarkers and Prevention; British Medical Journal; Chest; Circulation; Clinical Orthopedics and Related Research, Controlled Clinical Trials; European Journal of Clinical Nutrition; Health and Quality of Life Outcomes; Health Services Research; International Journal of Obesity; International Journal of Cancer; International Journal for Quality in Health Care; Journal of the American Medical Association (JAMA); J Clin Epidemiology; Journal of General Internal Medicine; Medical Care; Medical Decision Making; Proceedings of the American Thoracic Society; Quality of Life Research; The Lancet; Thorax; Cancer Prevention and Protection

Areas of Interest

Research

1. Methodology of developing guidance for clinicians (quality of evidence and strength of recommendations)
2. Measuring quality of life in patients with chronic disease
3. Clinical research design and methodology
4. Systematic Review Methodology
5. Evidence-based health-care education

Teaching

1. Evidence-based clinical practice for house staff and faculty, students of epidemiology
2. Masters and PhD Program in Health Research Methodology, Faculty of Health Sciences

3. National and International Evidence-based clinical practice and guideline development courses/workshops

Clinical

1. General Internal Medicine
2. Chronic obstructive pulmonary disease
3. Antithrombotic therapy

Awards and Honors

Student Travel Award, German Academic Exchange Program (DAAD), 1991

Scholarship Award by the German Academic Exchange Organization (DAAD), Biomedical Science Exchange Program (BMEP) with North America, 1991-1992

Postdoctoral Fellowship Award by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and Hannover Medical School, 1994 – 1996

Resident Scholarly Exchange Day Award, University at Buffalo, 2000

Buswell Fellowship, Hochstetter Medical Research Fund, Buffalo, USA, 2000 – 2001

Service Excellence Award, University at Buffalo, Evidence-Based Health Care: Teaching for Tomorrow, Project Team, 2002

New Investigator Award, International Society for Quality of Life Research, Prague, Czech Republic, 2003

University at Buffalo, Exceptional Scholar Award, 2004

European Union & Italian National Cancer Institute, Scientific reintegration Research Award, 2008

World Allergy Organization, Scientific Achievement Award, December, 2009

World Allergy Organization, Presidential Recognition and Collaboration, Award, December, 2011

Teaching Excellence Award, McMaster University, Internal Medicine Residency Program, 2014 – 2016

International Distinguished Alumnus Award, University of Buffalo, May 2017

Robert F. Lofthouse Memorial Lecture, distinguished guest speaker award, Orthopaedics Annual Academic Day, Hamilton, May 10, 2017

Leaders Circle Recognition Award, Leaders Circle, Toronto ON, April 2018

Courses and Workshops Taught

University at Buffalo

Course Development

SPM624, Introduction to Evidence-Based Medicine and Clinical Epidemiology, Graduate School of Medicine and Biomedical Sciences, 3 credit hours, every second year, 2002; 2004

Teaching

SPM 600, Small Group Leader, Epidemiology and Biostatistics for Medical Students, University at Buffalo, USA, 1996 - 2000

SPM 616, Lecturer, University at Buffalo, USA, 1997& 2000

Lung and Respiration Section, Lecturer, 1st and 2nd year Medical Students, 2000 - 2003

Weekly EBM workshop, Faculty, Department of Medicine, 2000 - 2003

Preceptor, University at Buffalo, Department of Medicine, 1 – 2 residents, 1 – 2 students, 2 months/year, 2000 – 2009.

MHI 501 (Intro Health Informatics 1), Lecturer, University at Buffalo, 2003

McMaster University

Tutor Trainee, Workshop “How to Teach Evidence-Based Clinical Practice”, McMaster University, Hamilton, Canada, 6/10-6/15/2001

Tutor, Workshop “How to Teach Evidence-Based Clinical Practice”, McMaster University, Hamilton, Canada (one week course with 40 contact hours every June in small and large group sessions), 2003, 2004, 2005, 2006, 2007, 2008

Tutor, HRM 743 Systematic Reviews, McMaster University, Hamilton, Canada, 2003 - 2008

International (selected)

Faculty, Evidence-Based Preventive Medicine Workshop, Pavia, Italy, June, 2000

Tutor, Workshop – “Discussion and Recommendations in Cochrane Reviews”. X Cochrane Colloquium, Stavanger, Norway, 2002

Tutor, Workshop – “Grades of Recommendation”. X Cochrane Colloquium, Stavanger, Norway, 2002

Facilitator/Tutor, Workshop – “Cochrane Workshop on Grading the Quality of Evidence”. XI Cochrane Colloquium, Barcelona, Spain, October 25 – 30, 2003

Facilitator/Tutor, Workshop – “Cochrane Workshop on Grading the Quality of Evidence”. XII Cochrane Colloquium, Ottawa, Canada, October 6, 2004

Tutor, Workshop – “GRADE workshop”. III International Conference on Health Technology Assessment (HTAi), Rome, Italy, June 2005

Facilitator/Tutor, Workshop – Das GRADE-System Von der Evidenz zur Empfehlung”. 50. GMDS-Jahrestagung 12. DAE-Jahrestagung, Freiburg, Germany, September 13, 2005

Tutor, Workshop – GRADE Workshop on Grading the Quality of Evidence”. XIII Cochrane Colloquium, Melbourne, Australia, October 24, 2005

Tutor, Workshops – 1. Systematic Reviews and 2. GRADE Leitlinien Entwicklung. Universität Freiburg, Deutsches Cochrane Zentrum, Freiburg, 23.-25 März, 2006 (now annual workshop)

GRADE Workshop, Pflegevereinigung Bozen, January 15, 2007 and April 13, 2007

GRADE Workshop for the Canadian Agency for Drugs and Technology in Health (CADTH), March 26 – 28, 2007

Organizer and Faculty, First workshop in evidence based health care for the surgical specialties, Perugia/Arrezzo, Italy, July 19 – 21, 2007

Organizer, 3 GRADE Workshops at Cochrane Colloquium, Sao Paola, Brazil, October 2007

GRADE Workshop, Agency for Healthcare Quality and Research, Washington, September, 2008

Organizer, GRADE Workshops at Cochrane Colloquium, Freiburg, Germany, October 2008

GRADE Workshop to WHO (one day), September 8, 2008

GRADE Development Workshop to WHO (one day), January 22, 2008

Organizer, 2 GRADE Workshops Spanish Ministry of Health, Madrid and Barcelona, November and December, 2008

Organizer, 2 GRADE Workshop, Bogota, Columbia, June 17 and 18, 2009

Co-organizer and faculty member, Cochrane Center Germany, Freiburg, Germany, spring 2007, 2008, 2009, 2010 (a 1.5 day workshop on GRADE)

WHO, 1 day workshop, GRADE for diagnostic studies. Geneva, Switzerland. October 29, 2010

WHO, 2 day workshop, GRADE for therapeutic interventions, Geneva, Switzerland, February 20 & 21, 2010

Over 30 GRADE workshops since 2010

Primary Supervisorships

Bachelors of Health Sciences Students

Jonathan Hsu, BHSc Program, McMaster University, 2009 – 2011 (now medical student at University of Toronto)

Adrienne Cheung, BHSc Program, McMaster University, 2010 – 2014 (now medical student at UBC)

Shreyas Gandhi, BHSc Program, McMaster University, 2012 – 2014 (now medical student at University of Toronto)

Tejan Baldeh, BHSc Program, Queens University, 2012 – 2016

Andrew Zikic, BHSc Program, 2015 (accepted to medical school, University of Toronto)

Master Students

Heather Ochs, M. Sc., University at Buffalo, 2000 – 2002

Elie Akl, M.D., Department of Social and Preventive, University at Buffalo, New York, USA, Master of Public Health (project), 2004

Steve Cramer, M.D., Department of Social and Preventive Medicine, University at Buffalo, New York, USA, Masters of Science in Epidemiology, 2004

Tejan Baldeh – Master of Public Health, McMaster Universtiy, 2016 -

PhD Doctoral Students

Heather Ochs, M.Sc., Department of Social and Preventive Medicine, University at Buffalo, New York, USA, Ph.D. in Epidemiology and Community Health, 2002 – 2004 (now: Associate Professor of Epidemiology, University at Buffalo, NY)

Milo Puhan, M.D., University of Amsterdam, The Netherlands/Horten Center for Evidence Based Medicine, Zürich, Switzerland; Co-promotor (Co-chair), Ph.D. Thesis, 2003 – 2006 (now: Chair, Department of Preventive Medicine, ETH University Zurich, Switzerland)

Elie Akl, M.D., M.P.H. Department of Social and Preventive, University at Buffalo, New York, USA, Ph.D. in Epidemiology, 2005 – 2008 (now: Associate Professor of Medicine and head of clinical research, American University of Beirut, Lebanon)

Maddalena Barba, M.D., Italian National Cancer Institute Regina Elena, Rome, Italy, Ph.D. in Digestive Oncology, La Sapienza University Rome, 2007 – 2010 (now senior scientist National Cancer Institute, Rome, Italy)

Nancy Santesso, MLIS, RD, Ph.D. in Health Research Methodology, Department of Clinical Epidemiology and Biostatistics, McMaster University, 2009 – 2014 (now faculty at McMaster University)

Reem Mustafa, M.D., MPH, Ph.D. in Health Research Methodology, Department of Clinical Epidemiology and Biostatistics (now Health Research Methods, Evidence, and Impact), McMaster University, 2010 – 2014 (now faculty at University of Kansas)

Yuan (Ray) Zhang, Department of Clinical Epidemiology and Biostatistics, McMaster University (now Health Research Methods, Evidence, and Impact), 2012 – 2017 (now a researcher at Health Quality Ontario)

Juan Jose Yepes Nunez, M.D., M.Sc., Ph.D. in Health Research Methodology, Department of Clinical Epidemiology and Biostatistics (now Health Research Methods, Evidence, and Impact), McMaster University, 2013 -

Carlos Alberto Cuello Garcia, M.D., Ph.D. in Health Research Methodology, Department of Clinical Epidemiology and Biostatistics (now Health Research Methods, Evidence, and Impact), McMaster University, 2013 – 2017.

Rebecca Morgan, M.P.H., Ph.D. in Health Research Methodology, Department of Clinical Epidemiology and Biostatistics (now Health Research Methods, Evidence, and Impact), McMaster University, 2014 –

Gian Paolo Morgan, M.Sc., Ph.D. in Health Research Methodology, Department of Clinical Epidemiology and Biostatistics, McMaster University, 2015 –

Wojtek Wiercioch, M.Sc., Ph.D. in Health Research Methodology, Department of Clinical Epidemiology and Biostatistics (now Health Research Methods, Evidence, and Impact), McMaster University, 2015 –

Andrea Darzi, M.D., BSc., Ph.D in Health Research Methodology, Department of Health Research Methods, Evidence, and Impact, 2017 -

Postdoctoral Research Fellows

Samer El-Dika, M.D., M.S., Fellow in Gastroenterology, 2002 – 2004 (2004: Associate Professor of Medicine, University of Virginia)

Milo Puhan, M.D., McMaster University, Hamilton, Canada/Horten Center for Evidence Based Medicine, Zürich, Switzerland, 8/2004 – 11/2004

Francesca Sperati, Ph.D., Italian National Cancer Institute Regina Elena, Rome, Italy, 2006 – 2008

Irene Terrenato, Ph.D., Italian National Cancer Institute Regina Elena, Rome, Italy, 2006 – 2008

Jan Brozek, M.D., Ph.D., Italian National Cancer Institute Regina Elena, Rome, Italy, 2006 – 2009

Maddalena Barba, M.D., Italian National Cancer Institute Regina Elena, Rome, Italy, 2006

Julia Kreis, Ph.D., Institute for Quality and Efficiency in Health (IQWiG), Germany, 2011 - 2012

Itziar Etxeandia Ikobaltzeta, Pharm. D., Basque Health Technology Assessment, 2013

Sergio Kowalski, M.D., M.Sc., McMaster University, 2014 – 2015

Yuan (Ray) Zhang, Ph.D., 2017 - 2018

Supervisory Committee membership

Pankaj Patel, M.D., Department of Social and Preventive Medicine, University at Buffalo, M. Sc. in Epidemiology, 2002

Michael Aronica, M.D., Department of Social and Preventive Medicine, University at Buffalo M. Sc. in Epidemiology, 2004

Simon McRae, M.D., McMaster University, Hamilton, Canada, M.Sc. HRM, Thesis, 2005

Reem Adel Mustafa, M.D, Social & Preventive Medicine, M.P.H. (project). The Graduate School University at Buffalo, New York, 2006 – 2007

Michelle Kho, MSc, McMaster University, Hamilton, Canada, Ph.D. Thesis, 2005 – 2010

Martin O'Donnell, M.D., McMaster University; committee member, Ph.D. Thesis, 2005 – 2008

Samantha Fox, MSc, Department of Clinical Epidemiology and Biostatistics, McMaster University, 2009 - 2010.

Alonso Carrasco, McMaster University, committee member, 2011 – 2015 (anticipated)

Ignacio Neumann, McMaster University, committee member, 2011 – 2014

Madison Zhang, McMaster University, committee member, 2012 – 2015 (anticipated)

Paul Alexander, McMaster University, committee member, 2013 – 2014

Karen Wong, McMaster University, committee member, 2013 – 2014 (independent study)

Ashely Bonner, McMaster University, committee member, 2013 - 2014 (independent study)

Ivan Florez, MD, MSc, McMaster University, PhD HRM Thesis Committee member, 2015 -

Others (selected)*Medical Students*

Cecilia Costiniuk, M.D., Third year medical student, McMaster University, 2004 - 2005

Diana Blank, M.D., Third year medical student, McMaster University, 2004 - 2005

Nicole Scouras, M.D., M.P.H., 2nd year Medical Student, University of Buffalo, 2002 – 2004

Residents

Elie Akl, M.D., Internal and Preventive Medicine Resident, 2000 – 2004

Sanjay Joseph, M.D., University of Buffalo, 2002 – 6/2003

Ifeoma Izuchukwu, M.D., M.P.H., Internal and Preventive Medicine Resident, 2002 – 2003 (now Assistant Professor of Medicine, UCLA)

Aasma Shaukat, M.D., M.P.H., Internal Medicine Resident, 2002 – 2003 (now Head of Gastroenterology, University of Minnesota)

Gabriela Negoe, M.D., Preventive Medicine Residency, 2002 – 2004 “ACCP Antithrombotic Guidelines”

Ranjan Chanda, M.D., Internal and Preventive Medicine Resident, 2003 – 2004

Gokul Krishan, M.D., M.P.H., Internal Medicine Resident, 2003 – 2004

Maddalena Barba, M.D., Internal Medicine/Oncology Resident, Italian National Cancer Institute Regina Elena, Rome, Italy, 2006 - 2009

Research Funding**Current support****Principal Investigator**

Pan American Health Organization (PAHO), Guidelines Project. \$9,200.00. 2018

World Health Organization, STI-4 Project. \$21,315.00. 2018

World Health Organization, Ablative project. \$30,551.00. 2018

World Health Organization, Methodological Support to the assessment of risk of bias in systematic reviews for Air Quality Guidelines. \$7,519.00 10/2017 – 02/2018.

World Health Organization, Reviews for Thermal Ablation. \$30,551.50 2017 - 2018

World Health Organization, Guidelines for Syndromic Case Management. \$21,314.40. 2017.

Pan American Health Organization/World Health Organization (PAHO/WHO), Guideline Development. \$9,200 USD. 2017.

World Health Organization, Systematic Reviews with GRADE Evidence Profiles for WHO for Clinical Management of Severe Influenza, Including Seasonal, Pandemic and Zoonotic. \$81,903 09/2017 – 12/2017

World Allergy Organization, Supporting Guideline Development for the Diagnosis and Management of Cow's Milk Allergy (DRACMA). US\$ 150,000. 2017 – 2018.

American Society of Hematology, Venous Thromboembolism Guidelines, Methods development and execution CAD\$ 4,594,692, 2015 – 2017

Saudi Arabia Ministry of Health. Second phase of Development of Saudi Clinical Practice Guidelines (CPG) and Capacity Building in Guideline Development. US\$ 1,200,000.00, 2014 – 2017

Canadian Institute of Health Research (CIHR), Use of Heparins in Cancer: Individual patient data meta-analysis. \$99,815 2013 – 2017

National Hemophilia Foundation (co-PI with Alfonso Iorio) Development of Clinical Practice Guidelines on the comprehensive Care Model for the Management of Hemophilia. US\$ 275,000, 2015 – 2017

National Toxicology Program, Initial Confidence in Evidence. US \$20,000. 01/2015 – 06/2017

The Cochrane UK Centre, The Cochrane Collaboration. \$61540. 04/2016 – 06/2017

ICF Incorporated, Scientific Information Management and Literature-Based Evaluations for the National Toxicology Program (NTP). \$23,100. 2016 – 2017

World Health Organization (WHO), STI Guidelines - 3. \$33,196. 2016 - 2017

Workpackage leader (PI)

EU Framework Program 6, DECIDE (PI of overall project: Shaun Treweek, Andrew Oxman), \$3,380,000 (3 Mill Euro), 2010 - 2015

Co-Investigator

Canadian Institutes of Health Research (CIHR) Foundation Grant. Predicting and preventing the major vascular complications of surgery. (PI: PJ Devereaux) \$8,439,205. 2015 – 2022

University of Maryland (via NIH), Cochrane Collaboration CAM Field: Resource for research. (PI: Brian M. Berman) US\$ 614,950. (Subaward PI: Schunemann \$10,800), 2012 – 2017

EU Framework Program 7 – Rare Best Practices Project. (PI: Domenica Taruscio) 60,000 Euro, 2012 – 2016

Canadian Institute of Health Research (CIHR). Innovations to enhance the capacity of practice guidelines to improve health and healthcare systems: AGREE-REX (Recommendation Excellence). (PI: Melissa Brouwers) \$602,124, April 2013 – March 2016

Canadian Institute of Health Research (CIHR) Guidelines for Guidelines: What Methodologic Instructions for Practice Guideline Development should we be using? (PI: Kathryn Bennett), \$10,000, 2015 – 2016

Past Support

Principal Investigator

Public Health Agency of Canada (PHAC), Training Sessions on the use of the GRADE System. \$7,350, 2015 – 2016.

Canadian Collaborative for Methods, Applications, and Capacity Development in Network Meta-Analysis for Drug Safety and Effectiveness. (Co-principal investigators G. A. Wells, D. Coyle, B. Reeves, H. Schünemann, L. Thabane) \$911,520. 2011 – 2015

World Allergy Organization, Supporting Guideline Development for the prevention of nutrition related allergies. US\$ 300,000 2013 – 2015

World Allergy Organization. Supporting guideline development for the prevention of nutrition related allergies, US\$300,000, 2013 - 2014

Saudi Arabia Ministry of Health. Development of the Saudi Clinical Practice Guidelines (CPG) Handbook. US\$ 519,375, 2013 – 2014

World Health Organization, Revised/updated chapters 7 and 8 of the 2012 WHO Handbook for Guideline Development. US\$ 3,850, 2014

World Health Organization. Use of Essential Medicines. \$ 24,840.32, 2014

World Health Organization, Development of the WHO STI case management syndromic-approach guidelines based on the new WHO standard guideline development approved by the Guidance Review Committee. US\$ 49,032.58, 2013 – 2014

World Health Organization, Development of guidelines for the use of diagnostic and therapeutic approaches in the prevention and management of cervical cancer; detailed review of diagnostic accuracy studies. US\$ 160,000, 2012 - 2013

German Insurance Fund, A systematic appraisal of diagnostic methods, evidence and judgment: The strength of the relation between diagnostic tests and patient/population outcomes. \$147,500 Euros, 2012 - 2013

Cochrane Collaboration, Enhancing the acceptance and implementation of Summary of Findings Tables in Cochrane Reviews. GBP\$ 40,000, 2012 – 2013

Agency for Healthcare Research And Quality, Teaching Evidence Assimilation for Collaborative Health Care (TEACH) (PI: Dr. Peter C. Wyer). Total direct cost: \$298,412, 2009 - 2011

World Health Organization, GRADE Profiler for ACCP clinical practice guidelines. \$43,350, 2011

World Health Organization, Guidelines methodologist for the development of WHO policy guidelines on anti-tuberculosis drug susceptibility testing. US\$ 6,600, 2012

World Health Organization, Guideline review committee GRADE training. \$ 14,676.51, 2011 - 2012

World Allergy Organization, Cow Milk Allergy Guidelines Evidence Reviews. Total direct cost: US\$ 120,000.00, 2009 - 2010

Cochrane Collaboration, Training and Capacity Building for Summary of Findings Tables: International training event. Total direct cost: GBP 25,000.00, 2011

World Health Organization, Evidence review for Cryotherapy in Uterine Cancer. Total direct cost: US\$ 20,000.00 + US\$ 60,000.00 + US\$ 25,000.00, 2009 - 2010

Cochrane Collaboration, Training and Capacity Building for Summary of Findings Tables. Total direct cost: GBP 20,000.00, 2009 – 2010

World Health Organization, Cryotherapy II, Development of PICO for use of cryotherapy to prevent cervical cancer. Total direct cost: US\$ 8,200.00, 2010

Pan American Health Organization/World Health Organization, GRADE capacity. Total direct cost: US\$ 18,600.00, 2010 -2011.

World Health Organization, A systematic review of influenza antiviral efficacy. Total direct cost: US\$ 26,600.00, 2010 – 2011

World Health Organization, Drug resistance Tuberculosis. US\$ 6,000.00, 2010

Canadian Institute of Health Research. McMaster Health Forum: Using Evidence Briefs and Deliberative Dialogues for Expedited Knowledge Synthesis. (PI: Dr. John Lavis). \$100,000.00, 2009 – 2010.

Italian Ministry of Health, Molecular Prevention of Breast Cancer, Molecular Medicine Program (PI: Paola Muti), Total direct cost: € 1,000,000.00, 2008

European Commission, Brussels, Marie Curie Reintegration Grant, Grading the quality of evidence and the strength of recommendations (GRADE). EU & IRE (IGR 42192). Total direct cost: € 240,000.00 (including institutional funding), 2006 - 2008

Merging Efforts in COPD Guideline Development International Lung Health Committee. Total direct cost: US\$ 32,000, 1 R13 HL090485-01 from the National Heart, Lung, and Blood Institute/NIH, USA, 2007 - 2008

Merging Efforts in COPD Guideline Development International Lung Health Committee, American Thoracic Society. Total direct cost: US\$ 30,000, 2007 - 2008.

GA²LEN, the Global Allergy and Asthma European Network, Total direct cost: € 60,000.00, 2008 – 2009

Barilla, Inc., Parma, Development of a Quality of Life Outcomes Questionnaire, Total direct cost: € 105,000.00, 2007 – 2008

Merging Efforts in COPD Guideline Development International Lung Health Committee, American Thoracic Society. Total direct cost: US\$ 37,000, 2006 - 2007.

American Lung Association of New York State (ALANYS), Clinical Epidemiology of Pulmonary Function. Total direct cost: \$68,000, 2002 – 2005

Pfizer, Inc. Patient Reported Outcomes, Total Direct Cost: \$43,968.00, 2004 – 2005

University at Buffalo, Buswell Research Support Funds. Total direct cost: \$135,000.00 (\$45,000 annually), 2000 – 2003. Award ended in 2001 because of Dr. Schünemann's promotion to Assistant Professor on tenure track.

AstraZeneca Pharmaceuticals, Inc., Randomized clinical study to compare two different frames of presenting clinical marker states with the "feeling thermometer" for assessing health-related quality of life in patients with Chronic Respiratory Disease. (Co-Principal Investigator with Dr. Gordon Guyatt). Total direct cost: Can\$ 64,697.00, 2001

AstraZeneca Pharmaceuticals, Inc., Randomized clinical study to measure the relative responsiveness and validity of two different administration modes of a "feeling thermometer" for assessing health-related quality of life in patients with Chronic Respiratory Disease (Co-Principal Investigator with Dr. Gordon Guyatt). Total direct cost: Can\$ 500,000, 2001 – 2003

Research for Health in Erie County Foundation, Clinical Epidemiology of Pulmonary Function (Principal Investigator). Total direct cost: \$15,000, 2002 – 2002

ACCP, Systematic Literature Searches for the 7th American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy. Total direct cost: \$50,194.15, 2002 – 2003

ACCP, 2nd phase of Systematic Literature Searches for the 7th American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy. Total direct cost: \$10,000.00, 2003

AstraZeneca Pharmaceuticals, Inc., Randomized clinical study to measure the relative responsiveness and validity of two different administration modes of a "feeling thermometer" for assessing health-related quality of life in patients with Gastro-esophageal Reflux Disease. (Co-Principal Investigator with Dr. Gordon Guyatt). Total direct cost: Can\$ 512,502.00; 2001 – 2004

Deutscher Akademischer Austauschdienst (DAAD), Biomedical Science Exchange Program between Europe and North America. CO₂-Transport in Human Blood and CO₂ Kinetics. Research, Total direct cost: DEM 12,000 (~ US\$ 7,000 in 1991), 1991 – 1992

Deutsche Forschungsgemeinschaft (DFG) and Hannover Medical School; Grant: SCHU: 1056-1/1; Molekulare Mechanismen zur Identifizierung der Lokalisation von Typ II Alveolarzellen auf der alveolären Basalmembran“. Postdoctoral Fellowship, DEM 120,000 (~ US\$ 80,000 in 1994), 1994 – 1996

Co-Investigator

ECDC (EU)- Developing a methodology for evaluating and grading evidence and strength of recommendations in Public Health/infectious disease prevention and control. (Project Coordinator Thomas Harder). \$100 000 Euro, 2012 –2014

Canadian Institutes of Health Research, McMaster Evidence Review and Synthesis Centre (MERSC), Knowledge Synthesis-Preventive HealthCare, Evidence Review (PI: Dr. Parminder Raina & Dr. Donna Ciliska). Total direct cost: \$3,192,354 11/2009 - 11/2014

Canadian Institutes of Health Research, Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study (PI: Dr. P.J. Devereaux). \$141,378/year, 2009 – 2014

Canadian Institute of Health Research. The Guideline-driven, Research priorities, Evidence synthesis, Application of evidence, and Transfer of knowledge: The GREAT Project. (PI: Sharon Strauss). \$25,000, 2010 – 2011.

European Union. - (Core Outcome Measures in Effectiveness Trials) COMET Initiative (Project Coordinator P.R. Williamson – University of Liverpool)– 497,360 Euros, 2012 – 2014

Canadian Institutes of Health Research Grant, Innovations to enhance the capacity of practice guidelines to improve health and healthcare systems: AGREE Application Appropriateness Action (AGREE A3) (PI: Dr. Melissa Brouwers). Total direct cost: \$207,252/year, 2009-2012

Canadian Institute of Health Research. Suicide Prevention in Children and Adolescents: Options and Evidence. (PI Kathryn Bennett) \$200,000, 04/2012 – 09/2012

American College of Chest Physicians and The CHEST Foundation, Developing and pilot testing a novel outcome performance measure for the ACCP recommendations for the prophylaxis and management of venous thromboembolism (PI: Dr. Eli Akl). \$100,968, 2009 – 2010

National Institute of Health, Conflict of Interest in Clinical Practice Guideline Development. (PI: Dr. Susan Norris). \$300,303./year 1,\$309,269/year 2. 2009 – 2010.

Agency for Healthcare Research and Quality, Project Title: GRADE - Moving Towards a Consensus on a Consistent Approach to Grading Evidence and Recommendations (PI: Dr. Yngve Falck-Ytter). Total direct cost: ~US\$ 32,000, 1 R13 HS016880-01, 2007 - 2008

Department of Defense, USA, Estrogen Metabolism and Prostate Cancer Risk: A Prospective Study (PI: Dr. Paola Muti). Total direct cost: \$372,023.00, 2002-2007

Department of Defense, USA, Endogenous 6-hydroxymelatonin excretion and subsequent risk of breast cancer: a prospective study (PI: Paola Muti). Total direct cost: \$ 308,300.00, 2004 - 2007

NIH, USA, Endogenous hormones and premenopausal breast cancer risk. (PI: Paola Muti). Total direct costs: \$1,210,804, 2003-2008

Research for Health in Erie County Foundation, USA, Evaluating an educational game to improve Internal Medicine residents' knowledge and adherence to clinical practice guidelines (PI: Dr. Elie Akl). Total direct cost: US\$ 22,310, 2007

Society of General Internal Medicine (SGIM) Founders Award 2008. "Evaluating an educational game's effect on residents' knowledge of practice guidelines" (PI: Dr. Elie A Akl). Total direct cost: \$20,000, 2008

NIH (NCI), Serum phytosterols and prostate cancer prevention (PI: Dr. Paola Muti, R21). Total direct cost: \$387,887 total cost, 2004-2006

NIH (NHLBI), USA, Hibernating Myocardium and Sudden Cardiac Death. Aim: Examines the presence of hibernating myocardium as a risk factor for sudden cardiac death in a prospective cohort study of patients at risk for sudden cardiac death (PI: Dr. John Canty; RO1). Total direct cost: \$2,467,355, 2004 – 2004 (left project due to leave of absence to Italy)

Research for Health in Erie County Foundation, USA, Evaluating an educational game to improve Internal Medicine residents' knowledge and adherence to clinical practice guidelines (PI: Dr. Elie Akl). Total direct cost: US\$ 12,183., 2006

Educational Technology Center, University at Buffalo, USA, Development of an educational game for teaching clinical practice guidelines in graduate medical education. (PI: Dr. Elie Akl). Total direct cost: US\$ 4000, 2006

NIH (NIAAA), USA, "Biological Specimen Bank" (PI: P. Muti). Total direct cost \$375,552, 1996 – 1997, Core component in "Center for Clinical and Medical Epidemiology", (Marcia Russell, Center Director) \$6,487,553 total direct cost, 1992 – 1997

Research Development Fund, Hamilton Health Sciences & Father Sean O'Sullivan Seed Funds, McMaster University, Systematic Review: Who profits in private for-profit versus private not-for-profit health care delivery systems? (PI: P.J. Devereaux). Total direct cost: \$9,000.00 and \$10,994, 2001 – 2002

Atkinson Foundation Grant, Ontario, Canada, Systematic review of the cost of care in private for-profit versus private not for-profit health care delivery systems (Co-Investigator; PI: P.J. Devereaux): \$44,399, 2002

Publications

Books

1. **Schünemann H**, editor. Quick Reference Guide on Antithrombotic Therapy. Sixth ACCP Consensus Conference on Antithrombotic Therapy. American College of Chest Physicians 2001; Chicago, IL.
2. Crowther M, Ginsberg J, **Schünemann H**, Meyer R, Lottenberg R (editors). Evidence Based Hematology. BMJ/Blackwell, 2008
3. **Schünemann H**, Brožek J, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group, 2009. Available from <http://www.cc-ims.net/gradepr> and www.gradepr.org.

Book Chapters

1. Guyatt G, Sinclair J, Cook D, Jaeschke R, **Schünemann H**. Grading Recommendations – A quantitative approach. In: User's Guides to Medical Literature. Editor: Guyatt G, Drummond R. Chicago, IL. American Medical Association, 2002.
4. Guyatt G, Sinclair J, Cook D, Jaeschke R, **Schünemann H**, Pauker S. Grading Recommendations – A qualitative approach. In: User's Guides to Medical Literature: A manual for evidence (p. 599-608). Editor: Guyatt G, Rennie D. Chicago, IL. American Medical Association, 2002.
5. **Schünemann H**, Guyatt G. Evidence-Based Medicine (p. 51-57). In: Hospital Medicine. Editors: Robert M. Wachter, Lee Goldman, Harry Hollander: 2nd edition. Lippincott, Williams & Wilkins, 2005
6. **Schünemann H**, Guyatt G. Clinical Epidemiology (p. 1169 – 1224). In: Handbook of Epidemiology. Editors: Pigeot I, Ahrens W., Springer Verlag,

- 2005.
7. **Schünemann H**, Guyatt G. Using the rehabilitation literature to guide patient care: a critical appraisal of trial evidence. (p. 46-53) In: Pulmonary Rehabilitation: Efficacy and Scientific Basis. Editors: Goldstein R, Donner C, 2005.
 8. **Schünemann H**, Zu Wallack RL. Evaluation of impairment and disability and outcome measures for pulmonary rehabilitation. (p. 150-163) In: Pulmonary Rehabilitation: Efficacy and Scientific Basis. Editors: Goldstein R, Donner C, 2005
 9. **Schünemann H**, Juniper E, Guyatt G. Measurement of Health Status. Encyclopedia of Biostatistics. Editors: P. Armitage, T. Colton. 2nd edition Volume 4, (p. 2393–2399), John Wiley & Sons, Ltd, Chichester, 2005.
 10. **Schünemann H**, Jaeschke R, Guyatt G Using Quality-of-Life Measurements in Pharmacoepidemiology Research. (p. 653-663) In: Pharmacoepidemiology. Editor: Brian Strom, 4th edition, 2005.
 11. Akl E, **Schünemann HJ**. Health related Quality of Life Measurement in Diabetes. (p. 179-205) In: Evidence Based Endocrinology, Editor: Victor Montori; Humana Press. Totowa, NJ, 2005.
 12. **Schünemann HJ**, Guyatt G. Interpreting the results of quality of life measures in clinical trials: the clinicians' perspective: the great merit of dichotomies for simple-minded clinicians. (p. 201-212) In: Quality of Life Research. Editor: D. Revicki. ISOQOL, 2005.
 13. **Schünemann H**, Cook D, Jaeschke R, Vist G, Kunz R, Guyatt G. Grading Recommendations. Editor: Guyatt G, Meade M, Drummond R. Chicago, IL. McGraw Hill, 2008.
 14. Cook DJ, Guyatt GH, **Schünemann HJ**, Akl EA, Foy R, Wall RJ. Changing Behavior to Apply Best Evidence in Practice. In: Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Editors: GH Guyatt, D. Rennie. McGraw Hill, 2008.
 15. Cerletti C, **Schünemann HJ**, de Gaetano G. Antithrombotic therapy: guidelines for the elderly. Blood Disorders in the Elderly (edited by Balducci, Ershler, and de Gaetano), 2008.
 16. Kunz R, Lelgemann M, Guyatt G, Antes G, Falck-Ytter Y, **Schünemann HJ**. Von der Evidenz zur Empfehlung In: Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis, 2007.
 17. **Schünemann HJ**, Oxman AD, Vist GE, Higgins JPT, Deeks J, Glasziou P, Guyatt GH. Interpreting results and drawing conclusions. In: Cochrane Collaboration Handbook, second edition. Higgins JPT, Green S (Editors), 2008.
 18. **Schünemann HJ**, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Presenting results and summary of findings tables. In: Cochrane Collaboration Handbook, second edition. Higgins JPT, Green S (Editors), 2008.
 19. **Schünemann HJ**, Stanulla M, Brozek J, Guyatt GH. Rating the quality of evidence and making recommendations: A guide to the spectrum of clinical

research. In Evidence Based Hematology: Crowther M, Schünemann H Ginsberg J, Lottenberg R, Meyer R (editors) Wiley-Blackwell, BMJ Books, West Sussex, UK, 2008.

20. **Schünemann HJ**, Gherzi D, Kreis J, Antes G, Bousquet J. Reporting Research: Are we in for better health care by 2020? (p. 83-102) In: Better Doctors, Better Patients, Better Decisions: Envisioning Healthcare 2020. Strüngmann Forum Report, vol. 6. Gigerenzer G., and Muir Gray, JA (editors) MIT Pres, Cambridge, MA, 2011.
21. Feufel M, Antes G, Steurer J, Gigerenzer G, Muir Gray J, Makela M, Mulley A, Nelson D, Schulkin J, **Schünemann HJ**, Wennberg J, Wild C. What is needed for better health care: Better systems, better patients or both? (p. 117-136) In: Better Doctors, Better Patients, Better Decisions: Envisioning Healthcare 2020. Strüngmann Forum Report, vol. 6. Gigerenzer G., and Muir Gray, JA (editors) MIT Pres, Cambridge, MA 2011.
22. **Schünemann HJ**, Johnston BC, Jaeschke R, Guyatt GH. Chapter 39: Using Quality of Life Measurements in Pharmacoepidemiologic Research. Pharmacoepidemiology, 5th Edition, pages 709-722, 2012. Editors: BL Strom, SE Kimmel, S Hennessy, 2012.
23. **Schünemann HJ**, Johnston BC, Jaeschke R, Guyatt GH. Using Quality of Life Measurements in Pharmacoepidemiologic Research. Textbook of Pharmacoepidemiology, 2nd Edition, Editors: BL Strom, SE Kimmel, S Hennessy, 2013.

Peer Reviewed Scientific Articles (published, in press and accepted for publication)

1. Böning D, **Schünemann HJ**, Maassen N, Busse MW. Reduction of oxylabile CO₂ in human blood by lactate. Journal of Applied Physiology 74 (2): 710-714, 1993.
2. **Schünemann HJ**. Klocke RA. Influence of CO₂ kinetics on pulmonary carbon dioxide exchange. Journal of Applied Physiology 74 (2): 715-721, 1993.
3. Klocke RA, **Schünemann HJ**, Grant BJB. Distribution of pulmonary capillary transit times. American Journal of Respiratory and Critical Care Medicine 152 (6): 2014 - 2020, 1995.
4. Kumar NM, Rabadi NH, Sigurdson L, **Schünemann HJ**, Lwebuga-Mukasa JS. Induction of Interleukin-1 and Interleukin-8 mRNAs and proteins by TGFβ₁ in rat alveolar epithelial cells. Journal of Cellular Physiology 169:186-199, 1996.
5. **Schünemann HJ**, Muti P, Freudenheim JL, Armstrong D, Browne R, Klocke RA, Trevisan M. Oxidative stress and lung function. American Journal of Epidemiology 146(11):939-948, 1997.
6. Muti P, Trevisan M, Micheli A, Krogh V, Bolelli GF, Sciajno R, **Schünemann HJ**, Berrino F. Alcohol consumption and total estradiol in

- premenopausal women. *Cancer Epidemiology, Biomarkers and Prevention* 7(3):189-193, 1998.
7. **Schünemann HJ**, Dillon D, Nielsen L, Lwebuga-Mukasa JS. Modulation of integrin laminin receptors in the postnatal and adult rat lung. *Differentiation* 63:181-191, 1998.
 8. Stanulla M, **Schünemann HJ**, Thandla S, Brecher M, Aplan PD. Pseudo-rearrangement of the MLL gene at chromosome 11q23: A cautionary note on genotype analysis of leukemia patients. *Journal of Clinical Pathology: Molecular Pathology* 51:85-89, 1998.
 9. **Schünemann HJ**, Stanulla M, Trevisan M, Aplan PD, Freudenheim JL, Muti P. Short-term storage of blood samples and DNA isolation in serum separator tubes for application in epidemiological studies and clinical research. *Annals of Epidemiology* 10(8): 538-544, 2000.
 10. Muti P, Stanulla M, Micheli A, Krogh V, Freudenheim JL, Yang J, **Schünemann HJ**, Trevisan M, Berrino F. Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: A prospective analysis of abdominal adiposity, sebum production, and hirsutism. *Cancer, Causes and Control* 11(8):721-730, 2000.
 11. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, **Schünemann HJ**, Stanulla M, Yang J, Sepkovic D.W, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: A prospective analysis of the 2:16 α -Hydroxyestrone ratio in urine in pre- and postmenopausal women. *Epidemiology* 11(6):635-640, 2000.
 12. Arab D, Valeti V, **Schünemann HJ**, Lopez-Candales A. Usefulness of the QTc interval in predicting myocardial ischemia in patients undergoing exercise stress testing. *American Journal of Cardiology*. 85(6):764-766, 2000.
 13. **Schünemann HJ**, Dorn J, Grant BJB, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: Twenty-nine year follow-up of the Buffalo Health Study. *Chest* 118:656-664, 2000.
 14. Guyatt G, **Schünemann HJ**, Cook D, Jaeschke R, Pauker S, Bucher H. Grades of recommendation for antithrombotic agents. *Chest* 119(1): 3S-7S, 2001.
 15. **Schünemann HJ**, Grant BJB, Freudenheim JL, Muti P, Browne RW, Drake JA, Klocke RA, Trevisan M. The relation of serum levels of antioxidant vitamins C and E, retinol and carotenoids with pulmonary function in the general population. *American Journal of Respiratory and Critical Care Medicine* 163(5); 1246-1255, 2001.
 16. **Schünemann HJ**, Freudenheim JL, Grant BJB. Epidemiologic evidence linking antioxidant vitamins to pulmonary function and airway obstruction. Systematic review. *Epidemiologic Reviews* 23; 248-267, 2001.
 17. **Schünemann HJ**, McCann S, Grant BJB, Muti P, Trevisan M, Freudenheim JL. Lung function in relation to dietary intake of carotenoids and other antioxidant vitamins in a population-based study. *American*

- Journal of Epidemiology 155; 463-471, 2002
18. **Schünemann HJ**, Grant BJB, Freudenheim JL, Muti P, McCann S, Kudalkar D, Ram M, Russell M, Trevisan M. Beverage specific alcohol intake in a population-based study: Evidence for a positive association between pulmonary function and wine intake. *BMC Pulmonary Medicine* 2:3, 2002. (also published as permitted duplicate publication in **Schünemann HJ**, Grant BJB, Freudenheim JL, Muti P, McCann S, Kudalkar D, Ram M, Russell M, Trevisan M. Evidence for a positive association between pulmonary function and wine intake in a population-based study. *Sleep and Breathing* 6(4);161-172, 2002)
 19. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A randomized controlled trial to evaluate the effect of informing patients about their pretreatment responses to two respiratory questionnaires. *Chest* 122;1701-1708, 2002.
 20. Devereaux PJ, T-L Choi P, Lacchetti C, Weaver B, **Schünemann HJ**, Haines T, Lavis J N, Grant BJB, Haslam DRS, Bhandari M, Sullivan T, Cook D.J, Walter S.D, Meade M, Khan H, Bhatnagar N, Guyatt GH. A systematic review and meta-analysis of studies comparing private for-profit and private not-for-profit hospital mortality. *CMAJ (Canadian Medical Association Journal)* 166;1399-1406, 2002.
 21. Muti P, Quattrin T, Grant B, Krogh V, Micheli A, **Schünemann HJ**, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F. Fasting glucose is a risk factor for breast cancer: A prospective study. *Cancer Epidemiology, Biomarkers and Prevention* 11(11):1361-1368, 2002.
 22. Devereaux PJ, **Schünemann HJ**, Weaver B, Ravindran N, Lacchetti C, Bhandari M, Garg AX, T-L Choi P, Grant BJB, Haines T, Lavis JN, Cook DJ, Haslam DRS, Sullivan T, Guyatt GH. A systematic review and meta-analysis of studies comparing mortality between private for-profit and private not-for-profit dialysis centers. *JAMA*; 288: 2449-2457, 2002.
 23. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J, **Schünemann H**, Hill H, Freudenheim JL, Carruba G, Bradlow L. Urinary estrogen metabolites and prostate cancer: A case-control study. *Cancer, Causes and Control* 13:947-955, 2002.
 24. **Schünemann HJ**, Bone L. Evidence based orthopedics – A primer. *Clinical Orthopedics* 413:117-132, 2003.
 25. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A clinical trial to evaluate the responsiveness and validity of two direct health state preference instruments administered with and without hypothetical marker states in chronic respiratory disease. *Medical Decision Making* 23;140 - 149, 2003.
 26. Vora T, Pendyala P, **Schünemann H**, Lopez-Candales A. Prolongation of QTc interval during dobutamin stress echocardiography: a marker for ischemia. *Coronary Artery Disease* 14(3): 233-237, 2003 (name misspelled as Schunneman – erratum *Coronary Artery Disease*. 14(8):557, December 2003).
 27. **Schünemann HJ**, Griffith L, Jaeschke R, Stubbing D, Goldstein R, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and St. Georges Respiratory questionnaire in patients with chronic airflow limitation. *J Clin Epidemiology* 56(12):1170-1176, 2003.

28. **Schünemann HJ**, Dmochowski J, Campbell LA, Grant BJB. A novel approach for quality control of total lung capacity in clinical pulmonary function laboratory: a study in a veteran population. *Respirology* 8(3):365-370, 2003.
29. Grant BJB, Kudalkar D, Muti P, McCann S, Trevisan M, Freudenheim JL, **Schünemann HJ**. Relation between lung function and red cell distribution width in a population-Based Study. *Chest* 124; 494-500, 2003.
30. **Schünemann HJ**, Griffith L, Jaeschke R, Stubbing D, Goldstein R, Austin P, Guyatt GH. A comparison of the original chronic respiratory questionnaire (CRQ) with a standardized CRQ version. *Chest* 124; 1421-1429, 2003.
31. **Schünemann HJ**, Best D, Vist G, Oxman AD for the GRADE working group. Letters, numbers, symbols, and words: How best to communicate grades of evidence and recommendations? *Canadian Medical Association Journal (CMAJ)* 169(7);677-80, 2003.
32. Freudenheim JL, Muti P, Trevisan M, Nie J, Shields PG, Campbell LA, Ram M, McCann SE, **Schünemann HJ**, Carosella AM, Vito D, Russell M, Nochajski TH, Goldman R, Bandera E. Lung cancer in humans is not associated with lifetime total alcohol consumption or with genetic variation in alcohol dehydrogenase 3 (ADH₃). *Journal of Nutrition* 133(11):3619-3624, 2003.
33. Muti P, Awad AB, **Schünemann H**, Fink CS, Hovey K, Freudenheim JL, Wu B, Bellati C, Berrino F. Effect of diet modification on plasma levels of phytosterols in hyperandrogenic postmenopausal women. *Journal of Nutrition* 133(12):4252-4255, 2003.
34. **Schünemann HJ**, Stahl E, Austin P, Akl E, Armstrong D, Stubbing D, Guyatt GH. A Comparison of Narrative and Table Formats for Presenting Hypothetical Health States to Patients with Gastrointestinal or Pulmonary Disease: results from two randomized studies. *Medical Decision Making* 24:53–60, 2004.
35. Guyatt G, **Schünemann H**, Cook D, Jaeschke R, Pauker S. Applying the Grades of Recommendation for Antithrombotic and Thrombolytic Therapy. *Chest* 126:S179-S187, 2004.
36. **Schünemann HJ**, Munger H, Brower S, O'Donnell M, Crowther M, Cook D, Guyatt G. Methodology for guideline development for the 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 126:S174-S178, 2004.
37. Bhandari M, Busse JW, Montori VM, **Schünemann H**, Jackowski D, Sprague S, Mears D, Schemitsch EH, Devereaux PJ. Money Talks: Pro-Industry Results in Medical and Surgical Randomized Trials. *Canadian Medical Association Journal* 17;170(4):477-80, 2004.
38. Puhan MA, Behnke M, Frey M, Grueter T, Brändli O, Lichtenschopf A, Guyatt G, **Schünemann HJ**. Self-administration and interviewer-administration of the German chronic respiratory questionnaire: Instrument development and clinical testing in a randomised trial. *Biomedcentral: Health and Quality of Life Outcomes* 2:1, 2004.

39. **Schünemann HJ**, Cook D, Grimshaw J, Liberati A, Heffner J, Tapson V, Guyatt G. Antithrombotic and thrombolytic therapy: From evidence to application. *Chest* 126:S688-S696, 2004.
40. Puhan MA, Behnke M, Laschke M, Lichtenschopf A, Brändli O, Guyatt GH, **Schünemann HJ**. Self-administration and standardisation of the chronic respiratory questionnaire: a randomised trial in three German-speaking countries. *Respiratory Medicine* 98(4):342-50, 2004.
41. Menon V, Harrington R, Hochman J, Cannon CP, Goodman SD, Wilcox RG, **Schünemann HJ**, Ohman EM. Intravenous Thrombolysis in Acute Myocardial Infarction. *Chest* 126:S549-S575, 2004.
42. Stein PD, **Schünemann HJ**, Dalen JE, Gutterman D. Antithrombotic Therapy in Patients with Saphenous Vein and Internal Mammary Artery Bypass Grafts. *Chest* 126:S600-S608, 2004.
43. Akl E[^], Izuchukwu I, El-Dika S, Fritsche L, Kunz R, **Schünemann HJ**. Integrating an evidence-based medicine (EBM) rotation into an Internal Medicine Residency Program. *Academic Medicine* 79:897–904, 2004.
44. Devereaux PJ, Choi PTL, El-Dika S, Bhandari M, Montori VM, **Schünemann HJ**, Garg AX, Busse JW, Heels-Ansdell D, Ghali WA, Manns BJ, Guyatt GH. An observational study found that authors of randomized controlled trials frequently used concealment of randomization and blinding, despite the failure to report these methods. *Journal Clinical Epidemiology* 57: 1232-1236, 2004.
45. Devereaux PJ, Heels-Ansdell D, Lacchetti C, Haines T, Burns K, Cook D, Ravindran N, Walter S, McDonald H, Stone SB, Patel R, Bhandari M, **Schünemann HJ**, Choi PT, Bayoumi A, Lavis JL, Sullivan T, Stoddart G, Guyatt GH. A Systematic Review and Meta-Analysis of Studies comparing the Charges for Care at Private For-Profit and Private Not-For-Profit Hospitals. *Canadian Medical Association Journal* 170; 1817-1824, 2004.
46. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, **Schünemann HJ**, HEdejer TT, HVaronen H, Vist GE, Williams JW Jr, Zaza S; GRADE Working Group*. Grading evidence and recommendations. *British Medical Journal* 328:1490 – 1494, 2004.
47. **Schünemann HJ**, Armstrong D, Fallone C, Barkun A, Degli'Innocenti A, Heels-Ansdell D, Wiklund I, Tanser L, Chiba N, Austin P, Van Zanten S, El-Dika S, Guyatt GH. A Randomized Multi-Center Trial to Evaluate Simple Utility Elicitation Techniques in Patients with Gastro Esophageal Reflux Disease. *Medical Care* 42(11):11-32-42, 2004.
48. Akl E[^], Maroun N, Klocke RA, **Schünemann HJ**. A survey of internal medicine residents and faculty about the duration of attendings' in-patient rotations. *Journal of General Internal Medicine* 19:1133–1139, 2004.
49. Puhan MA, Behnke M, Devereaux PJ, Montori V, Frey M, Brändli O, **Schünemann HJ**. Measurement agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians: a prospective study. *Respiratory Medicine* 98:1195-202, 2004.

50. Menon V, Ram M, Dorn J, Armstrong D, Muti P, Freudenheim JL, Browne R, **Schünemann H**, Trevisan M. Oxidative stress and glucose levels in a population-based sample. *Diabet Med*; 21(12):1346-52, 2004.
51. Puhan MA, **Schünemann HJ**, Bachmann LM. Exercise modalities to treat peripheral muscular dysfunction of patients with COPD - A Systematic Review. *Respiratory Research* 02;5(1):25, 2004.
52. Fallone C, Guyatt GH, Armstrong D, Wiklund I, Barkun A, Degli'Innocenti A, Heels-Ansdell D, Tanser L, Chiba N, Austin P, Van Zanten S, El-Dika S, **Schünemann HJ**. Do physicians correctly assess patient symptom severity in gastro esophageal reflux disease? *Alimentary Pharmacology and Therapeutics* 15;20(10):1161-9, 2004
53. Montori VM, Jaeschke R, **Schünemann HJ**, Bhandari M, Brozek JL, Devereaux PJ, Guyatt G. Users' guide to detecting misleading claims in clinical research reports. *British Medical Journal (BMJ)* 329;1093-6, 2004.
54. The GRADE* Working Group (Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, Liberati A, O'connell D, Oxman AD, Phillips B, **Schünemann H**, Tan-Torres Edejer T, Vist GE, Williams JW). A critical appraisal of systems for grading evidence and formulating recommendations. *Biomedcentral: BMC Health Services Research* 4:38, 2004.
55. Barba M, McCann SE, **Schünemann H**, Stranges S, Fuhrman B, DePlacido S, Carruba G, Freudenheim J, Trevisan M, Muti P. Lifetime Total And Beverage Specific Alcohol Intake And Prostate Cancer Risk: A Case-Control Study. *Nutrition Journal* 9;3(1):23, 2004.
56. Devereaux P, **Schünemann HJ**, Ravindran N, Bhandari M, Garg A, Choi P, Grant B, Haines T, Lacchetti C, Weaver B, Lavis J, Cook D, Haslam D, Sullivan T, Guyatt G. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. *JAMA* 14;291(2):186, 2004.
57. Platek M, Krogh V, Micheli A, Browne R, Meneghini E, Sieri S, **Schünemann HJ**, Pala V, Wilding GE, Berrino F, Muti P. Serum Fructosamine and Subsequent Breast Cancer Risk: the ORDET Prospective Study. *Cancer Epidemiology, Biomarkers & Prevention* 14(1):271-214, 2005.
58. Bhandari M, Bajammal S, Guyatt GH, Griffith L, Busse JW, **Schünemann H**, Einhorn TA. Do Bisphosphonates reduce peri-prosthetic Bone Loss after total Joint Arthroplasty? A Meta-Analysis. *Journal of Joint and Bone Surgery* 87-A(2):293-301, 2005.
59. Puhan MA, Guyatt G, Montori V, Devereaux PJ, Bhandari M, Griffith L, Goldstein R, **Schünemann HJ**. The standard gamble demonstrated lower reliability than the feeling thermometer. *J Clin Epidemiology* 58(5):458-65, 2005.
60. Fuhrman B, Barba, M, **Schünemann H**, Hurd T, Quattrin T, Cartagena R, Carruba G, Muti P. Basal Growth Hormone Concentrations in blood and the Risk for Prostate Cancer: A case-control study. *Prostate* 64(2):109-15, 2005.

61. **Schünemann HJ**, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic Respiratory Disease Questionnaire (CRQ) *Journal of COPD* 2;81-89, 2005.
62. Akl E, Maroun N, Klocke RA, Montori V, **Schünemann HJ**. Electronic mail was not better than postal mail for surveying residents and faculty. *J Clin Epidemiology* 58(4):425-429, 2005.
63. Devereaux PJ, Bhandari M, Clarke M, Montori VM, Cook DJ, Yusuf S, Sackett DL, Cinà C, Walter S, Haynes RB, **Schünemann HJ**, Norman GR, Guyatt GH. The Need for Expertise-Based Randomized Controlled Trials. *British Medical Journal* 330:88-91, 2005.
64. **Schünemann HJ**, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Puhan M, Grant BJB, Austin P, Collins R, Guyatt GH. A randomized controlled trial to evaluate the self-administered standardized CRQ. *European Respiratory Journal* 25(1):31-40, 2005.
65. Shaikat A, Sourcas N, **Schünemann HJ**. Role of Supplemental Calcium in the Recurrence of Colorectal Adenomas: A Meta-analysis of Randomized Controlled Trials. *American Journal of Gastroenterology* 100(2):390-4, 2005.
66. Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Devereaux PJ, Alonso J, Akl E, Domingo-Salvany A, Mills E, Jackowski D, **Schünemann HJ**, Jaeschke R, Guyatt GH. Validity of composite end points in clinical trials. *BMJ* 330:594–6, 2005.
67. Puhan MA, **Schünemann HJ**, Frey M, Scharplatz M, Bachmann LM. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction - A Systematic Review. *Thorax* 60(5):367-75, 2005.
68. Degli'Innocenti A, Guyatt GH, Fallone C, Armstrong D, Wiklund I, Barkun A, Heels-Ansdell D, Tanser L, Chiba N, Austin P, Van Zanten S, El-Dika S, **Schünemann HJ**. The influence of demographic factors and health-related quality of life evaluation of treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole. *BMC Health Qual Life Outcomes* 13;3(1):4, 2005.
69. Atkins D, Briss PA, Eccles M, Flottorp S, Guyatt GH, Harbour RT, Hill S, Jaeschke R, Liberati A, Magrini N, Mason J, O'Connell D, HOxman AD, Phillips B, **Schünemann H**, Edejer TT, Vist GE, Williams JW Jr; HGRADE Working Group. Systems for Grading the Quality of Evidence and Strength of Recommendations II: Pilot Study of a New System. *BMC Health Services Research*. 5(1):25, 2005.
70. Shaikat A[^], Freudenheim JL, Grant BJ, Muti P, Ochs-Balcom HM, McCann SE, Trevisan M, Iacoviello L, **Schünemann HJ**. Is being breastfed as an infant associated with adult pulmonary function? *J Am Coll Nutr*. Oct;24(5):327-33, 2005.
71. Montori V, Devereaux PJ, Adhikari N, Burns K, Eggert C, Briel M, Lacchetti C, Leung T, Darling E, Bryant D, Bucher H, **Schünemann H**, Meade M, Cook D, Erwin P, Sood R, Lo B, Thompson C, Zhou Q, Mills E, Guyatt G. Randomized Trials Stopped Early for Benefit. A Systematic Review. *JAMA*

- 294(17): 2203-2209, 2005.
72. Puhan MA, Bryant D, Guyatt GH, Heels-Ansdell D, **Schünemann HJ**. Internal consistency reliability is a poor predictor of responsiveness. *BMC Health Quality of Life Outcomes* 9;3(1):33, 2005.
 73. El-Dika S[^], Guyatt GH, Armstrong D, Degli'Innocenti A, Fallone C, Wiklund I, Barkun A, Heels-Ansdell D, Tanser L, Chiba N, Austin P, Van Zanten S, **Schünemann HJ**. The Impact of Illness in Canadian Patients with Moderate to Severe Gastro Esophageal Reflux Disease. *Biomedcentral Gastroenterology* 5(1):23, 2005.
 74. Ochs-Balcom H[^], Muti P, Sempos CT, Grant BJB, Freudenheim J, Browne RW, Trevisan M, Iacoviello L, Cassano PA, **Schünemann HJ**. Oxidative Stress and Pulmonary Function in the General Population. *American Journal of Epidemiology* 162 (12): 1137-45, 2005.
 75. **Schünemann HJ**, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Bayoumi A, Austin P, Guyatt GH. Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease. *Quality of Life Research*. 15(1):1-14, 2006.
 76. Akl E, Maroun N, Neagoe G, Guyatt G, **Schünemann HJ**. EBM user and practitioner models for graduate medical education: What are residents' preferences? *Medical Teacher*. 28(2):192-4, 2006.
 77. Guyatt G, Gutterman D, Baumann M, Adrizzio-Harris D, Hylek E, Phillips B, Raskob G, **Schünemann H**. Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines - Report from an ACCP working group. *Chest* 129(1):182-187, 2006.
 78. Guyatt G, Baumann M, Pauker S, Halperin J, Carlin B, Owens D, Tosteson A, Gutterman D, Mauer J, Prins M, Zelman Lewis S, **Schünemann H**. Consideration of Resource Allocation Issues in Clinical Practice Guidelines – Recommendations from an ACCP - sponsored taskforce. *Chest* 129(1):174-181, 2006.
 79. Sinuff T, Adhikari N, Cook DJ, **Schünemann H**, Rocker G, Griffith L, Walter S. Mortality Predictions in the Intensive Care Unit: Comparing Clinicians To Scoring Systems – A systematic review. *Critical Care Medicine* 34(3):878-885, 2006.
 80. Montori V, Leung TW, Devereaux PJ, **Schünemann HJ**, Akl E, Gafni A, Guyatt G. Can contraindications compromise evidence-based, patient-centered clinical practice? *Can J Clin Pharmacol* 13(1):e92-e101, 2006
 81. Ochs-Balcom H, Grant BJB, Freudenheim J, Muti P, McCann S, Trevisan M, Iacoviello L, **Schünemann HJ**. Antioxidants, Oxidative Stress and Pulmonary Function in Individuals diagnosed with asthma and COPD. *Eur J Clin Nutr* 60 (8):991-999, 2006.
 82. Ochs-Balcom H, Muti P, Grant BJB, Freudenheim J, Trevisan M, Iacoviello L, **Schünemann HJ**. Pulmonary Function and Abdominal Adiposity in the general population. *Chest* 129(4):853-62, 2006.
 83. Akl E, Bais A, Rich E, Izzo J, Grant BJ **Schünemann HJ**. *Internal Medicine*

- Residents', Attendings' and Nurses' Perceptions of the Night Float System. *Journal of General Internal Medicine* 21(5):494-7, 2006.
84. Puhan A, Guyatt G, Armstrong D, Wiklund I, Fallone C, Heels-Ansdell D, Degl'Innocenti A, Veldhuyzen van Zanten S, Tanser L, Barkun A, Chiba N, Austin P, El-Dika S, **Schünemann H**. Validation of a symptom diary for patients with gastro-esophageal reflux disease. *Alimentary Pharmacology & Therapeutics* 23(4):531-541, 2006.
 85. Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, **Schünemann HJ**, Tornetta P. Misuse of Baseline Comparison Tests and Subgroup Analyses in Surgical Randomized. *Clinical Orthopedics & Related Research* 447:247-51, 2006.
 86. Krishan G[^], Grant BJB, Muti P, Mishra A, Ochs-Balcom H, Freudenheim JL, Trevisan M, **Schünemann HJ**. Association between Anemia and Quality of Life in a Population Sample of Individuals with Chronic Obstructive Pulmonary Disease. *BMC Pulmonary Medicine* 6:23, 2006.
 87. **Schünemann HJ**, Jaeschke J, Cook D, Bria WF, El Solh AA, Ernst A, Fahy BF, Gould MK, Horan KL, Krishnan JA, Manthous CA, Maurer J, McNicholas W, Oxman AD, Rubenfeld G, Turino GM, Guyatt G and the ATS Documents Development and Implementation Committee. An official ATS statement: Grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. *American Journal of Respiratory and Critical Care Medicine*. 174(5):605-14, 2006.
 88. **Schünemann HJ**, Akl EA, Guyatt G. Interpreting the Results of Patient Reported Outcome Measures in Clinical Trials: The Clinicians Perspective. *Health and Quality of Life Outcomes*. 4(1):62, 2006.
 89. Puhan MA, Büsching G, **Schünemann H**, Van Oort E, Zaugg C, Frey M. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. *Annals of Internal Medicine*. 145(11):816-25, 2006.
 90. Oxman AD, Fretheim A, **Schünemann HJ**. Improving the Use of Research Evidence in Guideline Development: Introduction. *Health Research Policy System*. This article introduces a series of 16 articles that provide advice to the WHO for how to improve the use of evidence for guidance given by WHO. 4:12, 2006.
 91. **Schünemann HJ**, Fretheim A, Oxman AD. Improving the Use of Research Evidence in Guideline Development: 1. Guidelines for guidelines. *Health Research Policy System*. 4:13, 2006.
 92. Oxman AD, **Schünemann HJ**, Fretheim A. Improving the Use of Research Evidence in Guideline Development: 2. Priority setting. *Health Research Policy System*. 4:14, 2006.
 93. Fretheim A, **Schünemann HJ**, Oxman AD. Improving the Use of Research Evidence in Guideline Development: 3. Group composition and consultation process. *Health Research Policy System*. 4:15, 2006.
 94. Fretheim A, **Schünemann HJ**, Oxman AD. Improving the Use of Research Evidence in Guideline Development: 5. Group processes. *Health Research Policy System*. 4:17, 2006.

95. **Schünemann HJ**, Oxman AD, Fretheim A,. Improving the Use of Research Evidence in Guideline development: 6. Determining which outcomes are important. Health Research Policy System. 4:18, 2006.
96. Oxman AD, **Schünemann HJ**, Fretheim A. Improving the Use of Research Evidence in Guideline Development: 7. Deciding what evidence to include. Health Research Policy System . 4:19, 2006.
97. Oxman AD, **Schünemann HJ**, Fretheim A. Improving the Use of Research Evidence in Guideline Development: 8. Synthesis and presentation of evidence. Health Research Policy System. 4:20, 2006.
98. **Schünemann HJ**, Fretheim A, Oxman AD. Improving the Use of Research Evidence in Guideline Development: 9. Grading evidence and recommendations. Health Research Policy System. 4:21, 2006.
99. **Schünemann HJ**, Fretheim A, Oxman AD. Improving the Use of Research Evidence in Guideline Development: 10. Integrating values and consumer involvement. Health Research Policy System 4:22, 2006.
100. Oxman AD, **Schünemann HJ**, Fretheim A. Improving the Use of Research Evidence in Guideline Development: 12. Incorporating considerations of equity. Health Research Policy System. 4:24, 2006.
101. **Schünemann HJ**, Fretheim A, Oxman AD. Improving the Use of Research Evidence in Guideline Development: 13. Applicability, Transferability and Adaptation. Health Research Policy System 4:25, 2006.
102. Oxman AD, Fretheim A, **Schünemann HJ**. Improving the Use of Research Evidence in Guideline Development: 14. Reporting guidelines. Health Research Policy System. 4:26, 2006.
103. Fretheim A, **Schünemann HJ**, Oxman AD. Improving the Use of Research Evidence in Guideline Development: 15. Disseminating and implementing guidelines. Health Research Policy System. 4:27, 2006.
104. Oxman AD, Fretheim A, **Schünemann HJ**. Improving the Use of Research Evidence in Guideline Development: 16. Evaluation. Health Research Policy System. 4:28, 2006.
105. El-Dika S, Mahl T, Mehboob S, Miqdadi J, Heels-Ansdell D, Handley B, Sitrin M, **Schünemann HJ**. Is Blinding the Endoscopists to Bowel Preparations in Randomized-Controlled Trials a Reality? Cancer Detection and Prevention. 30(6):552-9, 2006.
106. Puhan AM, Soesilo I, Guyatt GH, **Schünemann HJ**. Combining scores from different patient reported outcome measures in meta-analyses: when is it justified? Health and Quality of Life Outcomes 4:94, 2006.
107. Barba M, Cavalleri A, **Schünemann HJ**, Krogh V, Evangelista A, Secreto G, et al. Reliability of urinary 6-sulfatoxymelatonin as a biomarker in breast cancer. Int J Biol Markers 21(4):242-5, 2006.
108. Akl E, Maroun N, Major S, Afif C, Chahoud B, Choucair J, Sacr M, **Schünemann H.J**. Why Are You Draining Your Brain? Factors Underlying Decisions of Graduating Lebanese Medical Students to Migrate. Social Sciences and Medicine. 64(6):1278-84, 2007.

109. Akl, E, Maroun N, Major S, Chachoud B, **Schünemann HJ**. Graduates of Lebanese medical schools in the United States: an observational study of international migration of physicians. *BMC Health Service Research* 7(1):49, 2007.
110. **Schünemann HJ**, Hill S, Kakad M, Bellamy R, Uyeki T, Hayden F, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, Farrar J, Tran TH, Özbay B, Sugaya N, Fukuda K, Shindo N, Stockman L, Vist G, Croisier A, Nagjdaliyev A, Roth C, Thompson G, Zucker H, Oxman, AD. WHO Rapid Advice Guidelines for the pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. *The Lancet Infectious Disease* 7(1):21-31, 2007.
111. Puhan M, Guyatt GH, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, **Schünemann HJ**. Relative responsiveness of the Chronic Respiratory Questionnaire St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. *Respiratory Medicine*. 101(2):308-316, 2007.
112. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonso-Coello P, Alonso J, Worster A, Upadhye S, Jaeschke R, **Schünemann HJ**, Permanyer-Miralda G, Pacheco-Huergo V, Domingo-Salvany A, Wu P, Mills EJ, Guyatt GH. Problems with the use of composite endpoints in cardiovascular trials: systematic review of randomised controlled trials. *BMJ* 334(7597):786, 2007.
113. Akl E, Mustafa R, Bdair F, **Schünemann HJ**. The US physician workforce and international medical graduates: trends and characteristics. *Journal of General Internal Medicine* 22(2):264-8, 2007.
114. **Schünemann HJ**, Hill S, Kakad M, Vist G, Bellamy R, Stockman L, Wisloff T, Del Mar C, Shindo N, Fukuda K, Hayden F, Uyeki T, Farrar Yazdanpanah Y, Zucker H, Beigel J, Chotpitayasunondh T, Hien TT, Ozbay B, Sugaya N, Oxman, AD. Transparent Development of the WHO Rapid Advice Guidelines. *PLoS Medicine* 4(5):e119, 2007.
115. Wahlquist P, Guyatt GH, Fallone C, Armstrong D, Degli'Innocenti A, Wiklund I, Barkun A, Heels-Ansdell D, Tanser L, Chiba N, Austin P, Van Zanten S, El-Dika S, **Schünemann HJ**. The Work Productivity and Activity Impairment questionnaire for patients with Gastro-Esophageal Reflux Disease (WPAI-GERD): Responsiveness to change and English language validation. *Pharmacoeconomics* 25(5):385-396, 2007.
116. Akl EA, Kamath G, Kim GY, Yosuico V, Barba M, Terrenato I, Sperati F, **Schünemann HJ**. Oral anticoagulation for prolonging survival in patients with cancer: a Cochrane Systematic Reviews. 18;(2):CD006466, 2007. (also published as permitted duplicate publication in: Akl EA, Kamath G, Kim SY, Yosuico V, Barba M, Terrenato I, Sperati F, **Schünemann HJ**. Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a cochrane systematic review. *J Exp Clin Cancer Res*. 2007 Jun;26(2):175-84. *Journal of Experimental and Clinical Cancer Research* 26(2):175-184, 2007**)
117. Dahm P, Kunz R, **Schünemann H**. Evidence-based clinical guidelines for prostate cancer: The need for a unified approach. *Current Opinion in Urology* 17(3):200-207, 2007.
118. Akl EA, Grant B, Guyatt G, Montori VM, **Schünemann H**. A decision aid for COPD patients considering inhaled steroid therapy: development before

- and after pilot testing. *BMC Medical Informatics and Decision Making* 15;7:12, 2007.
119. Bassler D, Ferreira-Gonzalez I, Briel M, Cook DJ, Devereaux PJ, Heels-Andell D, Kirpalani H, Meade M, Montori VM, Rozenberg A, **Schünemann HJ**, Guyatt G. Systematic reviewers neglect bias that results from trials stopped early for benefit. *J Clin Epidemiology* 60(9):869-73, 2007.
 120. Guyatt G, **Schünemann H**. How can quality of life researchers make their work more useful to health workers and their patients? *Quality of Life Research*. 16(17):1097-105, 2007.
 121. Frost M, Bonomi A, Capelleri J, **Schünemann HJ**, Moynihan TJ, Aaronson N. Applying Quality-of-Life Data Formally and Systematically into Clinical Practice. Clinical Significance Consensus Meeting Group. *Mayo Clinic Proceedings*. 82(10):1214-28, 2007.
 122. Puhan MA, **Schünemann HJ**, Wong E, Griffith L, Guyatt G. The standard gamble showed better construct validity than the time trade-off. *J Clin Epidemiology*. 60(10):1029-33, 2007.
 123. Capurso G, **Schünemann HJ** (corresponding author), Terrenato I, Morretti A, Koch M, Muti P, Capurso L, Delle Fave G. Meta-analysis: Use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. *Aliment Pharmacol Therapy*. 26(8):1089-1099, 2007.
 124. Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Terrenato I, Sperati F, Cook D, **Schünemann HJ**. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. *Cochrane Database of Systematic Reviews*. Jul 18 (3): CD006468, 2007.
 125. Akl EA, Van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO, **Schünemann HJ**. Parenteral anticoagulation for prolonging survival in cancer patients with cancer who have no other indication for anticoagulation. *Cochrane Database of Systematic Reviews*. Jul 18,(3): CD006652, 2007. (also published as permitted duplicate publication: Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO, Schünemann HJ. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. *Exp Clin Cancer Res* 27(1):4, 2008**)
 126. Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Möricke A, Zimmermann M, Schrauder A, Karawajew L, Ludwig WD, Welte K, **Schünemann HJ**, Schlegelberger B, Schrappe M, Stanulla M. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the central nervous system. *Journal of Clinical Oncology* 25(30):4813-20, 2007.
 127. **Schünemann HJ**, Norman G, Puhan M, Griffith L, Wiklund I, Heels-Andell D, Montori VM, Goldstein R, Mador JM, Guyatt GH. Application of generalizability theory confirmed lower reliability of the standard gamble than the feeling thermometer. *J Clin Epidemiology* 60;(12):1256-62, 2007.
 128. Akl EA, Maroun N, Guyatt G, Oxman A, Alonso-Coello P, Vist GE, Devereaux PJ, Montori VM, **Schünemann HJ**. Symbols were superior to numbers for presenting strength of recommendations to healthcare consumers: a randomised trial. *J Clin Epidemiology* 60;(12):1298-305, 2007.

129. Akl E, Sackett K, Pretorius R, Erdley S, Bhoopathi PS, Mustafa R, **Schünemann HJ**. Educational games for health professionals. A systematic review. *Cochrane Database of Systematic Reviews*. Jan 23;(1):CD006411, 2008.
130. Puhan MA, **Schünemann HJ**, Buesching G, Vanoort E, Spaar A, Frey M. COPD patients' ability to follow exercise influences short-term outcomes of rehabilitation. *Eur Respir J* 31(2):304-10, 2008.
131. Barba M, Terrenato I, **Schünemann H**, Fuhrman B, Sperati F, Teter B, Gallucci M, D'Amato A, Muti P. Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case control study. *Urology* 72(1):183-7, 2008..
132. Brozek JL, Beana-Cagnani C, Bonini S, Canonica GW, Rasi G, Gerth van Wijk R, Zuberbier T, Guyatt G, Bousquet J, **Schünemann HJ**. Methodology for development of the allergic rhinitis and its impact on asthma (ARIA) guideline 2008. update. *Allergy* 63(1):38-46, 2008.
133. Sinuff T, Adhikari NKL, Patel R, Meade MO, **Schünemann HJ**, Cook DJ. Quality of Professional Society Guidelines and Consensus Conference Statements. *Crit Care Medicine* 36(4):1049-58, 2008.
134. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, **Schünemann HJ**. GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations. *BMJ* 26;336(7650):924-6, 2008.
135. Swiglo BA, Murad MH, **Schünemann HJ**, Kunz R, Vigersky RA, Guyatt GH, Montori VM. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the GRADE system. *J Clin Endocrinol Metab* 93(3):666-73, 2008.
136. Akl EA, Kamath G, Sperati F, Kim SY, Yosuico V, Barba M, Cook DJ, **Schünemann HJ**. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. *Cancer* 112(11):2483-92, 2008. **
137. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, **Schünemann HJ**. What is 'quality of evidence' and why is it important to clinicians? *BMJ* 336;995-998, 2008.
138. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, **Schünemann HJ**. Going from evidence to recommendations. *BMJ* 336(7652):1049-51, 2008.
139. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Vist GE, **Schünemann HJ**. Grading Recommendations: Incorporating considerations of resources use. *BMJ* 24;336(7654):1170-3, 2008.
140. Akl EA, Kamath G, Sperati F, Kim SY, Yosuico V, Barba M, Cook DJ, **Schünemann HJ**. Low Molecular Weight Heparin versus Unfractionated Heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review. *Archives of Internal Medicine* 23;168(12):1261-9, 2008.
141. **Schünemann HJ**, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist G, Williams J, Kunz R, Craig J, Montori V, Bossuyt P, Guyatt GH. GRADEing

- the quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ* 336;1106-1110, 2008.
142. Prodosmo A, Giglio S, Moretti S, Mancini F, Barbi F, Avenia N, Di Conza G, **Schünemann H**, Pistola L, Ludovini V, Sacchi A, Pontecorvi A, Puxeddu E, Moretti F. Analysis of human MDM4 (HDMX) variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. *Journal of Molecular Medicine* 86(5):585-96, 2008.
 143. Lim W, Holinski P, Devereaux PJ, Tkaczyk A, McDonald E, Clarke F, Qushmaq I, Terrenato I, **Schünemann H**, Crowther M, Cook D. Detecting myocardial infarction in critical illness using screening troponin measurements and ECG recordings. *Critical Care* Mar 4;12(2):R36, 2008.
 144. Payne D, Koka HP, Karanicolas PJ, Chu MW, Nagpal AD, Briel MD, **Schünemann HJ**, Lonn E. Hemodynamic Performance of Stentless Versus Stented Valves: A Systematic Review and Meta-Analysis. *Journal of Cardiac Surgery* 23(5):556-64, 2008.
 145. Kunz R, Djulbegovic B, **Schünemann HJ**, Stanulla M, Muti P, Guyatt G. Misconceptions, challenges, uncertainty, and progress in developing treatment recommendations. *Seminars in Hematology* 45:167-75, 2008.
 146. Falck-Ytter Y, Kunz R, Guyatt G, **Schünemann HJ**. How strong is the evidence? *American Journal of Gastroenterology* 103(6):1334-8, 2008.
 147. Kunz R, Burnand B, **Schünemann HJ**. Das GRADE-System – Ein internationaler Ansatz zur Vereinheitlichung der Graduierung von Evidenz und Empfehlungen in Leitlinien. *Internist* 49(6):673-80, 2008.
 148. Bednarska E, Bryant D, Devereaux PJ; **Expertise-Based Working Group***** Orthopaedic surgeons prefer to participate in expertise-based randomized trials. *Clin Orthop Relat Res* 466(7):1734-44, 2008.
 149. Cercato MC, Nagore E, Ramazzotti V, Guillén C, Terrenato I, Villena J, Natali PG, Lomuscio M, **Schünemann HJ**. Self and parent-assessed skin cancer risk factors In school-age children. *Preventive Medicine* 47(1):133-5, 2008.
 150. Akl EA, Maroun N, Major S, Afif C, Abdo A, Choucair J, Sakr M, Li CK, Grant BJB, **Schünemann HJ**. Post-graduation migration intentions of students of Lebanese medical schools: a survey study. *BMC Public Health* 8:191, 2008.
 151. Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, Sieri S, Sempos CT, Cavalleri A, **Schünemann HJ**, Strano S, Muti P. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. *Journal of the National Cancer Institute* 100(12):898-905, 2008.
 152. Puhan M, Mador J, Held U, Goldstein R, Guyatt G, **Schünemann HJ**. Interpretation of treatment related changes in six-minute walk distance in patients with COPD and implications for designing clinical research. *European Respiratory Journal* 32(3):637-43, 2008.
 153. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Bclair F, **Schünemann HJ**. Anticoagulation for the initial treatment of venous

- thromboembolism in patients with cancer: a systematic review. *Cancer* 113(7):1685-94,2008** (also published as permitted duplicate publication in: Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, **Schünemann HJ**. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev*. Jan 23;(1):CD006649, 2011)
154. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, **Schünemann HJ**. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev*. Apr 16;(2):CD006650, 2008.
 155. **Schünemann HJ**, Cook D, Guyatt G. Methodology for Antithrombotic and Thrombolytic Therapy Guideline Development: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 133: 113S–122S, 2008.
 156. Guyatt GH, Cook DJ, Jaeschke R, Pauker S, **Schünemann HJ**. Grades of Recommendation for Antithrombotic Agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 133:123S–131S, 2008.
 157. Puhan M, Frey M, Buechi S, **Schünemann HJ**. The minimal important difference of the Hospital Anxiety and Depression Scale in patients with chronic obstructive pulmonary disease. *Health and Quality of Life Outcomes* 6:46, 2008.
 158. Jaeschke R, Guyatt GH, Dellinger P, **Schünemann H**, Levy MM, Kunz R, Norris S, Bion J; GRADE working group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. *BMJ* 337:744, 2008.
 159. Akl EA, Terrenato I, Barba M, Sperati F, Muti P, **Schünemann HJ**. Extended perioperative thromboprophylaxis in patients with cancer: a systematic review. *Thrombosis & Hemostasis* 100: 1176-1180, 2008.
 160. Carling C, Kristoffersen DT, Herrin J, Treweek S, Oxman AD, **Schünemann H**, Akl EA, Montori V. How should the impact of different presentations of treatment effects on patient choice be evaluated? A pilot randomized trial. *PLoS ONE* 3: e3693, 2008.
 161. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Thabane L, Cheng J, **Schünemann H**, Sears MR, Guyatt G. The safety of formoterol among patients with asthma inhaled corticosteroids. Systematic review and meta-analysis. *Pol Arch Med Wewn* 118: 627-635, 2008.
 162. Alonso-Coello P, Montori V, Sola I, **Schünemann H**, Devereaux P, Charles C, Roura M, Diaz M G, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G. Values and preferences in oral anticoagulation in patients with atrial fibrillation: physicians' and patients' perspectives. Protocol for two-phase study. *BMC Health Services Research* 8:221, 2008.
 163. Brožek JL, Guyatt GH, Heels-Ansdell D, degl'Innocenti A, Armstrong D, Fallone CA, Wiklund I, Veldhuyzen van Zanten S, Chiba N, Barkun AN, Akl EA, **Schünemann HJ (corresponding author)**. Specific HRQL instruments and symptom scores were more responsive than preference-based generic instruments in patients with GERD. *J Clin Epidemiol* 62: 102-110, 2009

164. Akl E, Mustafa R, Slomka T, Alaweh A, Vedavalli A, **Schünemann H**. An educational game for teaching clinical practice guidelines to Internal Medicine residents: development, feasibility and acceptability. *BMC Medical Education* 8: 50, 2008.
165. Barba M, **Schünemann HJ (corresponding author)**, Sperati F, Akl EA, Musicco F, Guyatt G, Muti P. The effects of metformin on endogenous androgens and sex-hormone binding globulin in women: a systematic review and meta-analysis. *Clin Endocrinol (Oxf)*;70(5):661-70, 2009.
166. **Schünemann HJ**, Woodhead M, Anzueto A, Buist S, MacNee W, Rabe K, Heffner J. A vision statement on guideline development for respiratory disease: the example of COPD. *The Lancet* 373: 774-779, 2009.
167. Turner D, **Schünemann HJ**, Griffith LE, Beaton DE, Griffiths AM, Critch JN, Guyatt GH. Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference. *J Clin Epidemiol* 62: 374-379, 2009.
168. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Thabane L, Cheng J, **Schünemann H**, Sears MR, Guyatt G. The safety of long acting beta agonists among patients with asthma using inhaled corticosteroids. *AM J Respir Crit Care* 178(10):2009.-16.
169. Sieri S, Krog V, Micheli A, Sara G, Tagliabue G, Evangelista A, Allemani C, **Schünemann H**, Berrino F, Muti P. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. *Cancer Epidemiology, Biomarkers & Prevention* 18: 169-176, 2009.
170. Busse JW, Kaur J, Mollon B, Bhandari M, Tornetta P, **Schünemann HJ**, Guyatt GH. Low-Intensity Pulsed Ultrasonography for Fractures: Systematic Review of Randomized Controlled Trials. *BMJ* 338: b351, 2009.
171. Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, Helfand M, Ueffing E, Alonso-Coello P, Meerpohl J, Phillips B, Horvath AR, Bousquet J, Guyatt GH, **Schünemann HJ (corresponding author)**. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. *Allergy* 64(8): 1109-16, 2009.
172. Dahm P, Yeung LL, Gallucci M, Simone G, **Schünemann HJ**. How to use a clinical practice guideline. *J Urol* 181: 472-479, 2009.
173. Elamin MB, Flynn DN, Bassler D, Briel M, Alonso-Coello P, Karanickolas PJ, Guyatt GH, Malaga G, Furukawa TA, Kunz R, **Schünemann H**, Murad MH, Barbui C, Cipriani A, Montori VM. Choice of data extraction tools for systematic reviews depends on resources and review complexity. *J Clin Epidemiol* 62: 506-510, 2009.
174. Karanickolas PJ, Montori VM, Devereaux PJ, **Schünemann H**, Guyatt GH. A new 'mechanistic-practical' framework for designing and interpreting randomized trials. *J Clin Epidemiol* 62: 479-484, 2009.
175. Karanickolas PJ, Montori VM, Devereaux PJ, **Schünemann H**, Guyatt GH. The Practicalists' Response. *J Clin Epidemiol* 62(5): 489-94, 2009.

176. Lim W, Tkaczyk A, Holinski P, Qushmaq I, Jacka M, Khera V, Devereaux PJ, Terrenato I, **Schünemann H**, Heels-Ansdell D, Crowther M, Cook D. The diagnosis of myocardial infarction in critically ill patients: An agreement study. *J Crit Care* 24(3): 447-52, 2009.
177. Poolman RW, Verheyen CC, Kerkhoffs GM, Bhandari M, **Schunemann HJ**. From evidence to action: Understanding clinical practice guidelines. *Acta Orthop* 80: 113-118, 2009.
178. Akl EA, Briel M, You JJ, Lamontagne F, Gangji A, Cukierman-Yaffe T, Alshurafa M, Sun X, Nerenberg KA, Johnston BC, Vera C, Mills E, Bassler D, Salazar A, Bhatnagar N, Busse JW, Khalid Z, Walter SD, Cook DK, **Schünemann HJ**, Altman DG, Guyatt GH. LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact. *Journal of Trials* 10: 40, 2009.
179. Carling C, Kristoffersen DT, Flottorp S, Fretheim A, Oxman AD, **Schünemann HJ**, Akl EA, Herrin J, MacKenzie TD, Montori V. The effect of alternative graphical displays used to present the benefits of antibiotics for sore throat on decisions about whether to seek treatment: a randomized trial. *PLoS Med*, 6(8): e1000140, 2009.
180. Carling C, Kristoffersen DT, Montori V, Herrin J, **Schünemann HJ**, Treweek S, Akl EA, Oxman AD. The effect of alternative summary statistics for communicating risk reduction on decisions about whether to take statins: a randomized trial. *PLoS Med*, 6(8): e1000134, 2009.
181. Akl E, Mustafa R, Wilson MC, Symons A, Moheet A, Rosenthal T, Guyatt GH, **Schünemann HJ**. Curricula for teaching the content of clinical practice guidelines to family medicine and internal medicine residents in the US: a survey study. *Implementation Science*, 4:59, 2009.
182. Barba M, Yang L, **Schünemann HJ**, Sperati F, Gioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Rossella L, Malorni L, Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. *Journal of Experimental & Clinical Cancer Research*, 28:135, 2009.
183. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CEH, Kapp A, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, **Schünemann HJ**, Staubach P, Vena GA, Wedi B, Maurer M. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. *Allergy*, 64: 1417-1426, 2009.
184. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CEH, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, **Schünemann HJ**, Staubach P, Vena GA, Wedi B. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. *Allergy*, 64: 1427-1443, 2009.
185. Jaeschke R, Gajewski P, Bates SM, Douketis J, Soinica B, Crowther M, Lesniak W, Brozek JL, **Schünemann HJ**, Zawilska K, Tomkowski W, Undas A, Sznajd J, Nizankowski R, Bala MM, Guyatt G. 2009. Evidence-based clinical practice guidelines for diagnosing a first episode of lower

- extremities deep vein thrombosis in ambulatory outpatients. *Polish Arch Med Wew.* 119(9): 541-9, 2009.
186. **Schünemann HJ**, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L, Ohar J, McDermott S, Lucas L, Jaeschke R; ATS Ethics and Conflict of Interest Committee and the Documents Development and Implementation Committee. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. *Am J Respir Crit Care Med* 180 (6): 564-80, 2009.
187. Comondore VR, Devereaux PJ, Xhou Q, Stone SB, Busse JW, Ravindran NC, Burns KE, Haines T, Stringer B, Cook DJ, Walter SD, Sullivan T, Berwanger O, Bhandari M, Banglawala S, Lavis JN, Petrisor B, **Schünemann HJ**, Walsh K, Bhatnagar N, Guyatt GH. Quality of care in for-profit and not-for-profit nursing homes: systematic review and meta-analysis. *BMJ* 339 - ,2009.
188. Schünemann HJ. Integrative assessment of evidence in healthcare: the GRADE system. *Z Evid Fortbild Qual Gesundheitswes.* 2009.; 103 (5):261-8.
189. Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, **Schünemann H**, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). *Trials.* 6; 10:49 2009.
190. Costa DJ, Bousquet PJ, Ryan D, Price D, Demoly P, Brozek J, **Schünemann HJ**, Bousquet J. Guidelines for allergic rhinitis need to be used in primary care. *Prim Care Respir J.* 18(4):250-7, 2009.
191. Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, Calderon M, Canonica GW, Compalati E, Daures JP, Delgado L, Demoly P, Dahl R, Durham SR, Kowalski ML, Malling HJ, Merk H, Papadopoulos N, Passalacqua G, Simon HU, Worms M, Wahn U, Zuberbier T, **Schünemann HJ**, Bousquet J. The CONSORT statement checklist in allergen-specific immunotherapy - A GA2LEN paper. *Journal of Allergy.* 64(12):1737-45, 2009.
192. Akl EA, Pretorius RW, Sackett K, Erdley WS, Bhoopathi PS, Alfaarah Z, **Schünemann HJ**. The effect of educational games on medical students' learning outcomes: a systematic review. *BEME Guide No 14. Med Tech.* 32 (1):16-27, 2010.
193. **Schünemann HJ**, Sperati F, Barba M, Santesso N, Melegari C, Akl EA, Guyatt G, Muti P. An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation. *Health Qual Life Outcomes.* 8: 26, 2010.

194. Akl EA, Gunukula S, Mustafa R, Wilson MC, Symons A, Moheet A, **Schünemann HJ**. Support for and aspects of use of educational games in family medicine and internal medicine residency programs in the US: a survey. *BMC Med Educ.* 10: 26, 2010.
195. Alfarah Z, **Schünemann HJ**, Akl EA. Educational games in geriatric medicine education: a systematic review. *BMC Geriatr.* 10:19, 2010.
196. Carling CL, Kristoffersen DT, Oxman AD, Flottorp S, Fretheim A, **Schünemann HJ**, Akl EA, Herrin J, MacKenzie TD, Montori VM. The effect of how outcomes are framed on decisions about whether to take antihypertensive medication: a randomized trial. *PLoS One* 1;5(3):e9469, 2010.
197. Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, Grioni S, Sempos CT, Cavalleri A, **Schünemann HJ**, Strano S, Muti P. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. *Cancer Epidemiol Biomarkers Prev.* 19(3):729-37, 2010.
198. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH; STOPIT-2 Study Group: Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, **Schünemann H**, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA.* 303(12):1180-7, 2010.
199. **Schünemann HJ**, Hill S, Guyatt G, Akl E, Ahmed F. The GRADE approach and Bradford Hill's criteria for causation. *Journal of Epidemiology and Community Health.* 65:5; 392-395, 2011.
200. Raad D, Gaddam S, **Schünemann HJ**, Irani J, Abou Jaoude P, Honeine R, Akl EA. Effects of waterpipe tobacco smoking on lung function: a systematic review and meta-analysis. *Chest.* 139:4; 764-774, 2011 .
201. Ibarгойen-Roteta N, Gutiérrrez-Ibarluzea I, Rico-Iturrioz R, López-Argumedo M, Reviriego-Rodrigo E, Cabriada-Nuño JL, **Schünemann HJ**. The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. *Implement Sci.* 16;5:48, 2010.
202. Guyatt G, Akl EA, Hirsh J, Kearon C, Crowther M, Gutterman D, Lewis SZ, Nathanson I, Jaeschke R, **Schünemann HJ**. The vexing problem of guidelines and conflict of interest: a potential solution. *Ann Intern Med* 152(11):738-41, 2010.
203. Kunz R, Wegscheider K, Fritsche L, **Schünemann HJ**, Moyer V, Miller D, Boluyt N, Falck-Ytter Y, Griffiths P, Bucher HC, Timmer A, Meyerrose J, Witt K, Dawes M, Greenhalgh T, Guyatt GH. Determinants of knowledge gain in evidence-based medicine short courses: an international

- assessment. *Open Med.* 4(1):e3-e10, 2010.
204. Terracciano L, Brozek J, Compalati E, **Schünemann HJ**. GRADE system: new paradigm. *Curr Opin Allergy Clin Immunol* 10(4):377-83, 2010.
205. Charles LE, Burchfiel CM, Mnatsakanova A, Fekedulegn D, Tinney-Zara C, Joseph PN, **Schünemann HJ**, Violanti JM, Andrew ME, Ochs-Balcom HM. Antioxidants and pulmonary function among police officers. *Journal Occupational Environmental Medicine* 52(11):1124-31, 2010.
206. Turner D, **Schünemann HJ**, Griffith LE, Beaton DE, Griffiths AM, Critch JN, Guyatt GH. The minimal detectable change cannot reliably replace the minimal important difference. *J Clin Epidemiol.* 63(1):28-36, 2010.
207. Johnston BC, Thorlund K, **Schünemann HJ**, Xie F, Murad MH, Montori VM, Guyatt GH. Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units. *Health Qual Life Outcomes.* 8:116, 2010.
208. Bousquet J, **Schünemann HJ**, Zuberbier T, Bachert C, Baena-Cagnani CE, Bousquet PJ, Brozek J, Canonica GW, Casale TB, Demoly P, Gerth van Wijk R, Ohta K, Bateman ED, Calderon M, Cruz AA, Dolen WK, Haughney J, Lockey RF, Lötvall J, O'Byrne P, Spranger O, Togias A, Bonini S, Boulet LP, Camargos P, Carlsen KH, Chavannes NH, Delgado L, Durham SR, Fokkens WJ, Fonseca J, Haahtela T, Kalayci O, Kowalski ML, Larenas-Linnemann D, Li J, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Papadopoulos N, Passalacqua G, Rabe KF, Pawankar R, Ryan D, Samolinski B, Simons FE, Valovirta E, Yorgancioglu A, Yusuf OM, Agache I, Ait-Khaled N, Annesi-Maesano I, Beghe B, Ben Kheder A, Blaiss MS, Boakye DA, Bouchard J, Burney PG, Busse WW, Chan-Yeung M, Chen Y, Chuchalin AG, Costa DJ, Custovic A, Dahl R, Denburg J, Douagui H, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Kaliner MA, Keith PK, Kim YY, Klossek JM, Kuna P, Le LT, Lemiere C, Lipworth B, Mahboub B, Malo JL, Marshall GD, Mavale-Manuel S, Meltzer EO, Morais-Almeida M, Motala C, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Ouedraogo S, Palkonen S, Popov TA, Price D, Rosado-Pinto J, Scadding GK, Sooronbaev TM, Stoloff SW, Toskala E, van Cauwenberge P, Vandenplas O, van Weel C, Viegi G, Virchow JC, Wang DY, Wickman M, Williams D, Yawn BP, Zar HJ, Zernotti M, Zhong N; In collaboration with the WHO Collaborating Center of Asthma and Rhinitis (Montpellier). Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. *Allergy* 65(10):1212-21, 2010.
209. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, **Schünemann HJ**; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol* 126(3):466-76, 2010.
210. Fiocchi A, Brozek J, **Schünemann H**, Bahna SL, von Berg A, Beyer K, Bozzola M, Bradsher J, Compalati E, Ebisawa M, Guzmán MA, Li H, Heine RG, Keith P, Lack G, Landi M, Martelli A, Rancé F, Sampson H, Stein A, Terracciano L, Vieths S; World Allergy Organization (WAO) Special

- Committee on Food Allergy. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. *Pediatr Allergy Immunol.* 21 Suppl 21:1-125, 2010. & World Allergy Organization Journal. 3(4):57-161, 2010.
211. Alonso-Coello P, Irfan A, Solà I, Gich I, Delgado-Noguera M, Rigau D, Tort S, Bonfill X, Burgers J, **Schünemann HJ**. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. *Quality and Safety in Health Care* 19(6):e58, 2010.
212. Fiocchi A, **Schünemann HJ**, Brozek J, Restani P, Beyer K, Troncone R, Martelli A, Terracciano L, Bahna SL, Rancé F, Ebisawa M, Heine RG, Assa'ad A, Sampson H, Verduci E, Bouygue GR, Baena-Cagnani C, Canonica W, Lockey RF. Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. *J Allergy Clin Immunol.* 126(6):1119-28, 2010.
213. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, Petrillo J, Powers J, Sethi S; EXACT-PRO Study Group **** . Development of the EXacerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. *Value Health.* 13(8):965-75, 2010.
214. Wilson K, **Schünemann H**. An appraisal of the Evidence Underlying Performance Measures for community-Acquired Pneumonia. *The American Journal of Respiratory and Critical Care Medicine.* 183(11):1454-62, 2011.
215. Brunetti M, Pregno S, **Schünemann H**, Plebani M, Trenti T. Economic evidence in decision making process in laboratory medicine. *Clin Chem Lab Med.* 49(4):617-21, 2011.
216. Kessler T, Backmann L, Minder C, Lohrer D, Umbehre M, **Schunemann H**, Kessels A. Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic approach. *PLoS ONE.* 6(2): e16718, 2011.
217. Levy M, Heels-Ansdell D, Hiralal R, Bhandari M, Guyatt G, Yusuf S, Cook D, Villar JC, McQueen M, McFalls E, Filipovic M, **Schünemann H**, Sear J, Foex P, Lim W, Landesberg G, Godet G, Poldermans D, Bursi F, Kertai M, Bhatnagar N, Devereaux, PJ. Prognostic Value of Troponin and Creatine Kinase Muscle and Brain Isoenzyme Measurement after noncardiac Surgery: A Systematic Review and Meta-analysis. *Anesthesiology.* 114(4):796-806, 2011.
218. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, Debeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, **Schünemann HJ**. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol.* 64(4):383-94, 2011.
219. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, **Schunemann HJ**. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol.* 64(4):395-400, 2011.
220. Guyatt GH, Oxman AD, **Schünemann HJ**, Tugwell P, Knottnerus A.

- GRADE guidelines: A new series of articles in the J Clin Epidemiology. *J Clin Epidemiol.* 64(4):380-2, 2011.
221. Balshem H, Helfand M, **Schunemann HJ**, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines 3: rating the quality of evidence-introduction. *J Clin Epidemiol.* 64(4):401-6, 2011.
222. Bousquet PJ, Calderón MA, Demoly P, Larenas D, Passalacqua G, Bachert C, Brozek J, Canonica GW, Casale T, Fonseca J, Dahl R, Durham SR, Merk H, Worm M, Wahn U, Zuberbier T, **Schünemann HJ**, Bousquet J. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA(2)LEN) article. *J Allergy Clin Immunol.* 127(1):49-56.e11, 2011.
223. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris S, Williams JW Jr. Atkins D, Meerpohl J, **Schunemann HJ**. GRADE guidelines: 4 Rating the quality of evidence-study limitations (risk of bias) and publication bias. *J Clin Epidemiol.* 64(4):407-15, 2011.
224. Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, Ueffing E, Andrews J, Alonso-Coello P, Meerpohl JJ, Lang DM, Jaeschke R, Williams JW Jr., Phillipa B, Lethaby A, Bossuyt P, Glasziou P, Helfand M, Watine J, Afilalo M, Welch V, Montedori A, Abraha I, Horvath AR, Bousquet J, Guyatt GH, **Schünemann HJ**: for the Grade Working Group, Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations. *Allergy.* 66 (5): 588–595. 2011.
225. Akl EA, Barba M, Yosuico VE, van Doormaal FF, Kuipers S, Middeldorp S, Dickinson HO, Bryant A, **Schünemann H**. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev.* 19;1:CD006652, 2011.
226. Vigil L, Güell MR, Morante F, López De Santamaría E, Sperati F, Guyatt G, **Schünemann H**. The Validity and Sensitivity to Change of the Spanish Self-Administered Version of the Chronic Respiratory Questionnaire (CRQ-SAS). *Arch Bronconeumol.* 47(7):343-9, 2011.
227. Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, **Schünemann H**, Briel M, Nordmann AJ, Pregno S, Oxman AD. Randomisation to protect against selection bias in healthcare trials. *Cochrane Database Syst Rev.* 13;4:MR000012. Review, 2011.
228. Akl EA, Gunukula S, Barba M, Yosuico VE, van Doormaal FF, Kuipers S, Middeldorp S, Dickinson HO, Bryant A, **Schünemann H**. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev.* 13;4:CD006652. Review, 2011.
229. Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, Muti P, **Schünemann H**. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev.*

- 13;4:CD006649. Review, 2011.
230. Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Sperati F, Cook D, **Schünemann H**. Anticoagulation for patients with cancer and central venous catheters. *Cochrane Database Syst Rev.* 13;4:CD006468. Review, 2011.
231. Brožek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, **Schünemann HJ**. Reply. *J Allergy Clin Immunol.* 127(6):1643-5, 2011.
232. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, **Schünemann HJ**; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 183(6):788-824, 2011.
233. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, **Schünemann HJ**, Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. *Int J Cancer.* 130 (4): 921–929, 2012.
234. Akl EA, Oxman AD, Herrin J, Vist GE, Terrenato I, Sperati F, Costiniuk C, Blank D, **Schünemann H**. Using alternative statistical formats for presenting risks and risk reductions. *Cochrane Database Syst Rev.* 3:CD006776, 2011.
235. **Schünemann HJ**. Guidelines 2.0: do no net harm-the future of practice guideline development in asthma and other diseases. *Curr Allergy Asthma Rep.* 11(3):261-8, 2011.
236. Akl EA, Gaddam S, Mustafa R, Wilson MC, Symons A, Grifasi A, McGuigan D, **Schünemann HJ**. The effects of tracking responses and the day of mailing on physician survey response rate: three randomized trials. *PLoS One.* 6(2):e16942, 2011.
237. Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Sperati F, Cook D, **Schünemann H**. Anticoagulation for patients with cancer and central venous catheters. *Cochrane Database Syst Rev.* 2011 Feb 16;2:CD006468. Review. Update in: *Cochrane Database Syst Rev.* 4:CD006468, 2011.
238. Qaseem A⁺, Humphrey LL, Chou R, Snow V, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. (member of ACP Clinical Practice Guideline Committee). *Ann Intern Med.* 154(4):260-7, 2011.
239. Chou R⁺, Qaseem A, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Diagnostic imaging for low back pain: advice for high-value health care from the American College

- of Physicians. (member of ACP Clinical Practice Guideline Committee. *Ann Intern Med.*;154(3):181-9, 2011.
240. Owens DK⁺, Qaseem A, Chou R, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. (member of ACP Clinical Practice Guideline Committee). *Ann Intern Med.* 154(3):174-80, 2011.
241. Costa DJ, Amouyal M, Lambert P, Ryan D, **Schünemann HJ**, Daures JP, Bousquet J, Bousquet PJ; Languedoc-Roussillon Teaching General Practitioners Group. How representative are clinical study patients with allergic rhinitis in primary care? *J Allergy Clin Immunol.* 127(4):920-6.e1, 2011.
242. Hsu J[^], Brozek J, Terraciano L, Kreis J, Compalati E, Stein A, Fiocchi A, **Schünemann J**. Application of GRADE: Making Evidence-Based Recommendations about Diagnostic Tests in Clinical Practice Guidelines. *Implementation Science.* 6:62, 2011.
243. Jones PW, Chen WH, Wilcox TK, Sethi S, Leidy NK; EXACT-PRO Study Group.**** Characterizing and quantifying the symptomatic features of COPD exacerbations.*Chest.* 139(6):1388-94, 2011.
244. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. **** Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary.*Am J Respir Crit Care Med.*183(3):323-9, 2011.
245. Ahmed F, Temte JL, Campos-Outcalt D, **Schünemann HJ**; for the ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). *Vaccine.* 29(49):9171-6, 2011.
246. Di Giuseppe R, Arcari A, Serafini M, Di Castelnuovo A, Zito F, De Curtis A, Sieri S, Krogh V, Pellegrini N, **Schünemann HJ**, Donati MB, de Gaetano G, Iacoviello L. Total dietary antioxidant capacity and lung function in an Italian population: a favorable role in premenopausal/never smoker women. *Eur J Clin Nutr.* 66(1): 61 – 8, 2012.
247. Bousquet J, **Schünemann HJ**, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen KH, Malling HJ, Passalacqua G, Simons FE, Anto J, Baena-Cagnani CE, Bergmann KC, Bieber T, Briggs AH, Brozek J, Calderon MA, Dahl R, Devillier P, Gerth van Wijk R, Howarth P, Larenas D, Papadopoulos NG, Schmid-Grendelmeier P, Zuberbier T. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. *Allergy* 66(6):765-74, 2011.
248. Santimone I, Di Castelnuovo A, De Curtis A, Spinelli M, Cugino D, Gianfagna F, Zito F, Donati MB, Cerletti C, de Gaetano G, Iacoviello L; MOLI-SANI Project Investigators*****. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. *Haematologica.*

- 96(8):1180-8, 2011..
249. Akl EA, Vasireddi SR, Gunukula S, Yosucio VE, Barba M, Terrenato I, Sperati F, **Schünemann H**. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev*. 15;(6), 2011.
250. Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, Roca J, Agusti A, Brightling C, Cambon-Thomsen A, Cesario A, Abdelhak S, Antonarakis SE, Avignon A, Ballabio A, Baraldi E, Baranov A, Bieber T, Bockaert J, Brahmachari S, Brambilla C, Bringer J, Dauzat M, Ernberg I, Fabbri L, Froguel P, Galas D, Gojobori T, Hunter P, Jorgensen C, Kauffmann F, Kourilsky P, Kowalski ML, Lancet D, Pen CL, Mallet J, Mayosi B, Mercier J, Metspalu A, Nadeau JH, Ninot G, Noble D, Oztürk M, Palkonen S, Préfaut C, Rabe K, Renard E, Roberts RG, Samolinski B, **Schünemann HJ**, Simon HU, Soares MB, Superti-Furga G, Tegner J, Verjovski-Almeida S, Wellstead P, Wolkenhauer O, Wouters E, Balling R, Brookes AJ, Charron D, Pison C, Chen Z, Hood L, Auffray C. Systems medicine and integrated care to combat chronic noncommunicable diseases. *Genome Med*. 3(7):43, 2011.
251. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, Atkins D, Kunz R, Brozek J, Montori V, Jaeschke R, Rind D, Dahm P, Meerpohl J, Vist G, Berliner E, Norris S, Falck-Ytter Y, Murad MH, **Schünemann HJ**; GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol*. 64(12):1311-6, 2011.
252. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl J, Shukla VK, Nasser M, **Schünemann HJ**; GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence--indirectness. *J Clin Epidemiol*. 64(12):1303-10, 2011.
253. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, Alonso-Coello P, Djulbegovic B, Atkins D, Falck-Ytter Y, Williams JW Jr, Meerpohl J, Norris SL, Akl EA, **Schünemann HJ**. GRADE guidelines: 5. Rating the quality of evidence--publication bias. *J Clin Epidemiol*. 64(12):1277-82, 2011.
254. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Glasziou P, Jaeschke R, Akl EA, Norris S, Vist G, Dahm P, Shukla VK, Higgins J, Falck-Ytter Y, **Schünemann HJ**; GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol*. 64(12):1294-302, 2011.
255. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, **Schünemann H**, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med*. 2;155(3):179-9, 2011.

256. Akl EA, Oxman AD, Herrin J, Vist GE, Terrenato I, Sperati F, Costiniuk C, Blank D, **Schünemann H**. Framing of health information messages. *Cochrane Database Syst Rev* (12):CD006777. Review, 2011.
257. Akl EA, Guyatt GH, Irani J, Feldstein D, Wasi P, Shaw E, Shaneyfelt T, Levine M, **Schünemann HJ**. "Might" or "suggest"? No wording approach was clearly superior in conveying the strength of recommendation. *J Clin Epidemiol*. 65(3):268-75, 2012
258. Fiocchi A, **Schunemann H**, Terracciano L, Albarini M, Martelli A, Landi M, Compalati E, Canonica GW. DRACMA one year after: which changes have occurred in diagnosis and treatment of CMA in Italy? *Ital J Pediatr.*;37:53, 2011.
259. Akl EA, Labedi N, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, Cook D, **Schünemann H**. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. *Cochrane Database Syst Rev.*;11:CD009447, 2011.
260. Lloyd NS, Douketis JD, Cheng J, **Schünemann HJ**, Cook DJ, Thabane L, Pai M, Spencer FA, Haynes RB. Barriers and potential solutions toward optimal prophylaxis against deep vein thrombosis for hospitalized medical patients: A survey of healthcare professionals. *J Hosp Med*. 7(1) 28 – 34, 2012.
261. Dainiak N, Gent RN, Carr Z, Schneider R, Bader J, Buglova E, Chao N, Coleman CN, Ganser A, Gorin C, Hauer-Jensen M, Huff LA, Lillis-Hearne P, Maekawa K, Nemhauser J, Powles R, **Schünemann H**, Shapiro A, Stenke L, Valverde N, Weinstock D, White D, Albanese J, Meineke V. First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. *Disaster Med Public Health Prep*. 5(3):202-12, 2011.
262. Dainiak N, Gent RN, Carr Z, Schneider R, Bader J, Buglova E, Chao N, Coleman CN, Ganser A, Gorin C, Hauer-Jensen M, Huff LA, Lillis-Hearne P, Maekawa K, Nemhauser J, Powles R, **Schünemann H**, Shapiro A, Stenke L, Valverde N, Weinstock D, White D, Albanese J, Meineke V. Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. *Disaster Med Public Health Prep*. 5(3):183-201, 2011.
263. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, **Schünemann HJ**. GRADE guidelines 6. Rating the quality of evidence--imprecision. *J Clin Epidemiol*. 64(12):1283-93, 2011.
264. Falzon D, Jaramillo E, **Schünemann HJ**, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsck-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO guidelines for the programmatic

- management of drug-resistant tuberculosis: 2011 update. *Eur Respir J*. 38(3):516-28, 2011.
265. Brouwers MC, Garcia K, Makarski J, Daraz L, Evidence Expert Panel; KT for Cancer Control in Canada Project Research Team.*****. The landscape of knowledge translation interventions in cancer control: What do we know and where to next? A review of systematic reviews. *Implementation Science*. 6:130, 2011.
266. Brozek J, Terracciano L, Hsu J, Kreis J, Compalati E, Santesso N, Fiocchi A, **Schünemann H**. Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis. *Clinical and Experimental Allergy* 42(3):363-74, 2012.
267. Akl EA, Briel M, You JJ, Sun X, Johnston BC, Busse JW, Mulla S, Lamontagne F, Bassler D, Vera C, Alshurafa M, Katsios CM, Zhou Q, Cukierman-Yaffe T, Gangji A, Mills EJ, Walter SD, Cook DJ, **Schünemann HJ**, Altman DG, Guyatt GH. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. *BMJ*. 344:e2809, 2012.
268. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, Djulbecovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, **Schünemann HJ**. GRADE guidelines 12. Preparing Summary of Findings tables-binary outcomes. *J Clin Epidemiol*. 66; (2): 158 – 72, 2013.
269. Arcari A, Magnacca S, Bracone F, Costanzo S, Persichillo M, Di Castelnuovo A, de Curtis A, Zito F, **Schünemann HJ**, Donati MB, de Gaetano G, Iacoviello L. Relation between pulmonary function and 10-year risk for cardiovascular disease among healthy men and women in Italy: the Moli-sani Project. *Eur J Prev Cardiol*. May 18, 2012.
270. Vandvik PO, Santesso N, Akl EA, You J, Mulla S, Spencer FA, Johnston BC, Brozek J, Kreis J, Brandt L, Zhou Q, **Schunemann H**, Guyatt G. Formatting modifications in GRADE evidence profiles improved guideline panelists comprehension and accessibility to information. A randomized trial. *J Clin Epidemiol*. 65(7): 748-55, 2012
271. Yorgancıoğlu A, Ozdemir C, Kalaycı O, Kalyocu AF, Bachert C, Baena-Cagnani CE, Casale TB, Chen YZ, Cruz AA, Demoly P, Fokkens WJ, Lodrup Carlsen KC, Mohammad Y, Mullol J, Ohta K, Papadopoulos NG, Pawankar R, Samolinski B, **Schünemann HJ**, Yusuf OM, Zuberbier T, Bousquet J. ARIA (Allergic rhinitis and its impact on asthma) Achievements in 10 years and future needs. *Turkish. Tuberk Toraks*. 60(1):92-7. 2012.
272. Terracciano L, **Schünemann H**, Brozek J, Agostoni C, Fiocchi A; on behalf of the DRACMA Implementation Committee, World Allergy Organisation. How DRACMA changes clinical decision for the individual patient in CMA therapy. *Curr Opin Allergy Clin Immunol*. 12(3):316-322, 2012.
273. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, Atkins D, Kunz R, Montori V, Jaeschke R, Rind D, Dahm P, Akl EA, Meerpohl J, Vist G, Berliner E, Norris S, Falck-Ytter Y, **Schünemann HJ**. GRADE guidelines 11-making an overall rating of confidence in effect

- estimates for a single outcome and for all outcomes. *J Clin Epidemiol.* 66; (2): 151 – 7,2012.
274. Santesso N[^], Akl EA, Bianchi M, Mente A, Mustafa R, Heels-Ansdell D, **Schünemann HJ**. Effects of higher- versus lower-protein diets on health outcomes: a systematic review and meta-analysis. *Eur J Clin Nutr.* Jul;66(7):780-8, 2012.
275. Norris SL, Burda BU, Holmer HK, Ogden LA, Fu R, Bero L, **Schünemann H**, Deyo R. Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. *J Clin Epidemiol.* Jul;65(7):725-33, 2012.
276. Qaseem A⁺, Denberg TD, Hopkins RH Jr, Humphrey LL, Levine J, Sweet DE, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for colorectal cancer: a guidance statement from the American College of Physicians. *Ann Intern Med.*;156(5):378-86, 2012.
277. Kreis J, Puhan MA, **Schünemann HJ**, Dickersin K. Consumer involvement in systematic reviews of comparative effectiveness research. *Health Expect.* 03/2012.
278. In collaboration with the WHO Collaborating Center for Asthma and Rhinitis. Severe Chronic Allergic (and Related) Diseases: A Uniform Approach - A MeDALL - GA(2)LEN - ARIA Position Paper. *Int Arch Allergy Immunol.* 158(3):216-231, 2012.
279. Hsu J[^], Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, Cheung A, Hovhannisyan G, Ivanova L, Flottorp SA, Saeterdal I, Wong AD, Tian J, Uyeki TM, Akl EA, Alonso-Coello P, Smaill F, **Schünemann HJ**. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. *Ann Intern Med.* Apr 3;156(7):512-24. 2012. Review
280. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, **Schunemann HJ**, Crowther M, Pauker SG, Makdissi R, Guyatt GH; American College of Chest Physicians. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 141(2 Suppl):e351S-418S, 2012.
281. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS, Lewis SZ, Gutterman DD, Cook DJ, **Schünemann HJ**; American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 141(2 Suppl):53S-70S, 2012.
282. Guyatt GH, Akl EA, Crowther M, **Schünemann HJ**, Gutterman DD, Zelman Lewis S; American College of Chest Physicians. Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 141(2 Suppl):48S-52S, 2012.
283. van der Weijden T, Boivin A, Burgers J, **Schünemann HJ**, Elwyn G. Clinical practice guidelines and patient decision aids. An inevitable

- relationship. *J Clin Epidemiol*. 65(6):584-9, 2012.
284. Matysiak-Klose D, Ahmed F, Duclos P, Falck-Ytter Y, Forland F, Houweling H, Kramarz P, Langley JM, Mertens T, **Schünemann H**, Senouci K, Temte J, Wichmann O. Report on the 1st international workshop on procedures for the development of evidence-based vaccination recommendations, Berlin, Germany. *Vaccine*. 30(14):2399-404, 2012.
285. Akl E, Kennedy C, Konda KCaceresC, Horvath T, Ayala G, Doupe A, Gerbase A, Wiysonge C, Segura E, **Schünemann H**, Lo YR. Using GRADE methodology for the development of public health guidelines for the prevention and treatment of HIV and other STIs among men who have sex with men and transgender people. *BMC Public Health*. 12(1):386, 2012.
286. Eccles M, Grimshaw J, Shekelle P, **Schünemann H**, Woolf S. Developing Clinical Practice Guidelines: Target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest. *Implementation Science*. Jul 4;7(1):60, 2012.
287. Woolf S, **Schünemann H**, Eccles M, Grimshaw J, Shekelle P. Developing Clinical Practice Guidelines: Types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations. *Implementation Science*. Jul 4;7:61, 2012.
288. Shekelle P, Woolf S, Grimshaw J, **Schünemann H**, Eccles M. Developing Clinical Practice Guidelines: Reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline development. *Implementation Science*. Jul 4;7(1):62, 2012.
289. Mills E, Ioannidis J, Thorlund K, **Schünemann H**, Puhan M, Guyatt G. How to use an article reporting a multiple treatment comparison meta-analysis. *JAMA*. 308 (12) 1246 – 1253, 2012.
290. Bousquet J, **Schünemann HJ**, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, Bonini S, Boulet LP, Bousquet PJ, Brozek JL, Canonica GW, Casale TB, Cruz AA, Fokkens WJ, Fonseca JA, Gerth van Wijk R, Grouse L, Haahtela T, Khaltayev N, Kuna P, Lockey RF, Lodrup Carlsen KC, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Palkonen S, Papadopoulos NG, Passalacqua G, Pawankar R, Price D, Ryan D, Simons FE, Togias A, Williams D, Yorgancioglu A, Yusuf OM, Aberer W, Adachi M, Agache I, Aït-Khaled N, Akdis CA, Andrianarisoa A, Annesi-Maesano I, Ansotegui IJ, Baiardini I, Bateman ED, Bedbrook A, Beghé B, Beji M, Bel EH, Ben Kheder A, Bennoor KS, Bergmann KC, Berrissoul F, Bieber T, Bindeslev Jensen C, Blaiss MS, Boner AL, Bouchard J, Braido F, Brightling CE, Bush A, Caballero F, Calderon MA, Calvo MA, Camargos PA, Caraballo LR, Carlsen KH, Carr W, Cepeda AM, Cesario A, Chavannes NH, Chen YZ, Chiriac AM, Chivato Pérez T, Chkhartishvili E, Ciprandi G, Costa DJ, Cox L, Custovic A, Dahl R, Darsow U, De Blay F, Deleanu D, Denburg JA, Devillier P, Didi T, Dokic D, Dolen WK, Douagui H, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, El-Meziane A, Emuzyte R, Fiocchi A, Fletcher M, Fukuda T, Gamkrelidze A, Gereda JE, Diaz SG, Gotua M, Guzmán MA, Hellings PW, Hellquist-Dahl B, Horak F, O'B Hourihane J,

- Howarth P, Humbert M, Ivancevich JC, Jackson C, Just J, Kalayci O, Kaliner MA, Kalyoncu AF, Keil T, Keith PK, Khayat G, Kim YY, Koffi N'goran B, Koppelman GH, Kowalski ML, Kull I, Kvedariene V, Larenas-Linnemann D, Le LT, Lemièrre C, Li J, Lieberman P, Lipworth B, Mahboub B, Makela MJ, Martin F, Marshall GD, Martinez FD, Masjedi MR, Maurer M, Mavale-Manuel S, Mazon A, Melen E, Meltzer EO, Mendez NH, Merk H, Mihaltan F, Mohammad Y, Morais-Almeida M, Muraro A, Nafti S, Namazova-Baranova L, Nekam K, Neou A, Niggemann B, Nizankowska-Mogilnicka E, Nyembue TD, Okamoto Y, Okubo K, Orru MP, Ouedraogo S, Ozdemir C, Panzner P, Pali-Schöll I, Park HS, Pigearias B, Pohl W, Popov TA, Postma DS, Potter P, Rabe KF, Ratomaharo J, Reitamo S, Ring J, Roberts R, Rogala B, Romano A, Roman Rodriguez M, Rosado-Pinto J, Rosenwasser L, Rottem M, Sanchez-Borges M, Scadding GK, Schmid-Grendelmeier P, Sheikh A, Sisul JC, Solé D, Sooronbaev T, Spicak V, Spranger O, Stein RT, Stoloff SW, Sunyer J, Szczeklik A, Todo-Bom A, Toskala E, Tremblay Y, Valenta R, Valero AL, Valeyre D, Valiulis A, Valovirta E, Van Cauwenberge P, Vandenplas O, van Weel C, Vichyanond P, Viegi G, Wang DY, Wickman M, Wöhrl S, Wright J, Yawn BP, Yiallourous PK, Zar HJ, Zernotti ME, Zhong N, Zidarn M, Zuberbier T; in collaboration with the World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. *J Allergy Clin Immunol.* 130 (5): 1049 – 62, 2012.
291. Guyatt GH, Oxman AD, **Schünemann HJ**. GRADE guidelines-an introduction to the 10th-13th articles in the series. *J Clin Epidemiol.* 66 (2): 121 – 3. 2013.
292. Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, Sisk J, Ruiz F, Hill S, Guyatt GH, Jaeschke R, Helfand M, Harbour R, Davoli M, Amato L, Liberati A, **Schünemann HJ**. Grade guidelines: 10. Considering resource use and rating the quality of economic evidence. *J Clin Epidemiol.* 66 (2): 140 – 50. 2013.
293. Meerpohl JJ, Langer G, Perleth M, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann H**. [GRADE guidelines: 4. Rating the quality of evidence - limitations of clinical trials (risk of bias)]. *Z Evid Fortbild Qual Gesundheitsw.* 106(6):457-69, 2012.#
294. Meerpohl JJ, Langer G, Perleth M, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann H**. [GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect)]. *Z Evid Fortbild Qual Gesundheitsw.* 106(6):449-56, 2012. #
295. Langer G, Meerpohl JJ, Perleth M, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann H**. [GRADE guidelines: 2. Framing the question and deciding on important outcomes]. *Z Evid Fortbild Qual Gesundheitsw.* 106(5):369-76, 2012.#
296. Langer G, Meerpohl JJ, Perleth M, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann H**. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables]. *Z Evid Fortbild Qual Gesundheitsw.* 106(5):357-68, 2012.#

297. Santesso N[^], **Schünemann H** (corresponding author), Blumenthal P, De Vuyst H, Gage J, Garcia F, Jeronimo J, Lu R, Luciani S, Quek SC, Awad T, Broutet N; World Health Organization Steering Committee for Recommendations on Use of Cryotherapy for Cervical Cancer Prevention. World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia. *Int J Gynaecol Obstet.* 118(2):97-102, 2012.
298. **Schünemann HJ**, Mustafa R, Brozek J. Diagnostic accuracy and linked evidence--testing the chain. *Z Evid Fortbild Qual Gesundheitswes.* 106(3):153-60, 2012.
299. Akl EA, Meerpohl JJ, Raad D, Piaggio G, Mattioni M, Paggi MG, Gurtner A, Mattarocci S, Tahir R, Muti P, **Schünemann HJ**. Effects of assessing the productivity of faculty in academic medical centres: a systematic review. *CMAJ.* 184(11):E602-12, 2012.
300. Akl EA, **Schünemann HJ**. Routine heparin for patients with cancer? One answer, more questions. *N Engl J Med.* 16;366(7):661-2, 2012.
301. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R, Brozek J, Vist G, Rind D, Akl EA, **Schünemann HJ**. GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol.* S0895-4356 (12) 00138-2. 2013.
302. Treweek S, Oxman AD, Alderson P, Bossuyt PM, Brandt L, Brozek J, Davoli M, Flottorp S, Harbour R, Hill S, Liberati A, Liira H, **Schünemann HJ**, Rosenbaum S, Thornton J, Vandvik PO, Alonso-Coello P; DECIDE Consortium. Developing and evaluating communication strategies to support informed decisions and practice based on evidence (DECIDE): protocol and preliminary results. *Implement Sci.* 9;8:6. 2013.
303. Yang K, Chen Y, **Schünemann HJ**; Members of the Lanzhou International Guideline Symposium. Editorial: can China master the guideline challenge? *Health Res Policy Syst.* 9;11(1):1. 2013.
304. Pai M, Lloyd NS, Cheng J, Thabane L, Spencer FA, Cook DJ, Haynes RB, **Schünemann HJ**, Douketis JD. Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. *Implement Sci.* 2;8:1.2013.
305. Grimshaw JM, **Schünemann HJ**, Burgers J, Cruz AA, Heffner J, Metersky M, Cook D; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Disseminating and Implementing Guidelines: Article 13 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. *Proc Am Thorac Soc.* 9(5):298-303. 2012.
306. **Schünemann HJ**, Oxman AD, Akl EA, Brozek JL, Montori VM, Heffner J, Hill S, Woodhead M, Campos-Outcalt D, Alderson P, Woitalla T, Puhan MA, Falck-Ytter Y, Bousquet J, Guyatt G; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Moving from Evidence to Developing Recommendations in Guidelines: Article 11 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. *Proc Am*

- Thorac Soc. 9(5):282-292. 2012.
307. Fabbri LM, Boyd C, Boschetto P, Rabe KF, Buist AS, Yawn B, Leff B, Kent DM, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. How to Integrate Multiple Comorbidities in Guideline Development: Article 10 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):274-281. 2012.
 308. Cluzeau F, Wedzicha JA, Kelson M, Corn J, Kunz R, Walsh J, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. stakeholder Involvement: How to Do It Right: Article 9 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):269-273. 2012.
 309. Kelson M, Akl EA, Bastian H, Cluzeau F, Curtis JR, Guyatt G, Montori VM, Oliver S, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Integrating Values and Consumer Involvement in Guidelines with the Patient at the Center: Article 8 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):262-268. 2012.
 310. Guyatt G, Akl EA, Oxman A, Wilson K, Puhan MA, Wilt T, Gutterman D, Woodhead M, Antman EM, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Synthesis, Grading, and Presentation of Evidence in Guidelines: Article 7 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):256-261. 2012.
 311. Hill SR, Olson LG, Falck-Ytter Y, Cruz AA, Atkins D, Baumann M, Jaeschke R, Woitalla T, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Incorporating Considerations of Cost-Effectiveness, Affordability, and Resource Implications in Guideline Development: Article 6 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):251-255. 2012.
 312. Wilt TJ, Guyatt G, Kunz R, Macnee W, Puhan MA, Viegli G, Woodhead M, Akl EA, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Deciding What Type of Evidence and Outcomes to Include in Guidelines: Article 5 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):243-250. 2012.
 313. Boyd EA, Akl EA, Baumann M, Curtis JR, Field MJ, Jaeschke R, Osborne M, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Guideline Funding and Conflicts of Interest: Article 4 in Integrating and

- Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):234-242. 2012.
314. Kunz R, Fretheim A, Cluzeau F, Wilt TJ, Qaseem A, Lelgemann M, Kelson M, Guyatt G, **Schünemann HJ**; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Guideline Group Composition and Group Processes: Article 3 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 9(5):229-233. 2012.
315. **Schünemann HJ**, Woodhead M, Anzueto A, Buist AS, Macnee W, Rabe KF, Heffner J; on behalf of the ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. A Guide to Guidelines for Professional Societies and Other Developers of Recommendations: Introduction to Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc.(5):215-218. 2012.
316. Bonini M, Bachert C, Baena-Cagnani CE, Bedbrook A, Brozek JL, Canonica GW, Cruz AA, Fokkens WJ, Gerth van Wijk R, Grouse L, Hellings PW, Howarth P, Kalayci O, Khaltaev N, Kuna P, Larenas Linnemann D, Nekam K, Palkonen S, Papadopoulos NG, Popov TA, Price D, Rosado Pinto J, Rasi G, Ryan D, Samolinski B, Scadding GK, **Schünemann HJ**, Thomas DM, Triggiani M, Yorgancioglu A, Yusuf OM, Zuberbier T, Pawankar R, Bousquet J, Bonini S; ARIA Initiative, in collaboration with the WHO Collaborating Center for Asthma, Rhinitis. What we should learn from the London Olympics. Curr Opin Allergy Clin Immunol. 13(1):1-3. 2013.
317. Rasch A, Perleth M, Langer G, Meerpohl JJ, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann HJ**. Z Evid Fortbild Qual Gesundheitswes. [GRADE guidelines: 8. Rating the quality of evidence - indirectness].106(10):745-53. 2012. German.
318. Perleth M, Langer G, Meerpohl JJ, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann HJ**. Z Evid Fortbild Qual Gesundheitswes. [GRADE guidelines: 7. Rating the quality of evidence - inconsistency] 106(10):733-44. 2012. German.
319. Shaheen NJ, Weinberg DS, Denberg TD, Chou R, Qaseem A, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 157(11):808-16. 2012.
320. Ferguson ND, Scales DC, Pinto R, Wilcox ME, Cook DJ, Guyatt GH, **Schünemann HJ**, Marshall JC, Herridge MS, Meade MO; for the Canadian Critical Care Trials Group. Integrating Mortality and Morbidity Outcomes: Using Quality-Adjusted Life Years in Critical Care Trials. Am J Respir Crit Care Med. Feb 1;187(3):256-61, 2013.
321. Kulig M, Perleth M, Langer G, Meerpohl JJ, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann HJ**. Z Evid Fortbild Qual Gesundheitswes. [GRADE guidelines: 6. Rating the quality of evidence: imprecision].

- 106(9):677-88. 2012. German#
322. Nolting A, Perleth M, Langer G, Meerpohl JJ, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann HJ**. Z Evid Fortbild Qual Gesundheitswes. [GRADE guidelines: 5. Rating the quality of evidence: publication bias].106(9):670-6. 2012. German#
323. Burford BJ, Rehfuss E, **Schünemann HJ**, Akl EA, Waters E, Armstrong R, Thomson H, Doyle J, Pettman T. Assessing evidence in public health: the added value of GRADE. J Public Health (Oxf). 34(4):631-5. 2012.
324. Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, Freire AX, Geehan D, Kohl B, Nasraway SA, Rigby M, Sands K, Schallom L, Taylor B, Umpierrez G, Mazuski J, **Schünemann H**. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 40(12):3251-76. 2012.
325. Spencer FA, Iorio A, You J, Murad MH, **Schünemann HJ**, Vandvik PO, Crowther MA, Pottie K, Lang ES, Meerpohl JJ, Falck-Ytter Y, Alonso-Coello P, Guyatt GH. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ. 14;345, 2012.
326. Arentz M, Pavlinac P, Kimerling ME, Horne DJ, Falzon D, **Schünemann HJ**, Royce S, Dheda K, Walson JL; ART study group. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One.7(11), 2012.
327. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanicolas P, Akl EA, Vist G, Kunz R, Brozek J, Kupper LL, Martin SL, Meerpohl JJ, Alonso-Coello P, Christensen R, **Schünemann HJ**. GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 66(2):173-183, 2013.
328. Iacoviello L, Rago L, Costanzo S, Di Castelnuovo A, Zito F, Assanelli D, Badilini F, Donati MB, de Gaetano G; Moli-sani Project Investigators.***** The Moli-sani project: computerized ECG database in a population-based cohort study. J Electrocardiol. 45(6):684-9. 2012.
329. **Schünemann HJ**, Langer G, Meerpohl JJ, Ollenschläger G, Perleth M. [The GRADE system: a prologue to the article series in the ZEFQ]. Z Evid Fortbild Qual Gesundheitswes. 106(5):354-6. 2012. German#
330. Perleth M, Matthias K, Langer G, Meerpohl JJ, Gartlehner G, Kaminski-Hartenthaler A, **Schünemann HJ**. [GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence]. Z Evid Fortbild Qual Gesundheitswes. 107(3):256-68. 2012. German#
331. Kien C, Gartlehner G, Kaminski-Hartenthaler A, Meerpohl JJ, Flamm M, Langer G, Perleth M, **Schünemann HJ**. [GRADE guidelines: 9. Rating up the quality of evidence]. Z Evid Fortbild Qual Gesundheitswes. 107(3):249-55. 2012. German#
332. **Schünemann HJ**, Langer G, Meerpohl JJ, Ollenschläger G, Perleth M. [The GRADE system: a prologue to the article series in the ZEFQ]. Z Evid Fortbild Qual Gesundheitswes. 106(5):354-6. 2012. German#

333. Wilson KC, Irwin RS, File TM Jr, **Schünemann HJ**, Guyatt GH, Rabe KF; ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. Reporting and publishing guidelines: article 12 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. *Proc Am Thorac Soc*. Dec;9(5):293-7. 2012.
334. Bousquet J, Anto J, Sunyer J, Nieuwenhuijsen M, Vrijheid M, Keil T; MeDALL Study Group; CHICOS Study Group; ENRIECO Study Group; GA²LEN Study Group *****. Pooling birth cohorts in allergy and asthma: European Union-funded initiatives - a MeDALL, CHICOS, ENRIECO, and GA²LEN joint paper. *Int Arch Allergy Immunol*. 161(1):1-10. 2013.
335. Johnston BC, Patrick DL, Busse JW, **Schünemann HJ**, Agarwal A, Guyatt GH. Patient-reported outcomes in meta-analyses - Part 1: assessing risk of bias and combining outcomes. *Health Qual Life Outcomes*. 11(1):109. 2013.
336. Schernhammer ES, Sperati F, Razavi P, Agnoli C, Sieri S, Berrino F, Krogh V, Abbagnato CA, Gioni S, Blandino G, **Schünemann HJ**, Muti P. Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. *Breast Cancer Res*. 15(3):R46. 2013.
337. Andrews JC, **Schünemann HJ**, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S, Elbarbary M, Post P, Nasser M, Shukla V, Jaeschke R, Brozek J, Djulbegovic B, Guyatt G. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. *J Clin Epidemiol*. 66(7):726-35. 2013.
338. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. *Ann Intern Med*. 158(10):761-9. 2013.*****
339. Akl EA, Kairouz VF, Sackett KM, Erdley WS, Mustafa RA, Fiander M, Gabriel C, **Schünemann H**. Educational games for health professionals. *Cochrane Database Syst Rev*. 3:CD006411. Review. 2013.
340. Silva JM, Stein AT, **Schünemann HJ**, Bordin R, Kuchenbecker R, de Lourdes Drachler M. Academic detailing and adherence to guidelines for Group B streptococci prenatal screening: a randomized controlled trial. *BMC Pregnancy Childbirth*. 13:68. 2013.
341. Akl EA, Sackett KM, Erdley WS, Mustafa RA, Fiander M, Gabriel C, **Schünemann H**. Educational games for health professionals. *Cochrane Database Syst Rev*. Jan 31;1:CD006411. Review. Update in: *Cochrane Database Syst Rev*.;3:CD006411. 2013.
342. Rada G, **Schünemann HJ**, Labedi N, El-Hachem P, Kairouz VF, Akl EA. Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer. *BMC Cancer*. 13:76. 2013.
343. Johnston BC, Patrick DL, Thorlund K, Busse JW, da Costa BR, **Schünemann HJ**, Guyatt GH. Patient-reported outcomes in meta-

- analyses-part 2: methods for improving interpretability for decision-makers. *Health Qual Life Outcomes*. Dec 21;11:211, 2013.
344. **Schünemann HJ**, Tugwell P, Reeves BC, Akl EA, Santesso N, Spencer FA, Shea B, Wells G, Helfand M. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. *Research Synthesis Methods*. 2013;4(1):49-62.
345. Calvert M, Brundage M, Jacobsen PB, **Schünemann HJ**, Efficace F. The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. *Health Qual Life Outcomes*. Oct 29;11:184, 2013.
346. Bonini M, Di Mambro C, Calderon MA, Compalati E, **Schünemann H**, Durham S, Canonica GW. Beta₂-agonists for exercise-induced asthma. *Cochrane Database Syst Rev*. Oct 2;10, 2013.
347. Neumann I, Akl EA, Valdes M, Bravo S, Araos S, Kairouz V, **Schünemann H**, Guyatt GH. Low anonymous voting compliance with the novel policy for managing conflicts of interest implemented in the 9th version of the American College of Chest Physicians antithrombotic guidelines. *Chest*. Oct;144(4):1111-6. 2013.
348. Ochs-Balcom HM, Lainhart W, Mnatsakanova A, Charles LE, Violanti JM, Andrew ME, Freudenheim JL, Muti P, Trevisan M, Burchfiel CM, **Schünemann HJ**. The association of depressive symptoms and pulmonary function in healthy adults. *Psychosom Med*. Oct;75(8):737-43, 2013.
349. Duong M, Islam S, Rangarajan S, Teo K, O'Byrne PM, **Schünemann HJ**, Igumbor E, Chifamba J, Liu L, Li W, Ismail T, Shankar K, Shahid M, Vijayakumar K, Yusuf R, Zatonska K, Oguz A, Rosengren A, Heidari H, Almahmeed W, Diaz R, Oliveira G, Lopez-Jaramillo P, Seron P, Killian K, Yusuf S; PURE-BREATH Study Investigators. Global differences in lung function by region (PURE): an international, community-based prospective study. *Lancet Respir Med*. Oct;1(8):599-609, 2013.
350. Baena-Cagnani CE, Sánchez-Borges M, Zernotti ME, Larenas-Linnemann D, Cruz AA, González-Díaz SN, Ivancevich JC, Aldrey-Palacios O, Sisul JC, Solé D, Cepeda AM, Jares EJ, Calvo Gil M, Valentin-Rostán M, Yáñez A, Gereda J, Cardona-Villa R, Rosario N, Croce VH, Bachert C, Canonica GW, Demoly P, Passalacqua G, Samolinski B, **Schünemann HJ**, Yorgancioglu A, Ansoategui IJ, Khaltayev N, Bedbrook A, Zuberbier T, Bousquet J. [ARIA (Allergic Rhinitis and its Impact on Asthma). Achievements in 10 years and future needs in Latin America]. *Rev Alerg Mex* ;60(4):184-92. 2013.
351. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, **Schünemann HJ**. Assessing and presenting summaries of evidence in Cochrane Reviews. *Syst Rev* Sep 23;2:81, 2013..
352. Bonaccio M, Di Castelnuovo A, Costanzo S, De Lucia F, Olivieri M, Donati MB, de Gaetano G, Iacoviello L, Bonanni A; Moli-sani Project Investigators. Nutrition knowledge is associated with higher adherence to Mediterranean diet and lower prevalence of obesity. Results from the Moli-sani study.

- Appetite. Sep;68:139-46. 2013. *****
353. Santesso N, Hsu J, Mustafa R, Brozek J, Chen YL, Hopkins JP, Cheung A, Hovhannisyann G, Ivanova L, Flottorp SA, Saeterdal I, Wong AD, Tian J, Uyeki TM, Akl EA, Alonso-Coello P, Smaill F, **Schünemann HJ**. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. *Influenza Other Respir Viruses*. Sep;7 Suppl 2:76-81, 2013.^
354. Guyatt G, Eikelboom JW, Akl EA, Crowther M, Gutterman D, Kahn SR, **Schunemann H**, Hirsh J. A guide to GRADE guidelines for the readers of JTH. *J Thromb Haemost*. Aug;11(8):1603-8. 2013.
355. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, Kulasegaram M, Christensen R, Guyatt GH, Falck-Ytter Y, Chang S, Murad MH, Vist GE, Lasserson T, Gartlehner G, Shukla V, Sun X, Whittington C, Post PN, Lang E, Thaler K, Kunnamo I, Alenius H, Meerpohl JJ, Alba AC, Nevis IF, Gentles S, Ethier MC, Carrasco-Labra A, Khatib R, Nesrallah G, Kroft J, Selk A, Brignardello-Petersen R, **Schünemann HJ**. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. *J Clin Epidemiol*. Jul;66(7):736-42; 2013.
356. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R, Brozek J, Vist G, Rind D, Akl EA, **Schünemann HJ**. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol*. Jul;66(7):719-25, 2013.
357. Langer G, Meerpohl JJ, Perleth M, Gartlehner G, Schünemann H. [GRADE guidelines: 12. Developing Summary of Findings tables - dichotomous outcomes]. *Z Evid Fortbild Qual Gesundheitsw*. 107(9-10):646-64. 2013.#
358. Kaminski-Hartenthaler A, Gartlehner G, Kien C, Meerpohl JJ, Langer G, Perleth M, **Schünemann H**. [GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes]. *Z Evid Fortbild Qual Gesundheitsw*. 107(9-10):638-45. 2013.
359. Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl EA, Sun X, Johnston BC, Briel M, Busse JW, Glujovsky D, Granados CE, Iorio A, Irfan A, Martínez García L, Mustafa RA, Ramirez-Morera A, Solà I, Tikkinen KA, Ebrahim S, Vandvik PO, Zhang Y, Selva A, Sanabria AJ, Zazueta OE, Vernooij RW, **Schünemann HJ**, Guyatt GH. Correction: A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic reviewS (ARROW): a study protocol. *Syst Rev* Jul 17;3(1):76, 2014.
360. Santesso N, Rader T, Nilsen ES, Glenton C, Rosenbaum S, Ciapponi A, Moja L, Pardo JP, Zhou Q, **Schünemann HJ**. A summary to communicate evidence from systematic reviews to the public improved understanding and accessibility of information: a randomized controlled trial. *J Clin Epidemiol*. Jul 14, 2014.
361. Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, **Schünemann H**. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst*

- Rev. Jul 8;7, 2014.
362. Järvinen TL, Sihvonen R, Bhandari M, Sprague S, Malmivaara A, Paavola M, **Schünemann HJ**, Guyatt GH. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias. *J Clin Epidemiol.* Jul;67(7):769-72. 2014.
 363. Akl EA, Kahale L, Terrenato I, Neumann I, Yosuico VE, Barba M, Sperati F, **Schünemann H**. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev.* Jul 1;7, 2014.
 364. Gopalakrishna G, Mustafa RA, Davenport C, Scholten RJ, Hyde C, Brozek J, **Schünemann HJ**, Bossuyt PM, Leeflang MM, Langendam MW. Applying Grading of Recommendations Assessment, Development and Evaluation (GRADE) to diagnostic tests was challenging but doable. *J Clin Epidemiol.* Jul;67(7):760-8, 2014.
 365. Akl EA, Kahale L, Sperati F, Neumann I, Labedi N, Terrenato I, Barba M, Sempos EV, Muti P, Cook D, **Schünemann H**. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. *Cochrane Database Syst Rev.* Jun 26;6, 2014.
 366. Akl EA, El-Hachem P, Abou-Haidar H, Neumann I, **Schünemann HJ**, Guyatt GH. Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study. *J Clin Epidemiol.* Jun 23, 2014.
 367. Akl EA, Kahale L, Neumann I, Barba M, Sperati F, Terrenato I, Muti P, **Schünemann H**. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev.* Jun 19;6, 2014.
 368. Harder T, Takla A, Rehfuess E, Sánchez-Vivar A, Matysiak-Klose D, Eckmanns T, Krause G, de Carvalho Gomes H, Jansen A, Ellis S, Forland F, James R, Meerpohl JJ, Morgan A, **Schünemann H**, Zuiderent-Jerak T, Wichmann O. Evidence-based decision-making in infectious diseases epidemiology, prevention and control: matching research questions to study designs and quality appraisal tools. *BMC Med Res Methodol.* May 21;14:69, 2014.
 369. Alonso-Coello P, Montori VM, Díaz MG, Devereaux PJ, Mas G, Diez AI, Solà I, Roura M, Souto JC, Oliver S, Ruiz R, Coll-Vinent B, Gich I, **Schünemann HJ**, Guyatt G. Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. *Health Expect.* May 12. 2014.
 370. Bonaccio M, Di Castelnuovo A, De Curtis A, Costanzo S, Persichillo M, Donati MB, Cerletti C, Iacoviello L, de Gaetano G; Moli-sani Project Investigators. Adherence to the Mediterranean diet is associated with lower platelet and leukocyte counts: results from the Moli-sani study. *Blood.* May 8;123(19):3037-44.2014. *****
 371. Uhlig K, Leff B, Kent D, Dy S, Brunnhuber K, Burgers JS, Greenfield S, Guyatt G, High K, Leipzig R, Mulrow C, Schmader K, **Schunemann H**, Walter LC, Woodcock J, Boyd CM. A framework for crafting clinical practice

- guidelines that are relevant to the care and management of people with multimorbidity. *J Gen Intern Med.* Apr;29(4):670-9, 2014.
372. Bousquet J, Jorgensen C, Dautzat M, Cesario A, Camuzat T, Bourret R, Best N, Anto JM, Abecassis F, Aubas P, Avignon A, Badin M, Blain H, Bourdin A, Bringer J, Camu W, Cayla G, Costa DJ, Courtet P, Cristol JP, Demoly P, de la Coussaye JE, Fesler P, Gouzi F, Gris JC, Guillot B, Hayot M, Jeandel C, Jonquet O, Journot L, Mathieu G, Morel J, Ninot G, Pelissier JY, Picot MC, Rabier-Pontal F, Robine JM, Rodier M, Sultan A, Wojtuszczyzn A, Auffray C, Balling R, Barbara C, Cambon-Thomsen A, Chavannes NH, Chuchalin A, Crooks G, Dedeu A, Fabbri LM, Garcia-Aymeric J, Hassan J, Gomes EM, Palkonen S, Piette F, Pison C, Price D, Samolinski B, **Schunemann HJ**, Sterk PJ, Yiallourous P, Roca J, Perre PV, Mercier J. System Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. *Curr Pharm Des.* 4 Mar 14, 2014.
373. Qaseem A, Chou R, Humphrey LL, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Inpatient glycemic control: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. *Am J Med Qual.* Mar-Apr;29(2):95-8, 2014.*****
374. Padjas A, Kehar R, Aleem S, Mejza F, Bousquet J, **Schünemann HJ**, Brożek JL. Methodological rigor and reporting of clinical practice guidelines in patients with allergic rhinitis: QuGAR study. *J Allergy Clin Immunol.* Mar;133(3):777-83, 2014.
375. Botto F, Alonso-Coello P, Chan MT, Villar JC, Xavier D, Srinathan S, Guyatt G, Cruz P, Graham M, Wang CY, Berwanger O, Pearse RM, Biccard BM, Abraham V, Malaga G, Hillis GS, Rodseth RN, Cook D, Polanczyk CA, Szczeklik W, Sessler DI, Sheth T, Ackland GL, Leuwer M, Garg AX, Lemanach Y, Pettit S, Heels-Ansdell D, Luratibuse G, Walsh M, Sapsford R, Schünemann HJ, Kurz A, Thomas S, Mrkobrada M, Thabane L, Gerstein H, Paniagua P, Nagele P, Raina P, Yusuf S, Devereaux PJ, Devereaux PJ, Sessler DI, Walsh M, Guyatt G, McQueen MJ, Bhandari M, Cook D, Bosch J, Buckley N, Yusuf S, Chow CK, Hillis GS, Halliwell R, Li S, Lee VW, Mooney J, Polanczyk CA, Furtado MV, Berwanger O, Suzumura E, Santucci E, Leite K, Santo JA, Jardim CA, Cavalcanti AB, Guimaraes HP, Jacka MJ, Graham M, McAlister F, McMurtry S, Townsend D, Pannu N, Bagshaw S, Bessissow A, Bhandari M, Duceppe E, Eikelboom J, Ganame J, Hankinson J, Hill S, Jolly S, Lamy A, Ling E, Magloire P, Pare G, Reddy D, Szalay D, Tittley J, Weitz J, Whitlock R, Darvish-Kazim S, Debeer J, Kavsak P, Kearon C, Mizera R, O'Donnell M, McQueen M, Pinthus J, Ribas S, Simunovic M, Tandon V, Vanhelder T, Winemaker M, Gerstein H, McDonald S, O'Bryne P, Patel A, Paul J, Punthakee Z, Raymer K, Salehian O, Spencer F, Walter S, Worster A, Adili A, Clase C, Cook D, Crowther M, Douketis J, Gangji A, Jackson P, Lim W, Lovrics P, Mazzadi S, Orovan W, Rudkowski J, Soth M, Tiboni M, Acedillo R, Garg A, Hildebrand A, Lam N, Macneil D, Mrkobrada M, Roshanov PS, Srinathan SK, Ramsey C, John PS, Thorlacius L, Siddiqui FS, Grocott HP, McKay A, Lee TW, Amadeo R, Funk D, McDonald H, Zacharias J, Villar JC, Cortés OL, Chaparro MS, Vásquez S, Castañeda A, Ferreira S, Coriat

- P, Monneret D, Goarin JP, Esteve CI, Royer C, Daas G, Chan MT, Choi GY, Gin T, Lit LC, Xavier D, Sigamani A, Faruqui A, Dhanpal R, Almeida S, Cherian J, Furuqh S, Abraham V, Afzal L, George P, Mala S, **Schünemann H**, Muti P, Vizza E, Wang CY, Ong GS, Mansor M, Tan AS, Shariffuddin II, Vasanthan V, Hashim NH, Undok AW, Ki U, Lai HY, Ahmad WA, Razack AH, Malaga G, Valderrama-Victoria V, Loza-Herrera JD, De Los Angeles Lazo M, Rotta-Rotta A, Szczeklik W, Sokolowska B, Musial J, Gorka J, Iwaszczuk P, Kozka M, Chwala M, Raczek M, Mrowiecki T, Kaczmarek B, Biccard B, Cassimjee H, Gopalan D, Kisten T, Mugabi A, Naidoo P, Naidoo R, Rodseth R, Skinner D, Torborg A, Paniagua P, Urrutia G, Maestre ML, Santaló M, Gonzalez R, Font A, Martínez C, Pelaez X, De Antonio M, Villamor JM, García JA, Ferré MJ, Popova E, Alonso-Coello P, Garutti I, Cruz P, Fernández C, Palencia M, Díaz S, Del Castillo T, Varela A, de Miguel A, Muñoz M, Piñeiro P, Cusati G, Del Barrio M, Membrillo MJ, Orozco D, Reyes F, Sapsford RJ, Barth J, Scott J, Hall A, Howell S, Loblely M, Woods J, Howard S, Fletcher J, Dewhirst N, Williams C, Rushton A, Welters I, Leuwer M, Pearse R, Ackland G, Khan A, Niebrzegowska E, Benton S, Wragg A, Archbold A, Smith A, McAlees E, Ramballi C, Macdonald N, Januszewska M, Stephens R, Reyes A, Paredes LG, Sultan P, Cain D, Whittle J, Del Arroyo AG, Sessler DI, Kurz A, Sun Z, Finnegan PS, Egan C, Honar H, Shahinyan A, Panjasawatwong K, Fu AY, Wang S, Reineks E, Nagele P, Blood J, Kalin M, Gibson D, Wildes T; Vascular events In noncardiac Surgery patlents cOhort evaluatioN (VISION) Writing Group, on behalf of The Vascular events In noncardiac Surgery patlents cOhort evaluatioN (VISION) Investigators; Appendix 1. The Vascular events In noncardiac Surgery patlents cOhort evaluatioN (VISION) Study Investigators Writing Group; Appendix 2. The Vascular events In noncardiac Surgery patlents cOhort evaluatioN Operations Committee; Vascular events In noncardiac Surgery patlents cOhort evaluatioN VISION Study Investigators. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. *Anesthesiology*. Mar;120(3):564-78, 2014.
376. **Schünemann HJ**, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R, Ventresca M, Brignardello-Petersen R, Laisaar KT, Kowalski S, Baldeh T, Zhang Y, Raid U, Neumann I, Norris SL, Thornton J, Harbour R, Treweek S, Guyatt G, Alonso-Coello P, Reinap M, Brozek J, Oxman A, Akl EA. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. *CMAJ*. Feb 18;186(3):E123-42, 2014.
377. Guyatt G, Montori V, **Schünemann H**, Alonso-Coello P, Dahm P, Brito Campana JP, Brozek J, Nasser M, Meerpohl J, Rind D, Jaeschke R, Fack-Ytter Y, Norris S. Letter reply to GRADE guidelines articles 14 and 15. *J Clin Epidemiol* ;67(2):240, 2014.
378. Wu D, Akl EA, Guyatt GH, Devereaux PJ, Brignardello-Petersen R, Prediger B, Patel K, Patel N, Lu T, Zhang Y, Falavigna M, Santesso N, Mustafa RA, Zhou Q, Briel M, **Schünemann HJ**. Methodological survey of designed uneven randomization trials (DU-RANDOM): a protocol. *Trials*. Jan 23;15:33, 2014.

379. Kunz R, **Schunemann HJ**, Guyatt GH. Perceived disagreement (mostly) not confirmed by evidence... A reply to Watine et al.: Clinical practice guidelines: myths and misconceptions. *J Clin Epidemiol.* Jan;67(1):10-4, 2014.
380. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, Annesi-Maesano I, Anto JM, Bachert C, Baena-Cagnani CE, Bai C, Baigenzhin A, Barbara C, Barnes PJ, Bateman ED, Beck L, Bedbrook A, Bel EH, Benezet O, Bennoor KS, Benson M, Bernabeu-Wittel M, Bewick M, Bindeslev-Jensen C, Blain H, Blasi F, Bonini M, Bonini S, Boulet LP, Bourdin A, Bourret R, Bousquet PJ, Brightling CE, Briggs A, Brozek J, Buhl R, Bush A, Caimmi D, Calderon M, Calverley P, Camargos PA, Camuzat T, Canonica GW, Carlsen KH, Casale TB, Cazzola M, Cepeda Sarabia AM, Cesario A, Chen YZ, Chkhartishvili E, Chavannes NH, Chiron R, Chuchalin A, Chung KF, Cox L, Crooks G, Crooks MG, Cruz AA, Custovic A, Dahl R, Dahlen SE, De Blay F, Dedeu T, Deleanu D, Demoly P, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dubakiene R, Eglin S, Elliot F, Emuzyte R, Fabbri L, Fink Wagner A, Fletcher M, Fokkens WJ, Fonseca J, Franco A, Frith P, Furber A, Gaga M, Garcés J, Garcia-Aymerich J, Gamkrelidze A, Gonzales-Diaz S, Gouzi F, Guzmán MA, Haahtela T, Harrison D, Hayot M, Heaney LG, Heinrich J, Hellings PW, Hooper J, Humbert M, Hyland M, Iaccarino G, Jakovenko D, Jardim JR, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Joos G, Jung KS, Kalayci O, Karunanithi S, Keil T, Khaltaev N, Kolek V, Kowalski ML, Kull I, Kuna P, Kvedariene V, Le LT, Lodrup Carlsen KC, Louis R, MacNee W, Mair A, Majer I, Manning P, de Manuel Keenoy E, Masjedi MR, Melen E, Melo-Gomes E, Menzies-Gow A, Mercier G, Mercier J, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, N'Diaye M, Nafti S, Nekam K, Neou A, Nicod L, O'Hehir R, Ohta K, Paggiaro P, Palkonen S, Palmer S, Papadopoulos NG, Papi A, Passalacqua G, Pavord I, Pigearias B, Plavec D, Postma DS, Price D, Rabe KF, Radier Pontal F, Redon J, Rennard S, Roberts J, Robine JM, Roca J, Roche N, Rodenas F, Roggeri A, Rolland C, Rosado-Pinto J, Ryan D, Samolinski B, Sanchez-Borges M, **Schünemann HJ**, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Small I, Sola-Morales O, Sooronbaev T, Stelmach R, Sterk PJ, Stiris T, Sud P, Tellier V, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valiulis A, Valovirta E, Van Ganse E, Vandenplas O, Vasankari T, Vestbo J, Vezzani G, Viegi G, Visier L, Vogelmeier C, Vontetsianos T, Wagstaff R, Wahn U, Wallaert B, Whalley B, Wickman M, Williams DM, Wilson N, Yawn BP, Yiallourous PK, Yorgancioglu A, Yusuf OM, Zar HJ, Zhong N, Zidarn M, Zuberbier T. Integrated care pathways for airway diseases (AIRWAYS-ICPs). *Eur Respir J.* 44(2):304-23. 2014.
381. Qaseem A, Humphrey LL, Harris R, Starkey M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 161(1):67-72, 2014.*****
382. Schell LK, Meerpohl JJ, Gartlehner G, Langer G, Perleth M, **Schünemann HJ**. [GRADE guidelines: 13. Preparing Summary of Findings tables and

- evidence profiles - continuous outcomes]. *Z Evid Fortbild Qual Gesundheitswes.*108(5-6):333-47, 2014.#
383. Qaseem A, Dallas P, Forcica MA, Starkey M, Denberg TD, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 161(6):429-40, 2014.*****
384. Puhan MA, **Schünemann HJ**, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH; GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ.* Sep 24;349, 2014.
385. Kairouz VF, Raad D, Fudyma J, Curtis AB, **Schünemann HJ**, Akl EA. Assessment of faculty productivity in academic departments of medicine in the United States: a national survey. *BMC Med Educ.* Sep 26;14:205. 2014.
386. Akl EA, Ramly EP, Kahale LA, Yosuico VE, Barba M, Sperati F, Cook D, **Schünemann H**. Anticoagulation for people with cancer and central venous catheters. *Cochrane Database Syst Rev.* Oct 15;10, 2014.
387. Zhang Y, Tikkinen KA, Agoritsas T, Ayeni OR, Alexander P, Imam M, Yoo D, Tsalatsanis A, Djulbegovic B, Thabane L, **Schünemann H**, Guyatt GH. Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: a protocol for a multinational structured interview-based study combined with a randomised survey on the optimal amount of information to elicit preferences. *BMJ Open* Oct 17;4(10). 2014.
388. Kaminski-Hartenthaler A, Meerpohl JJ, Gartlehner G, Kien C, Langer G, Wipplinger J, **Schünemann HJ**. [GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations]. *Z Evid Fortbild Qual Gesundheitswes.*108(7):413-20. 2014. German#
389. Nußbaumer B, Gartlehner G, Kien C, Kaminski-Hartenthaler A, Langer G, Meerpohl JJ, **Schünemann HJ**. [GRADE guidelines 15: Going from evidence to recommendation - determinants of a recommendation's direction and strength]. *Z Evid Fortbild Qual Gesundheitswes.* 108(7):421-31. 2014. German#
390. Akl EA, Kahale LA, Ballout RA, Barba M, Yosuico VE, van Doormaal FF, Middeldorp S, Bryant A, **Schünemann H**. Parenteral anticoagulation in ambulatory patients with cancer. *Cochrane Database Syst Rev.* Dec 10;12, 2014.
391. Stewart GB, Higgins JP, **Schünemann H**, Meader N. The use of Bayesian networks to assess the quality of evidence from research synthesis: 1. *PLoS One.* 10: e0114497, 2015.
392. **Schünemann HJ**, Moja L. Reviews: Rapid! Rapid! Rapid! ...and systematic. *Systematic reviews.* 4: 4, 2015.
393. Santesso N, Rader T, Nilsen ES, Glenton C, Rosenbaum S, Ciapponi A, Moja L, Pardo JP, Zhou Q, **Schünemann HJ**. A summary to communicate evidence from systematic reviews to the public improved understanding

- and accessibility of information: a randomized controlled trial. *J Clin Epidemiol.* 68: 182-90, 2015.
394. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, **Schünemann HJ**. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med.* 192: e3-e19, 2015.
395. Moayyedi P, Weinberg DS, **Schünemann H**, Chak A. Management of pancreatic cysts in an evidence-based world. *Gastroenterology.* 148: 692-5, 2015.
396. Jaeschke R, Guyatt GH, **Schünemann H**. Ten things you should consider before you believe a clinical practice guideline. *Intensive care medicine.* 41: 1340-2, 2015.
397. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, McGinn T, Hayden J, Williams K, Shea B, Wolff R, Kujpers T, Perel P, Vandvik PO, Glasziou P, **Schünemann H**, Guyatt G. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ.* 350, 2015.
398. Harder T, Abu Sin M, Bosch-Capblanch X, Bruno C, de Carvalho Gomes H, Duclos P, Eckmanns T, Elder R, Ellis S, Forland F, Garner P, James R, Jansen A, Krause G, Levy-Bruhl D, Morgan A, Meerpohl JJ, Norris S, Rehfuess E, Sanchez-Vivar A, **Schünemann H**, Takla A, Wichmann O, Zingg W, Zuiderent-Jerak T. Towards a framework for evaluating and grading evidence in public health. *Health Policy.* 2015.
399. Guyatt GH, **Schünemann HJ**, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. *J Clin Epidemiol.* 68: 597-600, 2015.
400. Fiocchi A, Pawankar R, Cuello-Garcia C, Ahn K, Al-Hammadi S, Agarwal A, Beyer K, Burks W, Canonica GW, Ebisawa M, Gandhi S, Kamenwa R, Lee BW, Li H, Prescott S, Riva JJ, Rosenwasser L, Sampson H, Spigler M, Terracciano L, Vereda-Ortiz A, Wasserman S, Yepes-Nunez JJ, Brozek JL, **Schünemann HJ**. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. *The World Allergy Organization journal.* 8: 4, 2015.
401. Davoli M, Amato L, Clark N, Farrell M, Hickman M, Hill S, Magrini N, Poznyak V, **Schünemann HJ**. The role of Cochrane reviews in informing international guidelines: a case study of using the Grading of Recommendations, Assessment, Development and Evaluation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. *Addiction.* 110: 891-8, 2015.
402. Cuello-Garcia CA, Brozek JL, Fiocchi A, Pawankar R, Yepes-Nunez JJ, Terracciano L, Gandhi S, Agarwal A, Zhang Y, **Schünemann HJ**. Probiotics for the prevention of allergy: A systematic review and meta-

- analysis of randomized controlled trials. *J Allergy Clin Immunol*, 2015.
403. Carrasco-Labra A, Brignardello-Petersen R, Santesso N, Neumann I, Mustafa RA, Mbuagbaw L, Ikbaltzeta IE, De Stio C, McCullagh LJ, Alonso-Coello P, Meerpohl JJ, Vandvik PO, Brozek JL, Akl EA, Bossuyt P, Churchill R, Glenton C, Rosenbaum S, Tugwell P, Welch V, Guyatt G, **Schünemann H**. Comparison between the standard and a new alternative format of the Summary-of-Findings tables in Cochrane review users: study protocol for a randomized controlled trial. *Trials*. 16: 164, 2015.
404. Bousquet J, **Schünemann HJ**, Fonseca J, Samolinski B, Bachert C, Canonica GW, Casale T, Cruz AA, Demoly P, Hellings P, Valiulis A, Wickman M, Zuberbier T, Bosnic-Anticevitch S, Bedbrook A, Bergmann KC, Caimmi D, Dahl R, Fokkens WJ, Grisle I, Lodrup Carlsen K, Mullol J, Muraro A, Palkonen S, Papadopoulos N, Passalacqua G, Ryan D, Valovirta E, Yorgancioglu A, Aberer W, Agache I, Adachi M, Akdis CA, Akdis M, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielle S, Arshad H, Baiardini I, Baigenzhin AK, Barbara C, Bateman ED, Beghe B, Bel EH, Ben Kheder A, Bennoor KS, Benson M, Bewick M, Bieber T, Bindeslev-Jensen C, Bjermer L, Blain H, Boner AL, Boulet LP, Bonini M, Bonini S, Bosse I, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Calderon MA, Camargos P, Camuzat T, Carlsen KH, Carr W, Cepeda Sarabia AM, Chavannes NH, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Ciprandi G, Cirule I, Correia de Sousa J, Cox L, Crooks G, Costa DJ, Custovic A, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fink Wagner A, Fletcher M, Fiocchi A, Forastiere F, Gamkrelidze A, Gemicioglu B, Gereda JE, Gonzalez Diaz S, Gotua M, Grouse L, Guzman MA, Haahtela T, Hellquist-Dahl B, Heinrich J, Horak F, Hourihane J, Howarth P, Humbert M, Hyland ME, Ivancevich JC, Jares EJ, Johnston SL, Joos G, Jonquet O, Jung KS, Just J, Kaidashev I, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Khaltsev N, Klimek L, N'Goran BK, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le L, Lieberman P, Lipworth B, Li J, Louis R, Magard Y, Magnan A, Mahboub B, Majer I, Makela MJ, Manning P, De Manuel Keenoy E, Marshall GD, Masjedi, Maurer M, Mavale-Manuel S, Melen E, Melo-Gomes E, Meltzer EO, Merk H, Miculinic N, Mihaltan F, Milenkovic B, Mohammad Y, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Mosges R, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Nyembue TD, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Scholl I, Palmer S, Panzner P, Papi A, Park HS, Pavord I, Pawankar R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Pohl W, Popov TA, Portejoie F, Postma D, Potter P, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Robalo-Cordeiro C, Rolland C, Rosado-Pinto J, Reitamo S, Rodenas F, Roman Rodriguez M, Romano A, Rosario N, Rosenwasser L, Rottem M, Sanchez-Borges M, Scadding GK, Serrano E, Schmid-Grendelmeier P, Sheikh A, Simons F, Sisul JC, Skrindo I, Smit HA, Sole D, Sooronbaev T, Spranger O, Stelmach R, Strandberg T, Sunyer J, Thijs C, Todo-Bom A,

- Triggiani M, Valenta R, Valero AL, van Hage M, Vandenplas O, Vezzani G, Vichyanond P, Viegi G, Wagenmann M, Walker S, Wang DY, Wahn U, Williams DM, Wright J, Yawn BP, Yiallourous PK, Yusuf OM, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J. MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation. *Allergy*. 2015.
405. Al-Hameed F, Al-Dorzi HM, Shamy A, Qadi A, Bakhsh E, Aboelnazar E, Abdelaal M, Al Khuwaitir T, Al-Moamary MS, Al-Hajjaj MS, Brozek J, **Schünemann H**, Mustafa R, Falavigna M. The Saudi clinical practice guideline for the diagnosis of the first deep venous thrombosis of the lower extremity. *Annals of Thoracic Medicine*. 10: 3-15, 2015.
406. Akl EA, Kahale LA, **Schünemann HJ**. Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery. *JAMA*. 313: 1364-5, 2015.
407. Alonso-Coello P, **Schunemann H**, Moberg J, Brignardello-Petersen R, Akl E, Davoli M, Treweek S, Mustafa R, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD. GRADE Evidence to Decision frameworks: 1. Introduction. *BMJ* 2016
408. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl E, Davoli M, Treweek S, Mustafa R, Vandvik, P, Meerpohl, J, Guyatt, GH, **Schunemann H**. GRADE Evidence to Decision frameworks: 2. Clinical practice guidelines. *BMJ* 2016
409. Trenti T, **Schunemann HJ**, Plebani M. Developing GRADE outcome-based recommendations about diagnostic tests: a key role in laboratory medicine policies. *Clinical chemistry and laboratory medicine: CCLM / FESCC*. 2016;54(4):535-43.
410. Santesso N, Mustafa RA, Wiercioch W, Kehar R, Gandhi S, Chen Y, Cheung A, Hopkins J, Khatib R, Ma B, Mustafa AA, Lloyd N, Wu D, Broutet N, **Schunemann HJ**. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia. *International journal of gynaecology and obstetrics*. 2016;132(3):266-71.
411. Santesso N, Mustafa RA, **Schunemann HJ**[&], Arbyn M, Blumenthal PD, Cain J, Denny L, De Vuyst H, Eckert LO, Forhan SE, Franco EL, Gage J C, Garcia F, Herrero R, Jeronimo J, Lu ER, Luciani S, Quek SC, Sankaranarayanan R, Tsu V, Broutet N. and Guideline Support, Group. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2016;132(3):252-8.
412. **Schünemann HJ**, Mustafa R, Brozek J, Santesso N, alonso-Coello P, Guyatt G, Scholten RJ, Langendam MW, Leeflang MM, Akl E, Singh JA, Meerpohl J, Hultcrantz M, Bossuyt P, Oxman A. GRADE Guidelines 16: GRADE Evidence to Decision (EtD) frameworks for tests in clinical practice and public health. *J Clin Epidemiol*, 76:89-98, 2016

413. Rooney AA, Cooper GS, Jahnke GD, Lam J, Morgan RL, Boyles AL, Ratcliffe JM, Kraft AD, **Schunemann HJ**, Schwingl P, Walker TD, Thayer KA, Lunn RM. How credible are the study results? Evaluating and applying internal validity tools to literature-based assessments of environmental health hazards. *Environ Int*, 2016.
414. Rochweg B, **Schunemann HJ**, Raghu G. Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? *BMC Med*. 14: 22, 2016.
415. Rochweg B, **Schunemann H**, Raghu G. Reply to "An Important Step Forward, but Still a Way to Go" and "Idiopathic Pulmonary Fibrosis and Prothrombotic State". *Am J Respir Crit Care Med*. 193: 343, 2016.
416. Neumann I, Santesso N, Akl EA, Rind DM, Vandvik PO, Alonso-Coello P, Agoritsas T, Mustafa RA, Alexander PE, **Schunemann H**, Guyatt GH. A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. *J Clin Epidemiol*. 72: 45-55, 2016.
417. Mustafa RA, Santesso N, Khatib R, Mustafa AA, Wiercioch W, Kehar R, Gandhi S, Chen Y, Cheung A, Hopkins J, Ma B, Lloyd N, Wu D, Broutet N, **Schunemann HJ**. Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. *International journal of gynaecology and obstetrics*. 132: 259-65, 2016.
418. Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl EA, Vernooij RW, Johnston BC, Sun X, Briel M, Busse JW, Ebrahim S, Granados CE, Iorio A, Irfan A, Martinez Garcia L, Mustafa RA, Ramirez-Morera A, Selva A, Sola I, Sanabria AJ, Tikkinen KA, Vandvik PO, Zazueta OE, Zhang Y, Zhou Q, **Schunemann H**, Guyatt GH. Systematic reviews experience major limitations in reporting absolute effects. *J Clin Epidemiol*. 72: 16-26, 2016.
419. Alexander PE, Li SA, Gionfriddo MR, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, **Schunemann HJ**, Guyatt GH. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. *J Clin Epidemiol*. 70: 123-8, 2016.
420. Alexander PE, Gionfriddo MR, Li SA, Bero L, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Norris SL, **Schunemann HJ**, Thabane L, Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. *J Clin Epidemiol*. 70: 111-22, 2016.
421. Alexander PE, Brito JP, Neumann I, Gionfriddo MR, Bero L, Djulbegovic B, Stoltzfus R, Montori VM, Norris SL, **Schunemann HJ**, Guyatt GH. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. *J Clin Epidemiol*. 72: 98-106, 2016.
422. Mustafa RA, Bdair F, Akl EA, Garg AX, Thiessen-Philbrook H, Salameh H, Kisra S, Nesrallah G, Al-Jaishi A, Patel P, Patel P, Mustafa AA,

- Schunemann HJ.** Effect of Lowering the Dialysate Temperature in Chronic Hemodialysis: A Systematic Review and Meta-Analysis. *Clin J Am Soc Nephrol.* 11: 442-57, 2016.
423. Morgan RL, Thayer KA, Bero L, Bruce N, Falck-Ytter Y, Gherzi D, Guyatt G, Hooijmans C, Langendam M, Mandrioli D, Mustafa RA, Rehfuss EA, Rooney AA, Shea B, Silbergeld EK, Sutton P, Wolfe MS, Woodruff TJ, Verbeek JH, Holloway AC, Santesso N, **Schunemann HJ.** GRADE: Assessing the quality of evidence in environmental and occupational health. *Environ Int.* 2016.
424. Langendam M, Carrasco-Labra A, Santesso N, Mustafa RA, Brignardello-Petersen R, Ventresca M, Heus P, Lasserson T, Moustgaard R, Brozek J, **Schunemann HJ.** Improving GRADE evidence tables part 2: a systematic survey of explanatory notes shows more guidance is needed. *J Clin Epidemiol.* 74:19-27, 2016.
425. Santesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P, Lasserson T, Opiyo N, Kunnamo I, Sinclair D, Garner P, Treweek S, Tovey D, Akl EA, Tugwell P, Brozek JL, Guyatt G, **Schunemann HJ.** Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. *J Clin Epidemiol.* 74:28-39, 2016
426. Kumar A, Miladinovic B, Guyatt GH, **Schunemann HJ,** Djulbegovic B. GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE. *J Clin Epidemiol,* 75:115-8, 2016
427. Cuello-Garcia CA, Fiocchi A, Pawankar R, Yepes-Nunez JJ, Morgano GP, Zhang Y, Ahn K, Al-Hammadi S, Agarwal A, Gandhi S, Beyer K, Burks W, Canonica GW, Ebisawa M, Kamenwa R, Lee BW, Li H, Prescott S, Riva JJ, Rosenwasser L, Sampson H, Spigler M, Terracciano L, Vereda A, Wasserman S, **Schunemann HJ[&],** Brozek JL. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics. *The World Allergy Organization journal.* 9: 10, 2016.
428. Carrasco-Labra A, Brignardello-Petersen R, Santesso N, Neumann I, Mustafa RA, Mbuagbaw L, Etxeandia Ikobaltzeta I, De Stio C, McCullagh LJ, Alonso-Coello P, Meerpohl JJ, Vandvik PO, Brozek JL, Akl EA, Bossuyt P, Churchill R, Glenton C, Rosenbaum S, Tugwell P, Welch V, Garner P, Guyatt G, **Schunemann H.** Improving GRADE evidence tables part 1: A randomized trial shows improved understanding of content in Summary-of-Findings Tables with a new format. *J Clin Epidemiol.* 74:7-18 2016
429. Akl EA, Kahale LA, Ebrahim S, Alonso-Coello P, **Schunemann HJ,** Guyatt GH. Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers. *J Clin Epidemiol,* 76:147-54, 2016
430. Rochweg B, Neupane B, Zhang Y, Garcia CC, Raghu G, Richeldi L, Brozek J, Beyene J, **Schunemann H.** Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. *BMC Med.* 14: 18, 2016.

431. **Schünemann HJ**. Interpreting GRADE's levels of certainty or quality of the evidence: GRADE for statisticians, considering review information size or less emphasis on imprecision? *J Clin Epidemiol*, 75:6-15, 2016
432. Neumann I, Brignardello-Petersen R, Wiercioch W, Carrasco-Labra A, Cuell C, Akl E, Mustafa R, Al-Hazzani W, Etzeandia-Ikobaltzeta I, Rojas MX, Falavigna M, Santesso N, Brozek J, Alonso-Coello P, **Schünemann HJ**. The GRADE Evidence-to-Decision Framework: A report of its testing and application in 15 guideline panels. *Implementation Science*, 15;11:93 2016
433. Arnav Agarwal A, Raad D, Kairouz V, Fudyma J, Curtis AB, **Schünemann H**, Akl E. The effect of a monetary incentive for administrative assistants on the survey response rate: a randomized controlled trial. *BMC Medical Research Methodology*, 16:94. 2016
434. Rochow N, Landau-Crangle E, Lee S, **Schünemann H**, Fusch, C. Quality indicators but not admission volumes of neonatal intensive care units are effective in reducing mortality rates of preterm infants. *PLOS ONE* Aug 10;11(8), 2016.
435. Al-Hameed FM, Al-Dorzi HM, Abdelaal MA, Alaklabi A, Bakhsh Alomi YA, Al Baik M, Aldahan S, **Schünemann H**, Brozek J, Wiercioch W, Darzi AJ, Waziry R, Akl EA. The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in medical and critically ill patients. *Saudi Med J*. 37(11):1279-1293, 2016.
436. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, **Schünemann HJ**, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*.;355:i4919, 2016.
437. **Schünemann HJ**, Wiercioch W, Brozek J, Etzeandia-Ikobaltzeta I, Mustafa RA, Manja V, Brignardello-Petersen R, Neumann I, Falavigna M, Alhazzani W, Santesso N, Zhang Y, Meerpohl JJ, Morgan RL, Rochweg B, Darzi A, Rojas MX, Carrasco-Labra A, Adi Y, AlRayees Z, Riva J, Bollig C, Moore A, Yepes-Nuñez JJ, Cuello C, Waziry R, Akl EA. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. *J Clin Epidemiol* 81:101-110, 2017.
438. Al-Mandeel HM, Sagr E, Sait K, Latifah HM, Al-Obaid A, Al-Badawi IA, Alkushi AO, Salem H, Massoudi NS, **Schunemann H**, Mustafa RA, Brignardello-Petersen R. Clinical Practice Guidelines on the Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention in Saudi Arabia. *Ann Saudi Med*. 36(5):313-320, 2016.
439. Alfadda AA, Al-Dhwayan MM, Alharbi AA, Al Khudhair BK, Al Nozha OM, Al-Qahtani NM, Alzahrani SH, Bardisi WM, Sallam RM, Riva JJ, Brožek JL, **Schünemann HJ**, Moore A. The Saudi clinical practice guideline for the management of overweight and obesity in adults. *Saudi Med J*.

- 37(10):1151-62, 2016.
440. Godah MW, Abdul Khalek RA, Kilzar L, Zeid H, Nahlawi A, Lopes LC, Darzi AJ, **Schünemann HJ**, Akl EA. A very low number of national adaptations of the World Health Organization guidelines for HIV and tuberculosis reported their processes. *J Clin Epidemiol* 80:50-56, 2016.
441. Yepes Nuñez JJ, Zhang Y, Xie F, Alonso-Coello P, Selva A, **Schünemann H**, Guyatt G. 42 systematic reviews generated 23 items for assessing the risk of bias in Values and Preferences' studies. *J Clin Epidemiol*. 2017
442. Zhang Y, Coello PA, Brožek J, Wiercioch W, Etzeandía-Ikobaltzeta I, Akl EA, Meerpohl JJ, Alhazzani W, Carrasco-Labra A, Morgan RL, Mustafa RA, Riva JJ, Moore A, Yepes-Nuñez JJ, Cuello-García C, AlRayees Z, Manja V, Falavigna M, Neumann I, Brignardello-Petersen R, Santesso N, Rochweg B, Darzi A, Rojas MX, Adi Y, Bollig C, Waziry R, **Schünemann HJ**. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. *Health Qual Life Outcomes*. 15(1):52 2017.
443. Writing Committee for the VISION Study Investigators, Devereaux PJ, Biccari BM, Sigamani A, Xavier D, Chan MTV, Srinathan SK, Walsh M, Abraham V, Pearse R, Wang CY, Sessler DI, Kurz A, Szczeklik W, Berwanger O, Villar JC, Malaga G, Garg AX, Chow CK, Ackland G, Patel A, Borges FK, Belley-Cote EP, Duceppe E, Spence J, Tandon V, Williams C, Sapsford RJ, Polanczyk CA, Tiboni M, Alonso-Coello P, Faruqui A, Heels-Ansell D, Lamy A, Whitlock R, LeManach Y, Roshanov PS, McGillion M, Kavsak P, McQueen MJ, Thabane L, Rodseth RN, Buse GAL, Bhandari M, Garutti I, Jacka MJ, **Schünemann HJ**, Cortes OL, Coriat P, Dvirnik N, Botto F, Pettit S, Jaffe AS, Guyatt GH. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. *JAMA*. 317(16):1642-1651, 2017.
444. Welch VA, Akl EA, Guyatt G, Pottie K, Eslava-Schmalbach J, Ansari MT, de Beer H, Briel M, Dans T, Dans I, Hultcrantz M, Jull J, Katikireddi SV, Meerpohl J, Morton R, Mosdol A, Petkovic J, **Schünemann H**, Sharaf R, Singh J, Stanev R, Tonia T, Tristan M, Vitols S, Watine J, Tugwell P. GRADE Equity guidelines 1: Health equity in guideline development-introduction and rationale. *J Clin Epidemiol*. 2017.
445. Darzi A, Abou-Jaoude EA, Agarwal A, Lakis C, Wiercioch W, Santesso N, Brax H, El-Jardali F, **Schünemann HJ**, Akl EA. Frameworks for adaptation of health guidelines: a methodological survey. *J Clin Epidemiol*. 2017
446. Welch VA, Akl EA, Pottie K, Ansari MT, Briel M, Christensen R, Dans A, Dans L, Eslava-Schmalbach JH, Guyatt G, Hultcrantz M, Jull J, Katikireddi SV, Lang E, Matovinovic E, Meerpohl JJ, Morton R, Mosdøl A, Murad MH, Petkovic J, **Schünemann H**, Sharaf R, Shea B, Singh JA, Solà I, Stanev R, Stein AT, Thabane L, Tonia T, Tristan M, Vitols S, Watine J, Tugwell P. GRADE Equity Guidelines 3: Health equity considerations in rating the certainty of synthesized evidence. *Clin Epidemiol*. 2017.
447. Falzon D, **Schünemann HJ**, Haraus E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K. World Health Organization treatment guidelines for

- drug-resistant tuberculosis, 2016 update. *Eur Respir J.* 22;49(3), 2017.
448. Murad MH, Mustafa RA, **Schünemann HJ**, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. *Evid Based Med.* 2017
449. Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber T, Agache I, Bernal-Sprekelsen M, Canonica GW, Gevaert P, Joos G, Lund V, Muraro A, Onerci M, Zuberbier T, Pugin B, Seys SF, Bousquet J; ARIA and EPOS working groups. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. *Allergy*, 2017.
450. Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, Robalo-Cordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braidó F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PAM, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakienė R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicioğlu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JOB, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Khaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N'Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LTT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Mohammad GMY, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G,

- Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, **Schunemann HJ**, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FER, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallourous PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). *Clin Transl Allergy*. 7:5, 2017.
451. El Dib R, Tikkinen KAO, Akl EA, Gomaa HA, Mustafa RA, Agarwal A, Carpenter CR, Zhang Y, Jorge EC, Almeida RAMB, do Nascimento Junior P, Doles JVP, Mustafa AA, Sadeghirad B, Lopes LC, Bergamaschi CC, Suzumura EA, Cardoso MMA, Corrente JE, Stone SB, **Schunemann HJ**, Guyatt GH. Systematic survey of randomized trials evaluating the impact of alternative diagnostic strategies on patient-important outcomes. *J Clin Epidemiol*. 84:61-69, 2017.
452. Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, Bewick M, Bindselev-Jensen C, Bosnic-Anticevitch S, Bucca C, Caimmi DP, Camargos PA, Canonica GW, Casale T, Chavannes NH, Cruz AA, De Carlo G, Dahl R, Demoly P, Devillier P, Fonseca J, Fokkens WJ, Guldemond NA, Haahtela T, Illario M, Just J, Keil T, Klimek L, Kuna P, Larenas-Linnemann D, Morais-Almeida M, Mullol J, Murray R, Naclerio R, O'Hehir RE, Papadopoulos NG, Pawankar R, Potter P, Ryan D, Samolinski B, **Schunemann HJ**, Sheikh A, Simons FE, Stellato C, Todo-Bom A, Tomazic PV, Valiulis A, Valovirta E, Ventura MT, Wickman M, Young I, Yorgancioglu A, Zuberbier T, Aberer W, Akdis CA, Akdis M, Annesi-Maesano I, Ankri J, Ansotegui IJ, Anto JM, Arnavielhe S, Asarj A, Arshad H, Avolio F, Baiardini I, Barbara C, Barbagallo M, Bateman ED, Beghé B, Bel EH, Bennoor KS, Benson M, Białoszewski AZ, Bieber T, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosse I, Bouchard J, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Bunu C, Burte E, Bush A, Caballero-Fonseca F, Calderon MA, Camuzat T, Cardona V, Carreiro-Martins P, Carriazo AM, Carlsen KH, Carr W, Cepeda Sarabia AM, Cesari M, Chatzi L, Chiron R, Chivato T, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, de Sousa JC, Cox L, Crooks G, Custovic A, Dahlen SE, Darsow U, Dedeu T, Deleanu D, Denburg JA, De Vries G, Didier A, Dinh-Xuan AT, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Du Toit G, Dykewicz MS, Eklund P, El-Gamal Y, Ellers E, Emuzyte R, Farrell J,

- Fink Wagner A, Fiocchi A, Fletcher M, Forastiere F, Gaga M, Gamkrelidze A, Gemicioğlu B, Gereda JE, van Wick RG, González Diaz S, Grisle I, Grouse L, Gutter Z, Guzmán MA, Hellquist-Dahl B, Heinrich J, Horak F, Hourihane JO, Humbert M, Hyland M, Iaccarino G, Jares EJ, Jeandel C, Johnston SL, Joos G, Jonquet O, Jung KS, Jutel M, Kaidashev I, Khaitov M, Kalayci O, Kalyoncu AF, Kardas P, Keith PK, Kerkhof M, Kerstjens HA, Khaltayev N, Kogevinas M, Kolek V, Koppelman GH, Kowalski ML, Kuitunen M, Kull I, Kvedariene V, Lambrecht B, Lau S, Laune D, Le LT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen KC, Louis R, Lupinek C, MacNee W, Magar Y, Magnan A, Mahboub B, Maier D, Majer I, Malva J, Manning P, De Manuel Keenoy E, Marshall GD, Masjedi MR, Mathieu-Dupas E, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Mercier J, Merk H, Miculinic N, Mihaltan F, Milenkovic B, Millot-Keurinck J, Mohammad Y, Momas I, Mösges R, Muraro A, Namazova-Baranova L, Nadif R, Neffen H, Nekam K, Nieto A, Niggemann B, Nogueira-Silva L, Nogues M, Nyembue TD, Ohta K, Okamoto Y, Okubo K, Olive-Elias M, Ouedraogo S, Paggiaro P, Pali-Schöll I, Palkonen S, Panzner P, Papi A, Park HS, Passalacqua G, Pedersen S, Pereira AM, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Pohl W, Popov TA, Portejoie F, Postma D, Poulsen LK, Price D, Rabe KF, Raciborski F, Roberts G, Robalo-Cordeiro C, Rodenas F, Rodriguez-Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rottem M, Sanchez-Borges M, Sastre-Dominguez J, Scadding GK, Scichilone N, Schmid-Grendelmeier P, Serrano E, Shields M, Siroux V, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Strandberg T, Sunyer J, Thijs C, Triggiani M, Valenta R, Valero A, van Eerd M, van Ganse E, van Hage M, Vandenplas O, Varona LL, Vellas B, Vezzani G, Vazankari T, Viegi G, Vontetsianos T, Wagenmann M, Walker S, Wang DY, Wahn U, Werfel T, Whalley B, Williams DM, Williams S, Wilson N, Wright J, Yawn BP, Yiallourous PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clin Transl Allergy* 6:47, 2016.
453. Al-Hameed FM, Al-Dorzi HM, Abdelaal MA, Alaklabi A, Bakhsh E, Alomi YA, Al Baik M, Aldahan S, **Schünemann H**, Brozek J, Wiercioch W, Darzi AJ, Waziry R, Akl EA. The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in long-distance travelers. *Saudi Med J.* 38(1):101-107. 2017.
454. Bousquet J, Bewick M, Cano A, Eklund P, Fico G, Goswami N, Guldemond NA, Henderson D, Hinkema MJ, Liotta G, Mair A, Molloy W, Monaco A, Monsonis-Paya I, Nizinska A, Papadopoulos H, Pavlickova A, Pecorelli S, Prados-Torres A, Roller-Wirnsberger RE, Somekh D, Vera-Muñoz C, Visser F, Farrell J, Malva J, Andersen Ranberg K, Camuzat T, Carriazo AM, Crooks G, Gutter Z, Iaccarino G, Manuel de Keenoy E, Moda G, Rodriguez-Mañas L, Vontetsianos T, Abreu C, Alonso J, Alonso-Bouzon C, Ankri J, Arredondo MT, Avolio F, Bedbrook A, Białoszewski AZ, Blain H, Bourret R, Cabrera-Umpierrez MF, Catala A, O'Caomh R, Cesari M, Chavannes NH, Correia-da-Sousa J, Dedeu T, Ferrando M, Ferri M, Fokkens WJ, Garcia-Lizana F, Guérin O, Hellings PW, Haahtela T, Illario

- M, Inzerilli MC, Lodrup Carlsen KC, Kardas P, Keil T, Maggio M, Mendez-Zorrilla A, Menditto E, Mercier J, Michel JP, Murray R, Nogues M, O'Byrne-Maguire I, Pappa D, Parent AS, Pastorino M, Robalo-Cordeiro C, Samolinski B, Siciliano P, Teixeira AM, Tsartara SI, Valiulis A, Vandenplas O, Vasankari T, Vellas B, Vollenbroek-Hutten M, Wickman M, Yorgancioglu A, Zuberbier T, Barbagallo M, Canonica GW, Klimek L, Maggi S, Aberer W, Akdis C, Adcock IM, Agache I, Albera C, Alonso-Trujillo F, Angel Guarcia M, Annesi-Maesano I, Apostolo J, Arshad SH, Attalin V, Avignon A, Bachert C, Baroni I, Bel E, Benson M, Bescos C, Blasi F, Barbara C, Bergmann KC, Bernard PL, Bonini S, Bousquet PJ, Branchini B, Brightling CE, Brugièrè V, Bunu C, Bush A, Caimmi DP, Calderon MA, Canovas G, Cardona V, Carlsen KH, Cesario A, Chkhartishvili E, Chiron R, Chivato T, Chung KF, d'Angelantonio M, De Carlo G, Cholley D, Chorin F, Combe B, Compas B, Costa DJ, Costa E, Coste O, Coupet AL, Crepaldi G, Custovic A, Dahl R, Dahlen SE, Demoly P, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Du Toit G, Dubakiene R, Dupeyron A, Emuzyte R, Fiocchi A, Wagner A, Fletcher M, Fonseca J, Fougère B, Gamkrelidze A, Garces G, Garcia-Aymeric J, Garcia-Zapirain B, Gemicioğlu B, Gouder C, Hellquist-Dahl B, Hermosilla-Gimeno I, Héve D, Holland C, Humbert M, Hyland M, Johnston SL, Just J, Jutel M, Kaidashev IP, Khaitov M, Kalayci O, Kalyoncu AF, Keijser W, Kerstjens H, Knezović J, Kowalski M, Koppelman GH, Kotska T, Kovac M, Kull I, Kuna P, Kvedariene V, Lepore V, MacNee W, Maggio M, Magnan A, Majer I, Manning P, Marcucci M, Marti T, Masoli M, Melen E, Miculinic N, Mihaltan F, Milenkovic B, Millot-Keurinck J, Mlinarić H, Momas I, Montefort S, Morais-Almeida M, Moreno-Casbas T, Mösges R, Mullol J, Nadif R, Nalin M, Navarro-Pardo E, Nekam K, Ninot G, Paccard D, Pais S, Palummeri E, Panzner P, Papadopoulos NK, Papanikolaou C, Passalacqua G, Pastor E, Perrot M, Plavec D, Popov TA, Postma DS, Price D, Raffort N, Reuzeau JC, Robine JM, Rodenas F, Robusto F, Roche N, Romano A, Romano V, Rosado-Pinto J, Roubille F, Ruiz F, Ryan D, Salcedo T, Schmid-Grendelmeier P, Schulz H, **Schunemann HJ**, Serrano E, Sheikh A, Shields M, Sifakas N, Scichilone N, Siciliano P, Skrindo I, Smit HA, Sourdret S, Sousa-Costa E, Spranger O, Sooronbaev T, Sruk V, Sterk PJ, Todo-Bom A, Touchon J, Tramontano D, Triggiani M, Tsartara SI, Valero AL, Valovirta E, van Ganse E, van Hage M, van den Berge M, Vandenplas O, Ventura MT, Vergara I, Vezzani G, Vidal D, Viegi G, Wagemann M, Whalley B, Wickman M, Wilson N, Yiallourous PK, Žagar M, Zaidi A, Zidarn M, Hoogerwerf EJ, Usero J, Zuffada R, Senn A, de Oliveira-Alves B. Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA. *J Nutr Health Aging*. 21(1):92-104, 2017.
455. Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, **Schünemann HJ**, Chan ES, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. *Ann Intern Med*. 166(2):128-132, 2017.
456. Zhang Y, Flórez ID, Colunga Lozano LE, Bakar Aloweni FA, Kennedy SA, Li A, Craigie S, Zhang S, Agarwal A, Lopes LC, Devji T, Wiercioch W, Riva

- JJ, Wang M, Jin X, Fei Y, Alexander P, Morgano GP, Zhang Y, Carrasco-Labra A, Kahale LA, Akl EA, **Schünemann HJ**, Thabane L, Guyatt G. Reporting and methods for handling missing participant data for continuous outcomes in randomized controlled trials: a systematic survey. *J Clin Epidemiol*. 2017
457. Selva A, Sanabria AJ, Pequeño S, Zhang Y, Solà I, Pardo-Hernandez H, Selva C, **Schünemann H**, Alonso-Coello P. Incorporating patients' views in guideline development: a systematic review of guidance documents. *J Clin Epidemiol*. 2017
458. Guyatt GH, Ebrahim S, Alonso-Coello P, Johnston BC, Mathioudakis AG, Briel M, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, Neumann I, Kahale LA, Iorio A, Meerpohl J, **Schünemann HJ**, Akl EA. GRADE guidelines 17: Assessing the Risk of Bias Associated with Missing Participant Outcome Data in a body of evidence. *J Clin Epidemiol*. 2017.
459. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, Katikireddi SV, Östlund P, Tranæus S, Christensen R, Gartlehner G, Brozek J, Izcovich A, **Schünemann H**, Guyatt G. The GRADE Working Group clarifies the construct of certainty of evidence. *J Clin Epidemiol*, 2017.
460. Doust J, Vandvik PO, Qaseem A, Mustafa RA, Horvath AR, Frances A, Al-Ansary L, Bossuyt P, Ward RL, Kopp I, Golligly L, **Schünemann H**, Glasziou P; Guidelines International Network (G-I-N) Preventing Overdiagnosis Working Group. Guidance for Modifying the Definition of Diseases: A Checklist. *JAMA Intern Med*. 2017
461. Akl EA, Welch V, Pottie K, Eslava-Schmalbach J, Darzi A, Sola I, Katikireddi SV, Singh J, Murad MH, Meerpohl J, Stanev R, Lang E, Matovinovic E, Shea B, Agoritsas T, Alexander PE, Snellman A, Brignardello-Petersen R, Gloss D, Thabane L, Shi C, Stein AT, Sharaf R, Briel M, Guyatt G, **Schünemann H**, Tugwell P. GRADE Equity Guidelines 2: Considering health equity in GRADE guideline development: Equity extension of the Guideline Development Checklist. *J Clin Epidemiol*. May, 2017
462. Dahm P, Oxman AD, Djulbegovic B, Guyatt GH, Murad MH, Amato L, Parmelli E, Davoli M, Morgan RL, Mustafa RA, Sultan S, Falck-Ytter Y, Akl EA, **Schünemann HJ**. Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions. *J Clin Epidemiol*. Jun;86:129-139, 2017.
463. Brožek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lødrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O'Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldán Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-

- Nuñez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, **Schünemann HJ**. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. *J Allergy Clin Immunol*. June, 2017
464. Magni P, Bier DM, Pecorelli S, Agostoni C, Astrup A, Brighenti F, Cook R, Folco E, Fontana L, Gibson RA, Guerra R, Guyatt GH, Ioannidis JP, Jackson AS, Klurfeld DM, Makrides M, Mathioudakis B, Monaco A, Patel CJ, Racagni G, **Schünemann HJ**, Shamir R, Zmora N, Peracino A. Perspective: Improving Nutritional Guidelines for Sustainable Health Policies: Current Status and Perspectives. *Adv Nutr*. Jul 14;8(4):532-545, 2017
465. Yepes-Nuñez JJ, Brožek JL, Fiocchi A, Pawankar R, Cuello-García C, Zhang Y, Morgano GP, Agarwal A, Gandhi S, Terracciano L, **Schünemann HJ**. Vitamin D supplementation in primary allergy prevention: Systematic review of randomized and non-randomized studies. *Allergy*. Jul 4. 2017.
466. Selva A, Solà I, Zhang Y, Pardo-Hernandez H, Haynes RB, Martínez García L, Navarro T, **Schünemann H**, Alonso-Coello P. Development and use of a content search strategy for retrieving studies on patients' views and preferences. *Health Qual Life Outcomes*. Aug 30;15(1):126, 2017.
467. Alonso-Coello P, **Schünemann HJ**, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD; el GRADE Working Group. [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. *Gac Sanit* Aug, 2017.
468. Pottie K, Welch V, Morton R, Akl EA, Eslava-Schmalbach JH, Katikireddi V, Singh J, Moja L, Lang E, Magrini N, Thabane L, Stanev R, Matovinovic E, Snellman A, Briel M, Shea B, Tugwell P, **Schunemann H**, Guyatt G, Alonso-Coello P. GRADE equity guidelines 4: guidance on how to assess and address health equity within the evidence to decision process. *J Clin Epidemiol* Aug 10, 2017
469. Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, **Schünemann H**, Paraskevaidis E, Arbyn M. Cytology versus HPV testing for cervical cancer screening in the general population. *Cochrane Database Syst Rev*. Aug. 10, 2017
470. **Schünemann HJ**, Mustafa R. Decision-making about healthcare related tests and diagnostic strategies Series. Paper 1 : Testing to improve people's health: A new series. *J Clin Epidemiol*. 2017
471. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Vandvik PO, Meerpohl J, Guyatt GH, **Schünemann HJ**; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. *Gac Sanit*. Sept, 2017
472. Mustafa RA, Wiercioch W, Arevalo-Rodriguez I, Cheung A, Prediger B, Ivanova L, Ventresca M, Brozek J, Santesso N, Bossuyt P, Garg AX, Lloyd N, Lelgemann M, Bühler D, **Schünemann H**. Decision-making about

- healthcare related tests and diagnostic strategies: International guidelines show variability in their approaches. *J Clin Epidemiol.* Sept, 2017.
473. Mustafa RA, Wiercioch W, Ventresca M, Brozek J, **Schünemann HJ**; DU-Diagnosis expert group. Decision-making about healthcare related tests and diagnostic strategies: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision-making. *J Clin Epidemiol.* Sept, 2017.
474. Meerpohl JJ, Naude CE, Garner P, Mustafa RA, **Schünemann HJ**. Comment on "Perspective: NutriGrade: A Scoring System to Assess and Judge the Meta-Evidence of Randomized Controlled Trials and Cohort Studies in Nutrition Research". *Adv Nutr.* Sep 15;8(5):789-790. 2017.
475. Mustafa RA, Wiercioch W, Falavigna M, Zhang Y, Ivanova L, Arevalo-Rodriguez I, Cheung A, Prediger B, Ventresca M, Brozek J, Santesso N, Bossuyt P, Garg AX, Lloyd N, Lelgemann M, Bühler D, **Schünemann HJ**. Decision-making about healthcare related tests and diagnostic strategies: A systematic review shows limitations in most tools designed to assess quality and develop recommendations. *J Clin Epidemiol.* Sep, 2017
476. Mustafa RA, Wiercioch W, Cheung A, Prediger B, Brozek J, Bossuyt P, Garg AX, Lelgemann M, Bühler D, **Schünemann HJ**. Decision-making about healthcare related tests and diagnostic strategies: A review of methodological and practical challenges. *J Clin Epidemiol.* Sept 2017
477. Akl EA, Meerpohl JJ, Elliott J, Kahale LA, **Schünemann HJ**; Living Systematic Review Network. Living systematic reviews: 4. living guideline recommendations. *J Clin Epidemiol.* Sept 2017
478. Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, Salanti G, Meerpohl J, MacLehose H, Hilton J, Tovey D, Shemilt I, Thomas J; Living Systematic Review Network. Living systematic review: 1. Introduction-the why, what, when, and how. *J Clin Epidemiol.* Sept 2017

479. Simmonds M, Salanti G, McKenzie J, Elliott J; Living Systematic Review Network. Living systematic reviews: 3. Statistical methods for updating meta-analyses. *J Clin Epidemiol.* Sept 2017. Review. *****
480. Pottie K, Mayhew AD, Morton RL, Greenaway C, Akl EA, Rahman P, Zenner D, Pareek M, Tugwell P, Welch V, Meerpohl J, Alonso-Coello P, Hui C, Biggs BA, Requena-Méndez A, Agbata E, Noori T, **Schünemann HJ**. Prevention and assessment of infectious diseases among children and adult migrants arriving to the European Union/European Economic Association: a protocol for a suite of systematic reviews for public health and health systems. *BMJ Open.* Sep 11;7(9) 2017
481. Akl EA, Kahale LA, Hakoum MB, Matar CF, Sperati F, Barba M, Yosucio VED, Terrenato I, Synnot A, **Schünemann H**. Parenteral anticoagulation in ambulatory patients with cancer. *Cochrane Database Syst Rev.* Sept 2017. Review.
482. Akl EA, Fadlallah R, Ghandour L, Kdouh O, Langlois E, Lavis JN, **Schünemann H**, El-Jardali F. The SPARK Tool to prioritise questions for systematic reviews in health policy and systems research: development

- and initial validation. *Health Res Policy Syst.* Sept 2017
483. Harder T, Takla A, Eckmanns T, Ellis S, Forland F, James R, Meerpohl JJ, Morgan A, Rehfuess E, **Schünemann H**, Zuiderent-Jerak T, de Carvalho Gomes H, Wichmann O. PRECEPT: an evidence assessment framework for infectious disease epidemiology, prevention and control. *Euro Surveill.* October 2017.
484. Morgano GP, Amato L, Parmelli E, Moja L, Davoli M, **Schünemann H**. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.] *Recenti Prog Med.* October 2017.
485. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochweg B, Hazlewood GS, Alhazzani W, Mustafa RA, Murad MH, Puhan MA, **Schünemann HJ**, Guyatt GH; GRADE Working Group. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. *J. Clin Epi.* October 2017
486. Darzi A, Harfouche M, Arayssi T, Alemadi S, Alnaqbi KA, Badsha H, Al Balushi F, Elzorkany B, Halabi H, Hamoudeh M, Hazer W, Masri B, Omair MA, Uthman I, Ziade N, Singh JA, Christiansen R, Tugwell P, **Schünemann HJ**, Akl EA. rection to: Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. *Health Qual Life Outcomes.* October 2017
487. Cuello-Garcia C, Fiocchi A, Pawankar R, Yepes-Nuñez JJ, Morgano GP, Zhang Y, Agarwal A, Gandhi S, Terracciano L, **Schünemann HJ**, Brozek JL. Prebiotics for the prevention of allergies: A systematic review and meta-analysis of randomized controlled trials. *Clin Exp Allergy.* November 2017,
488. Eslava-Schmalbach J, Mosquera P, Alzate JP, Pottie K, Welch V, Akl EA, Jull J, Lang E, Katikireddi SV, Morton R, Thabane L, Shea B, Stein AT, Singh J, Florez ID, Guyatt G, **Schünemann H**, Tugwell P. Considering health equity when moving from evidence-based guideline recommendations to implementation: a case study from an upper-middle income country on the GRADE approach. *Health Policy Plan.* 2017 Dec 1;32(10):1484-1490.

* Dr. Schünemann is a leading member of the GRADE working group and author on this article

** Large overlap between publication in Cochrane library and secondary journal

*** Dr. Schünemann is a member of the Expertise-Based Working Group and author on this article

**** Dr. Schünemann is one of 11 members of the EXACT-PRO Study Group and author on this article

***** Dr. Schünemann is a member of the MOLI-SANI Project Investigators and author on this article

***** Dr. Schünemann is a member of the Control in Canada Research

Team

***** Dr. Schünemann is a member of the GA²LEN study group and author on this article

***** Dr. Schünemann was a member of the American College of Physicians Guideline Committee and group author on this article

***** Dr. Schünemann is a member of the living systematic review network.

^ Articles by students or trainees working under supervision of Dr. Schünemann on the project

Translation and adaptation of previously published article

& Corresponding author (only indicated if not first, second or last author)

Other peer reviewed publications (including invited editorials)

1. **Schünemann HJ**, Muti P, Trevisan M. Serum indicators of free radical activity in idiopathic pulmonary fibrosis (letter). *American Journal of Respiratory and Critical Care Medicine* 155 (2): 769, 1997.
2. Devereaux PJ, **Schünemann HJ**, Cook DJ, Bhandari M, Ravindran N, Grant BJB, Lacchetti C, Lavis JN, Haslam DRS, Haines T, Sullivan T, Guyatt GH. Reply letter to comments on: A systematic review and meta-analysis of studies comparing mortality between private for-profit and private not-for-profit dialysis centers. *JAMA*;289:3089-3090, 2003
3. Bhandari M, Khera V, **Schünemann HJ**. Risky Business: How the presentation of the risks of medical and surgical therapies to patients affects their decisions (invited research article). *Canadian Journal of Diagnosis*; May: 27 – 28; 2003. (Name misspelled as Shünemann)
4. Akl E, **Schünemann HJ**. Goodbye, Number Needed to Treat. [Letter to the editor]. *J Clin Epidemiology* 57(2):219-20, 2004.
5. Puhan MA, Büsching G, van Oort E, Zaugg C, **Schünemann HJ**, Frey M. Interval Exercise versus Continuous Exercise in Patients with Moderate to Severe COPD - Study Protocol for a Randomized Controlled Trial. *BMC Pulmonary Medicine* Aug 13;4(1):5, 2004.
6. **Schünemann HJ**. Is there an association of impaired pulmonary function with mortality in never smokers? An unanswered question (letter). *Thorax* 59: 81, 2004.
7. Puhan M, **Schünemann HJ**. Testosterone supplementation during respiratory rehabilitation. Letter to the editor. *American Journal of Respiratory and Critical Care Medicine*;172(3):399, 2005.
8. Schwam E, Mueller C, **Schünemann HJ**, Akl E. Rapid measurement of B-type natriuretic peptides reduced time to discharge and treatment costs in patients with acute dyspnea (Letter). *ACP J Club*. 2005 Jan-Feb;142(1):A14
9. Carling C, **Schünemann HJ**, Oxman A. How should information about the

- effects of healthcare be presented? *Med Gen Med* 5;5(3):35, Sep 2003.
10. Hirsh J, Albers G, Guyatt G, **Schünemann H**. Introduction to the 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. *Chest* 126:S1-S2, 2004.
 11. Guyatt G, Devereaux PJ, Montori V, **Schünemann HJ**, Bhandari M. Putting the patient first: In our practice, and in our use of language. *ACP Journal Club* 2004 Jan-Feb;140:A11 – 2 & *Evidence Based Medicine*, 2004.
 12. **Schünemann HJ**. Commentary on: Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma published in *Cochrane Database Syst Rev*; (4):CD001186, 2003. *ACP Journal Club* 141:1, Sep-Oct 2004.
 13. Jaeschke R, **Schünemann HJ**, Devereaux PJ, Guyatt GH. Evidence based health care as a model for decision making. *Journal of Evidence Based Dental Practice* 4:4-7, 2004.
 14. **Schünemann HJ**, Akl E. Commentary on: Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea published in *N Engl J Med*. 2004;350:647-54. *ACP Journal Club* 141:16, Sep-Oct 2004.
 15. **Schünemann HJ**. Doubling the dose of inhaled corticosteroids during asthma deterioration did not improve asthma control. *ACP J Club* 141(2):37, 2004.
 16. **Schünemann HJ**, Guyatt GH. Goodbye (M)CID! Hello MID, where do you come from? *Health Services Research* 40(2):593-7, 2005.(invited editorial)
 17. Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, **Schünemann H**. An Emerging Consensus on Grading Recommendations? *ACP JC* 144(1):A8-9, 2006 and *Evid Based Med* 2006. 11: 2-a-4-a
 18. **Schünemann HJ**, Heffner JE. A New ATS Committee: Competing in the Marketplace of Ideas. *Am J Respir Crit Care Med* 1;172(9):1067-8, 2005 & *Am J Respir Cell Mol Biol*. 33(5):423-4, 2005 & *Proceedings of the American Thoracic Society* 2(4):249-50, 2005.
 19. **Schünemann HJ**, Heffner. A New ATS Committee: Competing in the Marketplace of Ideas. Filippatos GS, **Schunemann H**, Kremastinos DT. Management with a pulmonary artery catheter did not reduce all-cause mortality in critically ill patients. *ACP J Club*144(1):2, 2006.
 20. Brozek J, Guyatt G and **Schünemann HJ**. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. *Health Qual Life Outcomes* 27;4(1):69, Sep 2006.
 21. Stanulla M, **Schünemann HJ**. Thioguanine versus mercaptopurine in childhood ALL. *The Lancet*. 14;368(9544):1304-6, 2006. (invited editorial and meta analysis)
 22. Green S, Higgins JP, **Schünemann H**, Becker L. Response paper by Lang A, Edwards N, and Fleischer A. *J Clin Epidemiol* 60(6):598-9, 2007 (invited editorial)
 23. **Schünemann HJ**, Castell M, Muti P. Systematic reviews for the Journal of

- Experimental and Clinical Cancer Research: Going where the science takes us. *J. Exp. Clin. Cancer. Res.*26(2);169-174 2007.
24. Bryant D, Brozek L, Jaeschke R, **Schünemann H**, Guyatt G. Commentary: Can guideline-defined asthma control be achieved and how it influences patients' quality of life – the goal study. *Med. Prakt* 195(5):142-144, 2007.
 25. **Schünemann H**. Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease. *Evid Based Med.* 12(4):114, 2007.
 26. Gajewski P, Jaeschke R, Brozek J, **Schünemann H**. Can clinical practice guidelines lead astray?. *Pol Arch Med Wewn.* 117(4):12-5, 2007.
 27. Bryant D, **Schünemann H**, Brozek J, Jaeschke R, Guyatt G. Patient reported outcomes: general principles of development and interpretability. *Pol Arch Med Wewn.* 11(4):5-11, 2007.
 28. Akl EA, Pretorius R, Sackett K, Erdley S, Bhootpathi PS, **Schünemann H**. Educational Games for students in health care professions. Protocol. The Beme Collaboration 2008.
 29. Bousquet J, Bieber T, Fokkens W, Humbert M, Kowalski ML, Niggemann B, Simon HU, **Schünemann H**. Consensus statements, evidence-based medicine and guidelines in allergic diseases. *Allergy* 63(1):1-4, 2008.
 30. Capurso G, **Schünemann H**, Delle Fave G. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. *Cancer* 112(3):671-2, 2008.
 31. **Schünemann HJ**. COPD Dashboards – invited editorial. *European Respiratory Journal* 31(2):238-40, 2008.
 32. Hirsh J, Guyatt G, Albers GW, Harrington R, **Schünemann HJ**. Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 133;71S–109S, 2008.
 33. Hirsh J, Guyatt G, Albers GW, Harrington R, **Schünemann HJ**. Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 133;110S–112S, 2008.
 34. Akl EA, Muti P, **Schünemann HJ**. Anticoagulation in patients with cancer: an overview of reviews. *Pol Arch Med Wewn* 118(4):183-93, 2008.
 35. Bousquet J, Fokkens W, Burney P, Durham SR, Bachert C, Akdis CA, Canonica GW, Dahlen SE, Zuberbier T, Bieber T, Bonini S, Bousquet PJ, Brozek JL, Cardell LO, Cramer R, Custovic A, Demoly P, van Wijk RG, Gjomarkaj M, Holland C, Howarth P, Humbert M, Johnston SL, Kauffmann F, Kowalski ML, Lambrecht B, Lehmann S, Leynaert B, Lodrup-Carlsen K, Mullol J, Niggemann B, Nizankowska-Mogilnicka E, Papadopoulos N, Passalacqua G, **Schünemann HJ**, Simon HU, Todo-Bom A, Toskala E, Valenta R, Wickman M, Zock JP. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. *Allergy* 63(7):842-53, 2008.
 36. Karanickolas PJ, Montori VM, Devereaux PJ, **Schünemann H**, Guyatt GH. The practicalists' response. *J Clin Epidemiol* 62: 489-494, 2009

37. **Schunemann H**, Kunz R, Falck-Ytter Y, Santesso N. Procedures and methods of benefit assessments for medicines in Germany: give the child a name. *Eur J Health Econ* 10: 237-238, 2009
38. **Schunemann HJ**, Kunz R, Falck-Ytter Y. 2009. [Procedures and methods of benefit assessments for medicines in Germany - a comment - letter no. 2]. *Dtsch Med Wochenschr* 134: 319-320; author reply 320.
39. Akl EA, **Schünemann HJ**. Ask the Expert: Treatment of Thromboembolism in Cancer. *American Journal of Hematology/Oncology* 8 (6): 313-314, June 2009.
40. Puhan MA, **Schünemann HJ**. How to increase the value of randomized trials in COPD research. *European Respiratory Journal* 34 (3): 552-8, September 2009.
41. **Schünemann H**. From BODE to ADO to outcomes in multimorbid COPD patients. *The Lancet* 373:667-68, 2009.
42. Karanicolas PJ, Montori VM, **Schünemann HJ**, Guyatt GH. ACP Journal Club. "Pragmatic" clinical trials: from whose perspective? *Ann Intern Med.* 150(12): JC6-2, JC6-3, June, 2009.
43. Karanicolas PJ, Montori VM, **Schünemann HJ**. Guyatt GH. "Pragmatic" clinical trials: from whose perspective? *Evid Based Med.* 14(5):130-1, October, 2009.
44. Falck-Ytter Y, **Schünemann H**, Guyatt G. AHRQ series commentary 1: rating the evidence in comparative effectiveness reviews. *Clin Epidemiol.* 63(5):474-5, May 2010.
45. **Schünemann HJ**, Santesso N, Brozek J; on behalf of the Antivirals for Treatment of Influenza Observational Studies Group. Antivirals for Treatment of Influenza. *Ann Intern Med.* Sep 4;157(5):386-387, 2012.
46. Santesso N[^], Akl E, Mente A, Heels-Ansdell D, **Schünemann HJ**. Reply to higher- versus lower-protein diets. *Eur J Clin Nutr.* 2012.
47. Schunemann H, Xie F. Acknowledgement of manuscript reviewers 2015. *Health Qual Life Outcomes.* 14: 29, 2016.

Technical Reports - Peer reviewed (selected)

1. **WHO**. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. . Schünemann H, methods support. 2010 Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf
2. **WHO**. Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis: Policy Statement. Schünemann H, methods support. 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241502054_eng.pdf

Abstracts (selected)

1. Böning D, **Schünemann HJ**, N. Maassen, M.W. Busse: Oxylabile CO₂ and Lactate; *Pflügers Arch.* 418, Suppl. 1: R109, 1991.
2. Klocke RA, **Schünemann HJ**, Grant BJB. Distribution of pulmonary capillary transit Times. *American Journal of Respiratory and Critical Care Medicine* 151:A519, 1995.
3. **Schünemann HJ**, Trevisan M, Muti P, Markovic N, Armstrong D, Klocke RA, Freudenheim J. Oxidative stress and lung function in men. *American Journal of Respiratory and Critical Care Medicine* 153: A99, 1996.
4. Kumar M, **Schünemann HJ**, Lwebuga-Mukasa JS. Modulation of laminin isoform genes in neonatal and adult rat lungs. *American Journal of Respiratory and Critical Care Medicine* 153: A231, 1996.
5. **Schünemann HJ**, Nielsen LC, Lwebuga-Mukasa JS. Expression of β_1 mRNA in early postnatal and adult rat lungs. *American Journal of Respiratory and Critical Care Medicine* 153: A232, 1996.
6. Kumar NM, **Schünemann H**, Dillon D, Lwebuga-Mukasa JS. Regulation of Laminin β_1 , β_2 , β_3 , γ_1 , and γ_2 isoform chains in neonatal and adult rat lungs in vivo and alveolar epithelial cells in vitro. *Molecular Biology of the Cell* 7:53a, 1996.
7. Muti P, Trevisan M, Micheli A, Krogh V, Bolelli GF, **Schünemann HJ**, Sciajno R, Berrino F. Alcohol consumption and total estradiol in premenopausal women. Presented at: AACR conference on Basic and Clinical Aspects of Breast Cancer, March 7th - 13, 1997, Keystone, CO.
8. **Schünemann HJ**, Trevisan M, Muti P, Armstrong D, Brown R, Freudenheim JL. Serum levels of carotenoids and pulmonary function (results of the pilot study). *American Journal of Respiratory and Critical Care Medicine* 155: A188, 1997.
9. **Schünemann HJ**, Freudenheim JL, Muti P, Armstrong D, Carosella AM, Markovic N, Trevisan M. Cross-sectional study of vitamin C and a marker of lipid per-oxidation. *American Journal of Epidemiology* 145(11):S71, 1997.
10. Carosella AM, **Schünemann H.J**, Muti P, Freudenheim JL, Dorn J, Armstrong D, Markovic N, Trevisan M. Oxidation parameters and body fat. *American Journal of Epidemiology* 145(11):S71, 1997.
11. Trevisan M, **Schuenemann H**, Freudenheim JL, Muti P, Russell M, Carosella AM, Armstrong D. Alcoholic beverages and oxidation. *American Journal of Epidemiology* 145(11):S71, 1997.
12. Alam H, **Schünemann H**, Lopez-Candales A. Correlation between interatrial septal thickness and atrial fibrillation in the elderly. *American Journal of Geriatric Cardiology* 7: 54, 1998.
13. Alam H, **Schünemann H**, Lopez-Candales A. Significance of the lymphocyte count in elderly patients with acute coronary syndromes. *American Journal of Geriatric Cardiology* 7: 54, 1998
14. Alam H, **Schünemann H**, Lopez-Candales A. Abnormal indices of left ventricular diastolic filling during dobutamine stress echocardiography in

- women is dependent on age and not the presence of ischemia. *Journal of Investigative Medicine* 46:203A, 1998.
15. Alam H, **Schünemann H**, Lopez-Candales A. Slow heart rate recovery in the immediate post exercise period may be related to ischemia. *Journal of Investigative Medicine* 46:203A, 1998.
 16. Arab D, Valeti V, **Schünemann HJ**, Lopez-Candales A. Analysis of the qtc segment as a predictor to detect ischemia in patients undergoing exercise stress testing. Presented at the Annual Meeting of the American College of Physicians, New Orleans, April 1999.
 17. **Schünemann HJ**, Dorn J, Grant BJB, Winkelstein, Jr W, Trevisan M. Is pulmonary function a long-term predictor of mortality in the general population? *American Journal of Respiratory and Critical Care Medicine* 159: A320, 1999.
 18. **Schünemann HJ**, Dmochowski J, Campbell LA, Grant BJB. The relation of total lung capacities measured by helium dilution and body plethysmography. *American Journal of Respiratory and Critical Care Medicine* 161; 2001.
 19. **Schünemann HJ**, Grant BJB, Freudenheim J, Muti P, Browne R, Drake J, Klocke R, Trevisan M. The relation of antioxidant vitamins C and E serum levels with lung function in the general population. *European Respiratory Journal* 16 (Suppl 31): 176S, 2000.
 20. Muti P, Quattrin T, Miscagnia G, Krogh V, Micheli A, **Schünemann H**, Ram M, Freudenheim JL, Trevisan M, Browne R, Grant B, Berrino F. Fasting glucose and insulin, and subsequent risk of breast cancer in premenopausal and postmenopausal women: the ORDET Study. American Association for Cancer Research, Annual Meeting, New Orleans, March 2001.
 21. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A clinical trial to evaluate the responsiveness and validity of two direct health state preference instruments administered with and without hypothetical marker states in chronic respiratory disease. *American Journal of Respiratory and Critical Care Medicine* 163;A642, 2001.
 22. **Schünemann HJ**, McCann S, Grant BJB, Muti P, Trevisan M, Freudenheim JL. Lung function in relation to dietary intake of carotenoids and other antioxidant vitamins in a population-based study. *European Respiratory Journal* 18: S199, 2001 (discussion session)
 23. Grant BJB, Kadlubar D, McCann S, Muti P, Trevisan M, Freudenheim JL, **Schünemann HJ**. RDW and lung function. *European Respiratory Journal* 18: S506, 2001 (oral presentation)
 24. Oxman AD, Briss P, Eccles M, Grimshaw JM, Guyatt G, Phillips B, **Schünemann H**, Vist G, Zaza S. Grading evidence and recommendations. *BMC Meeting Abstracts: 9th International Cochrane Colloquium* 1:pc148, 2001
 25. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A clinical trial to evaluate the responsiveness and validity of two direct health state preference instruments administered with and without hypothetical marker

- states in chronic respiratory disease. *American Journal of Respiratory and Critical Care Medicine*. 165; A587, 2002 (discussion session)
26. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A randomized controlled trial to evaluate the effect of informing patients about their pretreatment responses to two respiratory questionnaires. *American Journal of Respiratory and Critical Care Medicine* 165; A45, 2002.
 27. **Schünemann HJ**, Grant BJB, Freudenheim JL, Muti P, McCann S, Kudalkar D, Ram M, Russell M, Trevisan M. What do your lungs prefer: Red wine or white wine? *American Journal of Respiratory and Critical Care Medicine* 165; A137, 2002. (discussion session)
 28. **Schünemann HJ**, Guyatt GH, Ståhl E, Stubbing D, Mador J, McKim D, Austin P, Goldstein R. Validation of a new version of the chronic respiratory questionnaire (CRQ): the self-administered standardized CRQ. *European Respiratory Journal* 20;156S, 2002. (Presentation in Stockholm, Sweden, September 15, 2002)
 29. **Schünemann H.**, Guyatt GH, Stahl E, Austin P, Akl E, Armstrong D, Stubbing D. A comparison of narrative and point-by-point formats for presenting hypothetical health states: results from two randomized trials (oral presentation at ISOQOL – International Society of Quality of Life, Orlando, FL, November 1, 2002). *Quality of Life Research* 11; 641, 2002
 30. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A clinical trial to evaluate the responsiveness and validity of two direct health state preference instruments administered with and without hypothetical marker states in chronic respiratory disease (oral presentation at ISOQOL – International Society of Quality of Life, Orlando, FL, November 1, 2002). *Quality of Life Research* 11; 644, 2002
 31. Ochs H, Grant BJB, Muti P, Freudenheim J, Browne R, Trevisan M, **Schünemann HJ**. The Relation of Serum Levels of Antioxidant Vitamins and Pulmonary Function in Individuals with Airway Disease. *American Journal of Respiratory and Critical Care Medicine* 167; A444, 2003
 32. Ochs HM, Freudenheim J, McCann S, Grant BJB, Muti P, Trevisan M, Potischman N, **Schünemann HJ**. A novel method of investigating the antioxidant vitamin-lung function association: Classification of Antioxidant Status Using Serum and Dietary Level. *American Journal of Respiratory and Critical Care Medicine* 167; A128, 2003
 33. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbing D, Goldstein R. A Comparison of the Original Chronic Respiratory Questionnaire (CRQ) with a Standardized Version. *American Journal of Respiratory and Critical Care Medicine* 167; A226, 2003
 34. **Schünemann HJ**, Stahl E, Mador J, McKim D, Stubbing D, Goldstein R, Guyatt GH. Validation of a Self-Administered, Standardized Version of the Chronic Respiratory Questionnaire (CRQ). *American Journal of Respiratory and Critical Care Medicine* 167; A226, 2003
 35. Akl EA, Grant BJB, Guyatt GH, **Schünemann HJ**. Development of a decision aid for COPD patients considering inhaled steroid therapy

- (Resident Scholarly Exchange Day University at Buffalo, April 24, 2003)
BMC Med Inform Decision Making 7:12, 2007
36. Shaukat A, Ochs H, Muti P, Freudenheim J, Grant BJB, McCann S, Trevisan M, **Schünemann HJ**. Is being breastfed as an infant associated with lung function as an adult? (Resident Scholarly Exchange Day University at Buffalo, April 24, 2003)
 37. **Schünemann HJ**, Guyatt GH, Griffith L, Stubbings D, Goldstein R. Evaluation of the Minimal Important Difference for the Feeling Thermometer and the St. George's Respiratory Questionnaire in Patients with Chronic Airflow Obstruction. *American Journal of Respiratory and Critical Care Medicine* 167; A224, 2003
 38. Ochs H, Grant BJB, Muti P, Freudenheim J, Browne R, Trevisan M, **Schünemann HJ**. Antioxidant Vitamins and Pulmonary Function in Individuals with Airway Disease (for oral presentation by HJ Schünemann, European Respiratory Society Congress, 2003) *European Respiratory Journal* 22; suppl 45; September; 352s, 2003
 39. Puhan M, Behnke M, Laschke M, Lichtenschopf A, Brändli O, Guyatt GH, **Schünemann HJ**. Self-administration and standardization of the CRQ: A randomised trial in three German-speaking countries. *European Respiratory Journal* 22; suppl 45; September; 56s, 2003
 40. **Schünemann HJ**, Herrin J, Vist G, Oxman A, Akl E. The impact of framing on decision making (oral presentation at XI Cochrane Colloquium, 2003)
 41. Frost MH, Bonomi AA, Cappelleri JC, **Schünemann H**, Moynihan TJ, Aaronson N. Applying quality-of-life data formally and systematically into clinical practice. *Clin Ther* 25 Suppl D:D10, 2003
 42. Akl EA, Maroun N, Klocke RA, **Schünemann HJ**. Is shorter better? A survey of internal medicine residents and faculty about the duration of attendings' in-patient rotations. (submitted to American College of Physicians annual meeting, 2004)
 43. Akl EA, Maroun N, Klocke RA, Montori V, **Schünemann HJ**. Electronic versus postal mail for surveying internal medicine residents and faculty: a randomized controlled trial. (submitted to American College of Physicians annual meeting, 2004)
 44. **Schünemann HJ** for the GERD Utilities Writing Group. A randomized multi-center trial to compare utility elicitation techniques with and without hypothetical health states. *Quality of Life Research* 12;7: 737, 2003. (oral presentation at International Society for Quality of Life Research, ISOQOL Meeting, November 2003)
 45. **Schünemann HJ**, Puhan M, Behnke M, Laschke M, Lichtenschopf A, Brändli O, Guyatt GH. Self-administration and standardization of the chronic respiratory questionnaire: A randomized trial. *Quality of Life Research* 12;7: 781, 2003.
 46. Arora N, Patel P, Sempos CT, **Schünemann HJ**, Grant BJB. Relation between Red Cell Distribution Width (RDW) and Spirometry in the Third National Health and Nutrition Examination Survey (NHANES III). *American Journal of Respiratory and Critical Care Medicine* 169: A356, 2004

47. Akl EA, Grant BJB, Guyatt GH, **Schünemann HJ**. Development of a Interactive Computer Decision Aid for COPD Patients: The Example of Inhaled Corticosteroid Therapy. *American Journal of Respiratory and Critical Care Medicine* 169: A730, 2004
48. Krishnan G, Grant BJB, Ochs H, Muti P, Freudenheim J, Trevisan M, **Schünemann HJ**. Between Anemia and Quality of Life in Individuals with Chronic Obstructive Pulmonary Disease (COPD). *American Journal of Respiratory and Critical Care Medicine* 169: A616, 2004
49. Ochs H, Grant BJB, Muti P, Freudenheim J, Browne R, Trevisan M, **Schünemann HJ** Pulmonary function and abdominal obesity. *American Journal of Respiratory and Critical Care Medicine* 169: A724, 2004
50. **Schünemann HJ**, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Grant BJB, Guyatt GH. Does self-administration of health-related quality of life instruments impair measurement properties? *American Journal of Respiratory and Critical Care Medicine* 169: A326, 2004
51. Kho ME, Choong K, Friedberg J, Weeks JC, **Schünemann H**. Application of GRADE in Hematological Malignancy: Watchful Waiting vs. Immediate Systemic Treatment in Indolent Non-Hodgkin's Lymphoma (XII. Cochrane Colloquium, Ottawa, Canada, October 2004).
52. C. A. Fallone, G. Guyatt, D. Armstrong, A. degli'Innocenti, I. Wiklund, L. Tanser, S. Veldhuyzen van Zanten, D. Heels-Ansdell, S. El-Dika, N. Chiba, A. N. Barkun, P. Austin, **Schünemann HJ**. How Well Do Physicians Assess Patient Symptom Severity and Health-Related Quality Of Life (HRQL) In Gastro-esophageal Reflux Disease (Gerd)? (12th UEGW CONGRESS, Prague, 25-30 September 2004)
53. Wahlqvist P, Guyatt G, Armstrong D, Austin P, Barkun A, Chiba N, degl'Innocenti A, El-Dika S, Fallone C, Heels-Ansdell D, Tanser L, Veldhuyzen van Zanten S, Wiklund I, **Schünemann H**. Responsiveness To Change And English Language Validation Of The Wpai-Gerd Questionnaire - Results From A Canadian Study. ISPOR 9th Annual, International Meeting, May 16-19, Arlington. *Value in Health* 7 (3): 349-349, may-June, 2004.
54. Shaukat A, Scouras N, **Schünemann HJ**. Role of supplemental calcium in the recurrence of colorectal adenomas: A meta-analysis of randomized controlled trials. *Gastroenterology* 126(4)suppl 2: P-200, 2004
55. Devereaux PJ, Choi P, El-Dika S, Bhandari M, Montori V, **Schünemann H**, Garg A, Busse J, Heels-Ansdell D, Ghali W, Manns B, Guyatt G. An observational study comparing what authors report in randomized controlled trial publications with what they subsequently state on direct contact. *Clinical Trials* 1: 234, 2004
56. Heels-Ansdell D, Guyatt G, Wiklund I, degl'Innocenti A, Armstrong D, **Schünemann H**. Relative responsiveness of health-related quality of life instruments for patients with gastro-esophageal reflux disease. *Clinical Trials* 1: 225, 2004.
57. **Schünemann HJ**, Goldstein R, Mador J, McKim D, Stahl E, Griffith L, Austin P, Grant BJB, Guyatt GH. Do Marker States improve measurement

- properties of utility instruments: a randomized multi-center trial in patients with chronic respiratory disease. *European Respiratory Journal* 24(48):296S, 2004
58. **Schünemann HJ**, Goldstein R, Mador MJ, McKim D, Stahl E, Austin P, Guyatt G. Do marker states improve measurement properties of utility instruments: a randomized multi-centre trial in patients with chronic obstructive pulmonary disease. *Quality of Life Research* 13(9):1500, 2004
 59. **Schünemann HJ**, Norman G, Stahl E, Wiklund I, Puhan M, Guyatt, G. Application of generalizability theory to assess reliability of health marker states. *Quality of Life Research* 13(9):1550, 2004
 60. Wiklund I, Guyatt GH, El-Dika S, **Schünemann HJ**. Comparison of the effects of gastro-esophageal reflux disease and other chronic diseases on utility values – results of the Canadian feeling thermometer study. *Quality of Life Research* 13(9):1587, 2004
 61. Wiklund I, Armstrong D, Heels-Ansdell D, Guyatt GH, **Schünemann HJ**. Symptom relief results in improved quality of life: The Canadian Feeling Thermometer Study in patients with uninvestigated reflux disease. *Quality of Life Research* 13(9):1588, 2004
 62. degl'Innocenti A, Guyatt GH, Wiklund I, Armstrong D, Heels-Ansdell, Chiba N, Austin P, Tanser L, Fallone CA, Barkun AN, vanZanten S, El-Dika S, **Schünemann HJ**. *Quality of Life Research* 13(9):1588, 2004
 63. **Schünemann HJ** Guidelines of the American College of Chest Physicians. *Haematologica* 89(8):2, 2004.
 64. Puhan MA, **Schunemann HJ**, Frey M, Bachmann LM. Supplemental Interventions to Enhance the Effectiveness of Respiratory Rehabilitation in Patients with COPD. *American Journal of Respiratory and Critical Care Medicine*: A53, 2005
 65. Puhan MA, **Schunemann HJ**, Frey M, Scharplatz M, Bachmann LM. How Should COPD Patients Exercise during Respiratory Rehabilitation? Comparison of Exercise Modalities and Intensities To Treat Skeletal Muscle Dysfunction. *American Journal of Respiratory and Critical Care Medicine*: A54, 2005
 66. Puhan MA, Guyatt GH, Goldstein R, McKim D, Stahl E, Griffith L, **Schunemann HJ**. Relative Responsiveness of Health-Related Quality of Life Instruments for Patients with COPD. *American Journal of Respiratory and Critical Care Medicine*: A644, 2005
 67. Ochs-Balcom HM, Grant BJB, Muti P, Sempos CT, Freudenheim, Browne RW, Trevisan M, Iacoviello L, **Schunemann HJ**. Oxidative Stress and Pulmonary Function in the General Population. *American Journal of Respiratory and Critical Care Medicine*: A410, 2005
 68. Puhan MA, Scharplatz M, **Schunemann HJ**, Steurer J. Effectiveness of Respiratory Rehabilitation after Acute Exacerbation of COPD. *American Journal of Respiratory and Critical Care Medicine*: A404, 2005
 69. Mear I, Guyatt G, Jost F, Zamora L, **Schunemann HJ**. Measuring the Impact of COPD on Patients' Lives in an International Study. *Eur Respir J*

- 26:49, 513s, 2005
70. Clayson D, Johnson A , Gilbert C, Jackson M, Hareendran A, Compton C, **Schunemann HJ**. Psychometric Validation of an Electronic Diary to Measure Symptoms of COPD. *European Respir J* 26:49, 514s, 2005
 71. Guyatt G, Montori V, Bucher H, Denereaux P, **Schunemann HJ**, Briel M. Stopping Early should be a methodologic quality criterion for Cochrane reviews. XIII Cochrane Colloquium-Program and Abstracts Guidebook, p. 51:22-26 Oct, 2005
 72. Claring C, Kristofferson D, Flootorp S, Fretheim A, Oxman A, **Schunemann HJ**, Akl E, Devereaux P. The Effect of Alternative Graphical Displays to present Benefits of Antibiotics for Sore Throat on Helping People to Make Treatment Choices Consistent with Their Own Values. XIII Cochrane Colloquium-Program and Abstracts Guidebook, p. 54 22-26 Oct, 2005.
 73. **Schunemann HJ**, Guyatt G, Vist G,. Grading Recommendations Assessment, Development and Evaluation (GRADE): an International Working Group. XIII Cochrane Colloquium-Program and Abstracts Guidebook, p.184 22-26 Oct, 2005
 74. Puhan MA, Buesching G, vanOort E, **Schünemann HJ**, Zaugg CE, Frey M. Interval exercise for patients with severe COPD – randomized trial [SRCTN11611768]. Oral presentation at European Respiratory Society Meeting, Munich, September 3, 2006. *European Respiratory Journal* 2006
 75. **Schünemann HJ**. Making Progress: Values and Preferences in American College of Chest Physicians Guidelines. International Society for Quality of life Research Meeting, Lisbon, Portugal, October 13. *The QLR Journal*, page A-7, Abstract 1918, 2006
 76. **Schünemann HJ**. Integrating Values Preferences in Clinical Practice Guidelines: How Can We Make It Happen? International Society for Quality of life Research Meeting, Lisbon, Portugal, October 13. *The QLR Journal*, page A-7, Abstract 1917, 2006
 77. **Schünemann HJ**. Values, Preferences and Guidelines: The Long Road to Make Clinical Decision Makers. International Society for Quality of life Research Meeting, Lisbon, Portugal, October 13. *The QLR Journal*, page: A-7, Abstract 1922, 2006
 78. Puhan MA, Soesilio I, Guyatt GH, **Schünemann HJ**. Strength and Nature of the Relationship between Chronic Respiratory Questionnaire (CRQ) and St. Georges Respiratory Questionnaire Scores (SGRQ). American Thoracic Society International Conference, San Diego, USA, May 21. *Proceedings of the American Thoracic Society*, Volume 3, publication page: A123, 2006
 79. Puhan MA, **Schünemann HJ**, Busching G, vanOort E, Zaugg CE, Frey M. The Exercise Tolerance Questionnaire for COPD Patients. American Thoracic Society International Conference, San Diego, USA, May 22. *Proceedings of the American Thoracic Society*, Volume 3, publication page: A318, 2006
 80. Puhan MA, **Schünemann HJ**. Reanalysis of respiratory rehabilitation trials

- reveals major heterogeneity across trials. American Thoracic Society International Conference, San Diego, USA, May 24. Proceedings of the American Thoracic Society, Volume 3, publication page: A814, 2006
81. Barba M, Terrenato I, Fuhrman B, Teter b, **Schünemann H**, Muti P. Secondary Sexual Characteristics and body Size at different stages in relation to risk of prostate cancer: results from case control study. Annual Meeting, American Association for Cancer Research, Washington, USA, April 3. Proc Amer Assoc Cancer Res, Volume 47, Abstract #2019, 2006
 82. Capurso G, Terrenato I, Moretti A, Koch M, Capurso L, **Schünemann HJ**, Delle Fave G. Aspirin and risk of pancreatic cancer: a systematic review. XXX Congresso Nazionale Associazione Italiana per lo studio del Pancreas, Milano, Italy, September 21-23. Journal of the Pancreas online 2006, 7 (5 Suppl.): 518-77, 2006
 83. Adhikari NKL, Sinuf T, Patel R, Meade MO, **Schünemann HJ**, Cook DJ. Professional Society Guidelines (CPGs) and Consensus Conference Statements (CCSs) in Critical Care: Critical Appraisal of Quality. ATS American Journal of Respiratory and Critical Care Medicine: A796, 2007
 84. Hareendran A, Martin ML, Bushnell DM, Gilbert C, **Schünemann HJ**, Patrick DL. Cross-Cultural Patient Endorsement of Distinct Sensations of Dyspnea in Chronic Obstructive Pulmonary Disease (COPD): Implications for Measurement. American Journal of Respiratory and Critical Care Medicine: A636, 2007
 85. Gilbert C, Martin ML, Hareendran A, Bushnell DM, Patrick DL, **Schünemann HJ**. Capturing Individual Variation in the Experience of Symptoms Reported by Patients with Chronic Obstructive Pulmonary Disease (COPD). American Journal of Respiratory and Critical Care Medicine: A285, 2007
 86. Jaeschke R, Mejza F, Lesniak W, Brozek, J, **Schünemann HJ**, Guyatt G, Nair P, Sears MR, O'Byrne PM. The Safety of Formoterol among Patients with Asthma Using Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine: A57, 2007
 87. Puhan MA, Busching G, **Schünemann HJ**, van Oort E, Spaar A, Zaugg C, Frey M. Tolerance of Interval and Continuous Exercise in Chronic Obstructive Pulmonary Disease: Subgroup analysis of a Randomized Trial. American Journal of Respiratory and Critical Care Medicine: A601, 2007
 88. Elie A. Akl, Deborah J. Cook, Paola Muti, Milo A. Puhan, Victor M. Montori, Gordon H. Guyatt, **Schünemann HJ**. Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer. Cochrane Colloquium. Sao Paulo, Brazil. Oct 2007 (poster presentation)
 89. E.A. Akl, N. Maroun, S. Major, C. Afif, A. Abdo, J. Choucair, M. Sakr, **Schünemann HJ**. The US is the top destination country of Lebanese medical students seeking abroad training and jobs. Third Annual AAMC Physician Workforce Research Conference. Bethesda, MD, May 2007 (poster presentation)
 90. R. Mustafa, B.J.B. Grant, J. Fudyma, **Schünemann HJ**, E.A. Akl. The

- effect of restructuring an Internal Medicine night float system: a before and after survey of residents and attendings. Resident Scholarly Exchange Day University at Buffalo, May 2007 (poster presentation)
91. E.A. Akl, B. Khater-Menassa, N. Maroun, S. Major, C. Afif, A Abdo, J. Choucair, M. Sakr, C.K. Li, B.J.B. Grant, **Schünemann HJ**. Factors influencing Lebanese medical students' decisions to train abroad: evaluation of a conceptual framework. Middle East Medical Asssembly. Beirut, Lebanon. May 2007 (poster presentation)
 92. 5. E.A. Akl, B. Khater-Menassa, N. Maroun, S. Major, C. Afif, A Abdo, J. Choucair, M. Sakr, C.K. Li, B.J.B. Grant, **Schünemann HJ**. The intentions of Lebanese medical students to train abroad: a survey study. Middle East Medical Asssembly. Beirut, Lebanon. May 2007 (poster presentation)
 93. Akl EA, Mustafa R, Alawneh A, Vedavalli A, **Schünemann HJ**. Improving Internal Medicine residents' knowledge and adherence to clinical practice guidelines using an educational game. Society of General Internal Medicine, Pittsburgh. April 2008 (poster presentation)
 94. Akl EA, Mustafa R, Wilson M, Moheet A, **Schünemann HJ**. Curricula for clinical practice guidelines in US Internal Medicine residency programs: a national survey study. Society of General Internal Medicine, Pittsburgh. April 2008 (poster presentation)
 95. Akl EA, Mustafa R, Wilson M, Moheet A, **Schünemann HJ**. Use of educational games in residency training: a survey of US Internal Medicine program directors. Society of General Internal Medicine, Pittsburgh. April 2008 (poster presentation)
 96. Jaeschke R, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, Cheng J, **Schünemann H**, Sears M, O Byrne P, Guyatt G. The safety of long acting beta agonists in patients with asthma using inhaled corticosteroids: A systematic review and meta-analysis. American Journal of Respiratory and Critical Care Medicine: A613, 2008.
 97. Cochrane 2007, Abstracts at AUA 2008, ATS 2008
 98. Dinapoli L, Maschio M, Jandolo B, Fabi A, Pace A, Sperati F, **Schünemann H**, Muti P. Preliminary data of open-label study on levetiracetam monotherapy in brain tumour-related epilepsy: seizure control and quality of life. 8th European Congress on Epilepsy, Berlin. September 2008 (poster presentation)
 99. Akl E, Oxman AD, Herrin J, Vist GE, Terrenato I, Sperati F, Costiniuk C, Blank D. **Schünemann HJ**. Negative versus positive framing of health information messages. Joint Cochrane & Campbell Colloquium, Keystone, USA, 2010 (oral presentation)
 100. Akl E, Briel M, Sun X, Busse JW, You JJ, Johnston BC, Mulla S, Lamontagne F, Bassler D, Vera C, Alshurafa M, Katsios CM, Mills E, Walter SD, Cook DJ, **Schünemann HJ**, Altman DG, Guyatt GH. LOST to follow-up Information in Trials (LOST-IT): the potential impact on the estimates of treatment effect.. Joint Cochrane & Campbell Colloquium, Keystone, USA, 2010 (oral presentation)

101. **Schünemann HJ**, Making use of your systematic review – working with guideline developers. The Cochrane Canada – 8th Annual Symposium – Workshop Ottawa, Canada May 19, 2010. (oral presentation)
102. **Schünemann HJ**, The vexing problem of guidelines and conflict of interest: a potential solution. Guidelines International Network (GIN) Conference, Chicago, August 25 - 28, 2010. (oral presentation)
103. **Schünemann HJ**, A model for an international collaboration across organizations for developing clinical practice guidelines. Guidelines International Network (GIN) Conference, Chicago August 25 - 28, 2010. (oral presentation)
104. **Schünemann HJ**, How to use GRADE approach to assess the quality of the evidence in systematic reviews. The Cochrane Canadian Symposium, Vancouver BC, February 16 – 17 2011. (oral presentation)
105. Santesso N, **Schünemann HJ**, How to use GRADEPro Software to create Summary of Findings Tables. The Cochrane Canadian Symposium, Vancouver BC, February 16 – 17 2011. (oral presentation)
106. **Schünemann HJ**, G.I.N. Scientific Committee Meeting, Seoul, South Korea August 28 – 31, 2011. ‘Antivirals for Influenza: Review of the Evidence from Observational Studies’ (oral presentation)
107. **Schünemann HJ**. Toward a Framework for International Guideline Collaboration. G.I.N. conference. Berlin, Germany. August 23, 2012 (oral presentation)
108. **Schünemann HJ**. Developments on tackling diagnostic test accuracy recommendations by the GRADE Working Group. G.I.N. conference, Berlin Germany. August 24, 2012. (oral presentation)
109. **Schünemann HJ**. How to Use the GRADE “Evidence-to-Recommendations Framework” to Develop Guideline Recommendations for Therapeutic Interventions. G.I.N Conference. San Francisco, USA. August 20, 2013. (oral presentation)
110. **Schünemann HJ** Evidence to recommendations frameworks: Diagnosis G.I.N Conference. San Francisco, USA. August 20, 2013. (oral presentation)
111. **Schünemann HJ**. Nonrandomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews and guidelines. G.I.N Conference. San Francisco, USA. August 20, 2013. (oral presentation)
112. **Schünemann HJ**. Setting new horizons in optimizing guideline utility G.I.N Conference. San Francisco, USA. August 21, 2013. (oral presentation)
113. Langendam M, Mustafa R, Santesso N, Carrasco A, Moustgaard R, Ventresca M, Heus P, Brozek J, Lasserson T, **Schünemann H** Harmonization of explanations for common judgments about the quality of evidence in Summary of Findings Tables. Cochrane Colloquium. Quebec City, Canada. September 23, 2013. (oral presentation)
114. Langendam M, Mustafa R, Santesso N, Carrasco A, Moustgaard R, Ventresca M, Heus P, Brozek J, Lasserson T, **Schünemann H** GRADE in

- Summary of findings tables: how to formulate informative footnotes on the assessment of the quality of evidence. Cochrane Colloquium. Quebec City, Canada. September 23, 2013. (oral presentation).
115. Brozek J, Lasserson T, **Schünemann H**. Upgrading the quality of evidence from RCTs? Examples from published Summary of Findings tables. Cochrane Colloquium. Quebec City, Canada. September 23, 2013. (oral presentation)
 116. **Schünemann** HJ, Wiercioch W, Etzeandía I, Falavigna M, Santess N, Mustafa R, Ventresca M, Brignardello-Petersen R, Laisaar KT, Kowalski S, Baldeh T, Zhang Y, Raid U, Neumann I, Norris S, Thornton J, Harbour R, Treweek S, Guyatt G, Alonso-Coello P, Reinap M, Brožek J, Oxman A, Akl E. Guidelines 2.0: Development of a comprehensive checklist for a trustworthy guideline enterprise. CE&B Annual Research Day. Hamilton, ON. March 27, 2014. (oral presentation)
 117. **Schünemann H**. The Guideline Development Checklist (GDC). GIN Conference, Melbourne. August 2014. (oral presentation)
 118. Alonso-Coello P, Zhang Y, Selva A, Sanabria AJ, Rigau D, Sol I, Guyatt G, **Schunemann H**. Rating the confidence we can place in studies that evaluate the importance of the outcomes of interest. GIN Conference, Melbourne. August 2014. (oral presentation)
 119. Sanabria AJ, Selva A, Zhang Y, Sol I, Rigau D, Martinez L, Garcia S, Pequeo S, **Schunemann H**, Alonso-Coello P. Overcoming methodological challenges of incorporating resource use and patient's values in clinical guidelines. GIN Conference, Melbourne. August 2014. (oral presentation)
 120. **Schünemann H**. Enhancing the acceptance and implementation of Summary of Findings (SoF) Tables in Cochrane Reviews – User testing study. The Cochrane Colloquium. Hyderabad, India. September 23, 2014.(oral presentation).
 121. **Schünemann H**. Enhancing the acceptance and implementation of Summary-of-Findings Tables in Cochrane Reviews – Two non-inferiority randomized controlled trials The Cochrane Colloquium. Hyderabad, India. September 23, 2014.(oral presentation).
 122. **Schünemann H**. Getting the O in PICO Right for Trustworthy Recommendations. GIN conference, Philadelphia USA. September 2016 (oral presentation)
 123. **Schünemann**. H. GRADE guidance for rating the certainty of a body of evidence describing the relative importance of outcomes or values and preferences. Global Evidence Summit. CapeTown, SA. Sept. 14, 2017. (oral presentation)
 - 124.

Other publications (non peer reviewed)

1. Coopersmith K, **Schuenemann HJ**. Radiotherapy and Quality of Life. In: Tackling Problems in Idea Analysis. Editors: Weiner JM, Horowitz RS, Schuster JHR. Wilmington, DE: 24th Century Press, 1995.

2. **Schuenemann HJ.** Diagnosis of asthma. In: tackling problems in idea analysis. Editors: Weiner JM, Horowitz RS, Schuster JHR. Wilmington, DE: 24th Century Press 1995.
3. **Schuenemann HJ.** Quality of Life Studies. In: Tackling Problems in Idea Analysis. Editors: Weiner JM, Horowitz RS, Schuster JHR. Wilmington, DE: 24th Century Press 1995.
4. **Schünemann H, Guyatt G.** ACCP Consensus Conference on Antithrombotic Treatment. Evidence Based Newsletter, November 1999. McMaster University
5. **Schünemann HJ.** The relation of serum levels of antioxidant vitamins with pulmonary function in a sample from the general population. Doctor of Philosophy (Ph.D.) - Dissertation, University at Buffalo, USA, 2000
6. **Schünemann H.** Update from the ACCP Consensus Conference on Antithrombotic Treatment. Evidence Based Newsletter, November 2000. McMaster University
7. **Schünemann H.** Reviewer for: Chronic Respiratory Disease Questionnaire (CRQ). In: Physical Rehabilitation Outcome Measures. Editors: E Finch, D Brooks, P Stratford, N Mayo. Hamilton, On. BC Becker, 2002.
8. **Schünemann HJ.** Der Kohlendioxidtransport im Organismus - Untersuchungen zur Kinetik des pulmonalen CO₂-Austauschs und zum Einfluß des Laktats auf das oxylabile CO₂ (German). Doctor of Medicine (Dr. med.) - Dissertation, Hannover Medical School, Germany, 1994.
9. Devereaux PJ, Meade M, Guyatt GH, Choi PTL, Lacchetti C, Weaver B, Lavis JN, Grant BJB, **Schünemann HJ**, Sullivan T. Quality of care in for-profit hospitals (reply letter). eCMAJ 167: 740-741, 2002
10. Carling C, **Schünemann HJ**, Herrin J, Dyrnes JA, Treweek S, Kristoffersen DT, Akl E, Guyatt GH, Dvereaux PJ, Montori VM, Oxman AD. We need more evidence of effectiveness about ways to communicate risk to patients - a proposal. Response to article by Paling, "Strategies to help patients understand risk". BMJ October 3, 2003, at: <http://bmj.bmjournals.com/cgi/eletters/327/7417;745>
11. **Schünemann HJ**, Best D, Vist G, Oxman AD. Grading evidence (reply letter). CMAJ 2004; 170:929-930
12. **Schünemann HJ**, Hirsh J. Highlights from the 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. The Hematologist: An official Journal of the American Society for Hematology.
13. **Schünemann HJ.** Do antioxidants improve pulmonary function? The Journal of Respiratory Diseases; 24: 55 – 60, 2003.

Invited Presentations and Chairing at Scientific Meetings (selected)

1. "The Chronic Respiratory Questionnaire", Investigator Meeting, Boehringer Ingelheim, Brussels, Belgium, February, 23 – 24, 2001 "Implementing ACCP guidelines", ACCP Consensus Conference Chairs Meeting:, Chicago, IL, 1/31/2002

2. "Measuring Preferences: Do we need hypothetical health states?" Department of Public Health, Oslo, Norway, 3/15/02
3. "Mortality in for-profit versus not-for-profit hospitals", University of Zürich, Horten Zentrum, Zürich, Switzerland, 11/8/2002
4. "Utility and Preference Measures" AstraZenca Workshop on Health-Related Quality of Life measurements, Toronto, Canada, 11/27-11/28/2002
5. "Utilities and Health-Related Quality of Life". Polish Institute of Public Health (Pharmacoeconomics), Warsaw, Poland, 4/4/2003
6. "Efficacy, Effectiveness & Efficiency and Health-Related Quality of Life". Academy of Entrepreneurship and Management: Center for Health Education, Research and Information (Cheri), Warsaw, Poland, 3/30/2003
7. "Do Antioxidants from Fruits and Vegetables Play a Role in Airways Obstruction? Results from a Population-based Study and a Systematic Review" Università Cattolica del Sacro Cuore Centro di Ricerca e Formazione ad alta Tecnologia nelle Scienze Biomediche, Campobasso, Italy, 4/24/2003
8. "Effective guideline implementing strategies". American College of Chest Physicians (ACCP) 2003 Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines, Phoenix, IL, 9/12/2003
9. "Anemia and health-related quality of life in COPD". Amgen, Inc., Los Angeles, CA, 9/15/2003
10. "Minimal Clinically Important Differences (MCID) in COPD: Quality of Life IV (Chronic Respiratory Disease Questionnaire)", MCID workshop, Miami, FL, January 12 – 14, 2004
11. "The Feeling Thermometer" & "Latest developments in the use of multi-attribute utility tools", Utility Workshop, AstraZeneca, Toronto, Canada, January 15, 2004
12. "Asthma Guidelines: The Importance of Evidence-Based Medicine", American Academy of Allergy, Asthma and Immunology (AAAAI), San Francisco, CA, March 23, 2004
13. "How Guidelines on antithrombotic agents are generated", National Congress of the Italian Society on Thrombosis and Haemostasis, October 1, 2004
14. "Interpreting the Results of Quality of Life Measures in Clinical Trials: The Clinicians Perspective" substituting Dr. Gordon Guyatt at: ISOQOL 2004 Symposium "Stating the Art: Advancing Outcomes Research Methodology and Clinical Applications", Boston, MA, USA, June 27-29, 2004
15. "ACCP Antithrombotic Guidelines" Coalition to prevent DVT. Washington, September 16, 2004
16. "Do marker states help patients in valuing their own health", International Society for Quality of Life Research (ISOQOL), Hong Kong, October 19, 2004
17. "Guidelines and Recommendations on antithrombotic agents", Consensus meeting with representatives of the European Society of Cardiology,

- Groupe Interdisciplinaire Trousseau sur les Antithrombotiques (GITA), Paris, November 22, 2004
18. CHAIR “Grades of Recommendations Session” Consensus meeting with representatives of the European Society of Cardiology, Groupe Interdisciplinaire Trousseau sur les Antithrombotiques (GITA), Paris, November 22, 2004
 19. “What’s EBM”. European Association of Urology. Joint work force on EBM. March 14th, 2005
 20. “The GRADE grading system for clinical practice guidelines”. European Association of Urology. Joint work force on EBM. March 14th, 2005
 21. “Statistical outcome measures in clinical research: an introduction” American Thoracic Society, International Conference, San Diego, USA, May 2005
 22. “Evidence Based Medicine and Pharmacotherapy”, American Thoracic Society, International Conference, San Diego, USA, May 22, 2005
 23. “The GRADE working Group”, Evidenced Based Urology, Paris, 23 Jun, 2005
 24. “The GRADE approach to grading the quality of evidence and strength of recommendation”, National Institutes of Health and Clinical Excellence, London, UK, July 27th, 2005
 25. “The GRADE approach to grading the quality of evidence and strength of recommendation”, BMJ Clinical Evidence, London, UK, September 21st, 2005
 26. “Users’ Guide to Detecting Misleading Claims in Clinical research Reports”, 7° Corso di Evidence Based Gastroenterology 6 Hepatology, Torgiano, Italy, November 27th, 2005
 27. “GRADE group methodology”, European Association of Urology, Guidelines Office Chairmen Meeting, Rome, 2 Dec, 2005
 28. “The Science of Guidelines”, European Task Force for sharing Expertise in Thrombosis, Brussels, Belgium, December 3rd, 2005
 29. “Evidence-Based Guidelines For Venous Thromboembolism”, American Thoracic Society, San Diego, May 23, 2006
 30. “The Why And How Of Guideline Development”, American Thoracic Society, San Diego, May 22, 2006.
 31. “Critical Appraisal of COPD guidelines”. American Thoracic Society, ERS and GOLD leadership, Munich, Sep 2 2006.
 32. “The GRADE System”. IPF Committee guideline group, Munich, Sep 2 2006.
 33. “EBUrology and the GRADE system”. Congress: Quality Based Urology, Padova/Venezia, Sep 8-9, 2006.
 34. “Grading the Quality of Evidence and Strength of Recommendations – the GRADE System” Institute für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Cologne, September 25, 2006

35. "Integrating values and preferences in Clinical Practice Guidelines", International Society for Quality of Life Research (ISOQOL), Lisbon, October 13, 2006 (session chair and presenter)
36. "Study quality" (session chair) Cochrane Colloquium 2006, October 24, 2006
37. "Trials Stopped for Early Benefit : Should We Believe Them?" 8th Course Evidence-based Gastroenterology and Hepatology, Torgiano, Italy, November 27, 2006
38. "How the Lung influences the Heart" Primary Prevention in Cardiovascular disease: New Risk factors. (La Prevenzione Primaria delle Malattie Cardiovascolari: Nuovi Fattori di Rischio) Università Cattolica del Sacro Cuore, Campobasso, Italy, November 22, 2006
39. NICE training workshop and lecture: GRADE – grading the quality of evidence; London, December 11, 2006
40. Grading the quality of evidence and strength of recommendation/GRADE workshop, South Tyrol Nursing Association, Bozen, Italy, January 15th, 2007
41. Developing Clinical Practice Guidelines, University of Chieti, Italy, January 22, 2007
42. Introduction to Evidence Based Health Care, Department of Orthopaedics, University of Perugia, Italy, March 7, 2007
43. CADTH training workshop and lecture: GRADE – "Grading the quality of evidence, Ottawa, March 26-28, 2007
44. Speaker "Introduction to Evidence Based Medicine" and "GRADE – an Introduction", March 29, 2007
45. Postgraduate M.A.D Day, "Future of Medicare in Canada". University of McMaster, Hamilton, Canada, April 4, 2007.
46. Invited Keynote speaker: Merging efforts in guideline development in COPD and Asthma. Chiesi Foundation Respiratory Research Conference June 8, 2007
47. Invited speaker: International Society for Thrombosis and Haemostasis. "Study design, quality of evidence and guidelines", Geneva, Switzerland, July 8, 2007.
48. Invited speaker, Summary of findings and interpreting reviews, Australasian Cochrane Center, Brisbane (via teleconference), Australia, July 12th, 2007
49. Invited session chair and lecturer for symposium on "Dyspnea and Health Related Quality of Life" at the European Respiratory Society Annual Meeting, September, 2007
50. Invited speaker: 3rd Summit Meeting of Thrombosis Quorum. "Issues in vascular clinical trial design and endpoints", organized by AstraZeneca, Assisi, Italy, 2nd – 4th October 2007
51. Invited speaker, "Developing evidence-based guidelines: what users need

- to know” Young Investigators Meeting in Thoracic Oncology, Torino, Italy, 5th October 2007
52. Invited speaker: Kidney International (KDIGO). Guideline development methodology – WHO experience. New York, USA, October 11, 2007
 53. Invited keynote speaker: Cochrane Colloquium. Using diagnostic technologies. Sao Paolo, October 24, 2007
 54. Invited speaker, “Guías de práctica clínica en atención primaria en nuestro entorno: metodología y práctica”, Spanish Society for Family and Community Medicine, Valladolid/Salamanca, Spain, November 8, 2007
 55. Invited speaker, “Integrating values and preferences in clinical practice guidelines”, Spanish National Guideline Meeting, Madrid, Spain, December 5, 2007
 56. Invited speaker (workshop organizer), “GRADE” Austrian Institute for Health Technology Assessment, Vienna, Austria, December 16 – 18, 2007
 57. Invited Speaker, Agency for Health Care Research and Quality, Washington, USA, January, 2008
 58. Invited Speaker, National Institutes of Health (Infectious Disease Division, Feb 4, 2008
 59. Invited speaker, “GRADE”, Italian Federation of Medical Societies Meeting Rome, March 3, 2008
 60. Invited speaker, Emerging challenges for the development and implementation of clinical guidelines, Meeting International Guidelines on Rhinitis, Asthma and COPD, University of Ferrara, March 8, 2008
 61. Invited speaker, “Guideline and Systematic Review Methodology”, Infectious Disease Society of America, Arlington, Virginia, March 18, 2008
 62. Invited speaker, “Emerging challenges to the development and implementation of clinical guidelines”, Horten Center, Zurich, March 28, 2008
 63. Invited Workshop Tutor and Workshop organizer “GRADE”, Basque Guidelines Section, Regional Government, San Sebastian Spain, May 12 to 14, 2008
 64. Speaker, Workshop “From the Black Box to Transparent Development”, American Thoracic Society International Conference, Toronto, May 18, 2008
 65. Invited Speaker, “The Importance of Grading Evidence”, American Thoracic Society International Conference, Toronto, May 18, 2008
 66. Invited Speaker, National Academy of Science, Institute of Medicine “Systematic reviews and other strategies to protect against bias in guidelines development”, US, Washington, May 22, 2008
 67. Invited speaker, “The GRADE approach to developing guidance for diagnostic questions”, Agency for Healthcare Research and Quality, Washington, DC May 29, 2008
 68. Invited speaker, “Globalize the evidence – individualize Decisions”,

- Evidence Based Clinical Practice Workshop, McMaster University, June 11, 2008
69. Invited Speaker, "GRADE", German EBM Network, Deutsches EBM Netzwerk, GRADE Working Group, Berlin, Germany, June 18, 2008
 70. Invited Grand Rounds Speaker, Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT), Palermo, Italy, July 24, 2008
 71. Invited speaker, "Adverse outcomes of long acting beta agonists in Asthma: a systematic review", XXXII Annual Congress of the AAAeIC, Buenos Aires, Argentina, August 15, 2008
 72. Invited speaker, "Study design, levels of evidence and guidelines (GRADE)", XXXII Annual Congress of the AAAeIC, Buenos Aires, Argentina, August 15, 2008
 73. Invited Speaker, "Applying GRADE" and "GRADE - From Evidence to EMS Practice: Building the National Model (NHTSA, FICEMS, NEMSAC)", Washington, DC, September 4, 2008
 74. Invited speaker, "Grading Evidence and Recommendations", Agency for Healthcare Research and Quality, Washington, DC, September 8, 2008
 75. Invited speaker, "GRADE Methodology In Use & GRADE Tips and Tools", Agency for Healthcare Research and Quality, Washington, DC, September 8, 2008
 76. Invited tutor, "GRADE Introduction", WHO – GRADE Workshop, Geneva, September 10, 2008
 77. Workshop Tutor/Organizer, "GRADE", Utrecht, NL, September 18 - 19, 2008
 78. Invited speaker, Grand Rounds, Dept. of Clinical Epidemiology, University of Utrecht, NL, "Guideline Implementation and Grading recommendations", September 19, 2008
 79. Workshop Tutor "GRADE", Agency for Healthcare Research and Quality, Washington, DC, September 8, 2008
 80. Invited speaker, World Congress of Epidemiology, "GRADE - Guideline development methodology using the GRADE approach", Porto Alegre, Brasil, September 24, 2008
 81. Invited speaker, University of Porto Alegre, "GRADE - Guideline development methodology using the GRADE approach", Porto Alegre, Brasil, September 25, 2008
 82. Invited speaker, "Understanding and interpretation of patient reported outcomes", Cochrane Colloquium, Freiburg, Germany, October 3, 2008
 83. Invited speaker "Emerging challenges to the development and implementation of clinical practice guidelines – COPD as a case in point", European Respiratory Society, October 5, 2008
 84. Invited speaker (plenary), "Globalizing Clinical and Health Care Policy Processes", Cochrane Colloquium, Freiburg, Germany, October 7, 2008
 85. Invited speaker, German Ministry of Health/IQWiG, "GRADE: Von der

- Evidenz zur Empfehlung Beschreibung des Systems und Lösungsbeitrag zur Übertragbarkeit von Studienergebnissen“, Berlin, October 21, 2008
86. Invited speaker, Spanish Ministry of Health/Iberoamerican Cochrane Center, „GRADE Introduction“, Madrid, Spain, November 26, 2008
 87. Invited speaker, IQWiG, “Integrative Beurteilung der Evidenz – Das GRADE System“, November 28, 2008
 88. Invited speaker, Spanish Ministry of Health/Iberoamerican Cochrane Center, „GRADE Introduction“, Barcelona, Spain, December 3, 2008
 89. Invited speaker, GA2LEN Urticaria Conference, “Principles of consensus guidelines and the GRADE system“, December 4, 2008
 90. Invited speaker and tutor, WHO workshop “GRADE Introduction“, Geneva, Switzerland, January 19, 2009
 91. Invited speaker, Society of Critical Care Medicine, “Development of Clinical Practice Guidelines and the GRADE approach“, Nashville, TN, January 31, 2009
 92. Invited speaker, Italian Respiratory Guideline Conference, “The Future (of practice guidelines)“, Modena, Italy, March 3, 2009
 93. Invited speaker (via teleconference), WHO Radiation Guideline Meeting, “The GRADE system“, March 13, 2009
 94. Invited speaker, IQWiG Scientific Board, “GRADE“, March 20, 2009
 95. Speaker “The impact of stopping trials early“, Department of Clinical Epidemiology and Biostatistics Grand Rounds, McMaster University, Hamilton, Canada, March 23, 2009
 96. Tutor, Freiburg Cochrane Center, “Vom Profil zur Empfehlung“, March 27, 2009
 97. Invited speaker, WHO, “Identifying and Prioritizing questions for Prevention of Asthma and COPD“, April 8, 2009
 98. Invited tutor, “GRADEpro“, Cochrane Mid-year Meeting, Copenhagen, April 19, 2009
 99. Invited speaker “How Can We Assist Practitioners to Assess and Implement Meaningful Therapies for Their Patients: The Example of the GRADE Approach“, Society for Pediatric Research, Baltimore, MD, May 5, 2009
 100. Invited Speaker “The GRADE approach. 3: How should grades and guidelines be presented and implemented?“, Scottish Intercollegiate Guideline Network (SIGN), Edinburgh, Scotland, May 6, 2009
 101. Speaker “What's New in Document & Guideline Development: GRADE“, Documents Forum, San Diego, CA, May 17, 2009
 102. Invited Speaker “Overview of the ATS COI Policy“, San Diego, CA, May 19, 2009
 103. Invited Speaker “From Evidence to action“, 2009 Evidence Based Medicine & Traditional Chinese Medicine Conference, Guangzhou, China, May 23,

2009

104. Invited Speaker “Methodological issues In the development of clinical practice guideline”, 2009 Evidence Based Medicine & Traditional Chinese Medicine Conference, May 24, 2009
105. Invited speaker “Evidence-Based Medicine: How to Incorporate it into Clinical Decision making in Managing Asthma and Allergies”, XXVIIIth Congress of the European Academy of Allergology & Clinical Immunology, Warsaw, Poland, June 2-9, 2009
106. Invited speaker, LatinCLEN – Cochrane Meeting, “GRADE for developing practice guidelines”, “Methods for guidelines development.”, “. Presenting statistical and other information to consumers of systematic reviews reviews” Bogota, Columbia, June 18-21, 2009
107. Invited speaker “How to Collect and GRADE Evidence”, Ga2len Course on Clinical Trials, Global Allergy & Asthma Network, Rome, Italy, July 6-7, 2009
108. Invited speaker “GRADE Introduction and Judgments about the quality of evidence”, 2 AHRQ Workshops, Making well-informed coverage decisions, Washington, DC, 14 and 15 July 2009
109. Invited speaker “Healthcare Recommendations: Why GRADE”, TEACH Workshop, New York, New York, August 12-13, 2009
110. Symposium Chair, Idiopathic Pulmonary Fibrosis, European Respiratory Society, Vienna, Austria, September 16, 2009
111. Invited speaker “Rating the Evidence: Using GRADE to Develop Clinical Practice Guidelines”, Annual AHRQ meeting “Research to Reform: Achieving Health System Change”, Washington, MD, September 14, 2009
112. Invited speaker, “Aligning Advances in Health Research Methodology with Guidance for Healthcare Practice: Introduction to the GRADE System”, Department of Social and Preventive Medicine Grant Rounds, University at Buffalo, Buffalo, NY, September 18, 2009
113. Invited presentation “WHO process for developing guidelines for pharmacologic management of pandemic influenza & Issues around implementing GRADE”, CDC-ACIP, Evidence Based Health care Working Group, September 30, 2009
114. Invited Speaker “GRADE”, Canadian Thoracic Society, Toronto, Canada, October 1, 2009
115. Invited speaker “The practice of GRADE and why guidance developers use it”, Guidelines International Network, Lisbon, Portugal, November 2, 2009
116. Invited speaker “alternative methods for appraising the evidence and strength of recommendations”, Institutes of Medicine (IOM) Clinical Practice Guideline Committee, Washington, MD, November 9, 2009
117. Invited speaker, “From Einstein to Guidelines”, Medical Grant Rounds, Mayo Clinic, Rochester, MN, USA, November 18, 2009
118. Postgraduate Course “Evidence Based Medicine: Cochrane systematic reviews and metaanalysis, Methods for grading evidence” XXI World Allergy

- Congress, Buenos Aires, Argentina, December 7, 2009
119. Symposium Talk: "Update on clinical research: growing in importance and complexity – Will your study make the GRADE? at XXI World Allergy Congress, Buenos Aires, Argentina, December 8, 2009
 120. Invited session chair for "Evidence based medicine and methodology", XXI World Allergy Congress, Buenos Aires, Argentina, December 7, 2009
 121. Invited speaker, 1 day lecture series, "Health Surveys" Riyadh, Saudi Arabia. January 17 – 20, 2010
 122. Invited speaker, lecture, "Knowledge Translation", Riyadh, Saudi Arabia. January 17 – 20, 2010
 123. Invited speaker, "Experience in using GRADE for developing clinical practice guidelines to the ASL in Rome". Rome, Italy. January 21-22, 2010.
 124. Invited speaker, "Applying the GRADE approach to the WAO Cow Milk Allergy Guidelines" MILAN, Italy. February 5th – 6th, 2010
 125. Invited speaker, "GRADE", McGill University Montreal, Quebec. February 12th – 13th, 2010
 126. Invited speaker, 1 day workshop – 3 lectures given, "1. Guideline Process and introduction to GRADE; 2. Combining the Evidence and 3. Developing Recommendations". Clinical Practice Guideline Institute, CPGI, April 24, 2010
 127. Invited speaker- Presentation: Primary prevention of chronic respiratory disease by addressing environmental factors such as indoor and outdoor air pollution". Global Alliance against Chronic Respiratory Diseases (GARD) Meeting. Toronto, ON Canada. June 1 – 2, 2010.
 128. Invited Speaker, (presentation), "Non-Randomized Studies in Systematic Reviews" Cochrane Collaboration - Ottawa, June 9-11
 129. Invited presentation, GRADE, CDC-ACIP, Atlanta, GA. June 21 - 23, 2010
 130. Invited speaker, 1 day workshop, GRADE, CDC-ACIP, Atlanta, GA. June 21 - 23, 2010
 131. Invited speaker, lecture "WHO Guidelines: GRADE", Geneva Switzerland, July 19-22, 2010.
 132. Invited speaker, WHO, GRADE Special Challenges Observational Studies. Geneva, Switzerland, October 28, 2010.
 133. Invited speaker, DECIDE Meeting: Database of evidence profiles and further development of GRADEPro, Geneva, Switzerland. January 10 – 12 2011
 134. Invited speaker, McMaster University, ENKIN Lecture. Hamilton ON. March 23, 2011
 135. Invited speaker, McMaster University, Global Health Seminar Series: The World Health Organization (WHO): Use of Research Evidence to Guide International Health Care. Hamilton ON. March 24, 2011

136. Invited participant, CIHR Strategy for Patient Oriented Research's Roundtable Meeting on Pan Canadian SUPPORT Units. Ottawa, March 22, 2011
137. Invited participant and speaker at the Common Methods for the Summarizing of Pain Reviews' meeting and present Cochrane Review. Oxford, UK. July 8, 2011.
138. Invited participant at the Asthma Outcomes Group meeting to discuss ways to improve the selection of outcomes in clinical trials in children with asthma. Liverpool, England. July 11, 2011.
139. Invited speaker at the COMET meeting. Presentation - Do no net harm: Using GRADE to select outcomes for healthcare decision making. Bristol, UK. July 11 – 12.
140. Invited Speaker, G.I.N. Scientific Committee meeting - attended meeting and gave a training workshop 'The GRADE approach to assessing the quality of a body of evidence and the strength of recommendations. Seoul, South Korea. August 28 – 31.
141. Invited participant at the American College of Physicians Clinical Guidelines Committee Meeting. Philadelphia, PA. September 12 - 13, 2011
142. Invited participant and speaker at the German Ministry of Health on GRADE - Using GRADE to develop recommendations for immunization: recent advances. Berlin, Germany. September 12 – 13, 2011.
143. Invited participant and speaker at the Agency for Healthcare Research and Quality (AHRQ) Conference. Presentation Facing Challenging Situations when Grading the Strength of Evidence. Bethesda, USA. September 20, 2011.
144. Invited speaker at the opening of Chinese GRADE Center at Lanzhou University. Gave 2 presentations on GRADE 1) Recent Developments in the Evidence based medicine 2) How to develop evidence based guideline. Lanzhou, China. September 12 – 25, 2011.
145. Invited participant at the annual methodological retreat of the Medical Advisory Secretariat. Toronto, Canada. October 7, 2011.
146. Invited participant and Keynote Speaker at the Joint session of the WHO, The Estonian Health Insurance Fund and the University of Tartu Faculty of Medicine Scientific conference. Tallin Estonia. October 13, 2011.
147. Invited speaker, Q&A for the Cochrane Exchange, Cochrane colloquium, Madrid, Spain. October 19, 2011.
148. Invited speaker – Plenary lecture at the Cochrane Colloquium, Implementing the evidence into the system. Madrid, Spain. October 20, 2011.
149. Invited participant, (gave lecture on GRADE Pro) at the AHRQ meeting. Bethesda, USA. November 17, 2011.
150. Invited participant and reviewer of candidates at the Gairdner Medical Review Panel meeting. Toronto, Canada. November 17, 2011.

151. Invited participant and speaker (lecture at symposium) at the Institute for Quality and Efficiency in Health Care (IQWiG) meeting of the Advisory Board. Cologne, Germany. November 25, 2011.
152. Invited speaker/participant. Publishing Policy Co-ordination Group annual meeting : Quality criteria for information products-the need for evidence based guidelines. Geneva, Switzerland. November 28-29, 2011.
153. Invited speaker, World Allergy Congress – 2 lectures; 1) How Can the GRADE System Improve Guideline Driven Care?, 2) WAO Position Paper: Diagnosis and Rational for Action Against Cows Milk Allergy (DRACMA). Cancun, Mexico. December 4 – 8, 2011.
154. “GRADEPro” training session, AHRQ (online), December 22, 2011
155. Invited speaker, DECIDE Meeting, Strategies for collaboration among European guideline developers and health technology assessment. Barcelona, Spain. January 10 – 12, 2012.
156. Invited speaker, The 6th International Meeting on Pediatric Allergy, The contribution of evidence-based guidelines to food allergy medicine. Milan, Italy. February 9 – 12. 2012
157. Invited speaker, Clinical Practice Guidelines or RARE Diseases. GRADE system and rare diseases: how to make weak recommendations more transparent. Rome, Italy. February 24, 2012
158. NTP Office of Health Assessment and Translation (OHAT). Approaches for Evaluating the Body of Evidence Across Studies-1 (webinar) Hamilton ON. February 28, 2012.
159. NTP Office of Health Assessment and Translation (OHAT). Approaches for Evaluating the Body of Evidence Across Studies-2 (webinar) Hamilton ON. March 8, 2012.
160. Invited speaker and participant. WHO Policy guidance on anti-tuberculosis drug susceptibility testing and Hain MTBDRsl second-line drug molecular line probe assays EXPERT GROUP MEETING, Grading quality of evidence and strength of recommendations: Brief overview of GRADE Geneva, Switzerland. March 19 – 21, 2012.
161. Invited speaker, The Cochrane Collaboration meeting. Transparency and clinical guidelines Paris, France. April 15 – 19, 2012.
162. Invited speaker, Public Health and Preventative Medicine Program academic half day. : What makes Public Health guidelines trustworthy? Hamilton, ON.(McMaster University). April 20, 2012.
163. Invited speaker, Comprehensive cervical cancer control: a guide to essential practice Meeting. (WHO) Process for development of the recommendations. Geneva, Switzerland. April 24 – 25, 2012.
164. Invited speaker, TB Meeting (Introduction of new drugs for treatment of TB) (WHO) The development of policy recommendations at the WHO and GRADE. Geneva Switzerland. April 26, 2012.
165. Invited speaker, Ontario Health Technology Advisory Committee (OHTAC) Decision Determinants Meeting. Development of GRADE. Toronto ON.

- May 8, 2012.
166. Invited speaker, Medical Imaging Informatics and Teleradiology Conference : Evidence-Based Methodology Applied to Diagnostic Imaging. Toronto ON. April 11, 2012.
 167. Invited speaker, Ontario Health Technology Advisory Committee (OHTAC) Decision Determinants Meeting. Development of GRADE. Toronto ON. May 8, 2012.
 168. Invited participant at the American College of Physicians Clinical Guidelines Committee Meeting. Philadelphia, PA. September 10 - 11, 2012
 169. Invited speaker, EPC Strength of Evidence Retreat. GRADE Presentation. May 18. Crystal City, USA.
 170. Invited speaker, XI Meeting of the Iberoamerican Cochrane Network. Using GRADE to assess the quality of evidence in diagnostic test accuracy studies. Lima, Peru. May 23, 25 2012.
 171. Invited speaker, International Clinical Practice Guideline Symposium & GRADE Workshop. Introductions. Lanzhou, China. May 28 – 29, 2012,
 172. Invited speaker/participant, Strategic and Technical Advisory Group for Tuberculosis (STAG TB) Meeting, World Health Organization. Geneva. June 18 – 19, 2012
 173. Invited speaker/participant. Interpreting results and drawing conclusions from systematic reviews of test accuracy Meeting. Birmingham, UK. July 1-3, 2012.
 174. Invited speaker, Evidence Based Health Care: Why? How? Seminar. Beyond diagnostic test accuracy: GRADE for diagnosis. Oslo, Norway. August 21, 2012.
 175. Invited moderator, Guidelines International Network (GIN) conference. Berlin, Germany. August 23, 2012
 176. Invited speaker, (Keynote lecture) Quality of Care and Guidelines. Dubai International Conference on Clinical Practice Guideline, Development, Adaptation, Implementation, and Monitoring. Dubai. September 15 – 17, 2012.
 177. Invited speaker, Special Challenges in Guideline Development. Dubai International Conference on Clinical Practice Guideline, Development, Adaptation, Implementation, and Monitoring. Dubai. September 15 – 17, 2012
 178. Invited speaker, Moving from Evidence to Recommendations. Dubai International Conference on Clinical Practice Guideline, Development, Adaptation, Implementation, and Monitoring Dubai. September 15 – 17, 2012..
 179. Invited speaker, How to organize and EBM workshop. Dubai International Conference on Clinical Practice Guideline, Development, Adaptation, Implementation, and Monitoring Dubai. September 15 – 17, 2012.
 180. Invited keynote speaker, Methodological bases for evaluation evidence of

- therapeutic and diagnostic procedures. Braunschweig, Germany. September 18, 2012.
181. Invited participant (Chair of session) Knowledge translation and communicating evidence. Cochrane Colloquium, Auckland, NZ. October 2, 2012
 182. Invited speaker/participant Challenges for epidemiology in the context of the National Health Service Workshop (Advisory Group Meeting). (Discussant) Arsenic emergency in water supply in 91 municipalities of the Lazio region. Rome, Italy. October 15, 2012.
 183. Invited participant. Pan American Health Organization ACHR meeting. Hamilton Canada. October 19, 2012.
 184. Invited Speaker, American Society of Hematology Quality Task Force Meeting on Guideline Development. Washington, DC. October 22, 2012.
 185. Invited speaker, From Clinical Trials to Clinical Practice: Towards Bridging the Gap International Society for Quality of Life Research (ISOQOL) – Budapest. October 25, 2012.
 186. Invited participant. Consolidated ART Guideline Development Group Meeting. WHO Geneva. November 6 -8, 2012.
 187. Invited participant to review a German Application (ACTING ON KNOWLEDGE) for the German Ministry of Health. Freiburg, Germany November 22, 2012.
 188. Invited participant and speaker at the Institute for Quality and Efficiency in Health Care (IQWiG) meeting of the Advisory Board. Cologne, Germany. November 23-24, 2012.
 189. Invited participant and reviewer of candidates at the Gairdner Medical Review Panel meeting. Toronto, Canada. November 23, 2012.
 190. Invited participant and member of the Expert Advisory Panel on GAMUNEX, Health Canada, Ottawa ON. November 27, 2012.
 191. Invited speaker, Translating the best evidence to recommendations: The GRADE approach The Health Technology assessment international (HTAi) LatinoAmerican Meeting , Bogota, Columbia. December 5, 2012.
 192. Invited Speaker, How to develop pragmatic and trustworthy guidelines Guidelines International Network North American Meeting. New York, NY USA. December 10, 2012.
 193. Invited Speaker, GKV, Berlin, Germany. January 15, 2013
 194. Invited Speaker and participant, GRADE approach for WHO guidelines, WHO Expert meeting. Geneva. January 29 – 30, 2013.
 195. Invited Speaker and participant, The PICO question for provisional guidance on use of bedaquiline in the treatment of MDRTB, WHO Expert meeting. Geneva. January 29 – 30, 2013.
 196. Invited participant and speaker at the Institute for Quality and Efficiency in Health Care (IQWiG) meeting, Methodological characteristics, conditions and challenges in studies with non-randomized studies-drug and non-

- randomized studies-technical treatment procedures. Berlin Germany. (MOH) January 31, 2013.
197. Invited participant, RARE Best Practices kick-off meeting. 2 day discussion and approval of the detailed plan of activities. (Italian National Institute of Health). Rome. February 11 – 12, 2013.
 198. Invited speaker. How to apply or develop clinical practice guidelines focused on patients with chronic disease and multimorbidity. (online presentation) Scientific Conference of the National Clinical Practice Guidelines Program: Clinical Practical Guidelines and multimorbidity. Spain. February 21, 2013.
 199. Invited participant. 2.5 day DECIDE meeting. Rome. February 26 – 28, 2013.
 200. Invited Chair and participant. Review Board meeting for Quantitative studies without intervention in Health Care Research. Berlin. March 6, 2013
 201. Invited speaker, Discussion: Evidence based medicine. Life Sciences University Network. Hannover, Germany. March 8, 2013.
 202. Invited speaker. New MPH Program & Potential Links with Health Units. Central West Medical Officers of Health (CWMOH). Guelph, Canada. April 19, 2013.
 203. Invited participant. Meeting of the Task force for the development of new policies for the treatment of TB. WHO, Geneva. April 22 – 23, 2013.
 204. Invited speaker. Grading quality of evidence and strength of recommendations: Brief overview of GRADE. WHO Expert Group meeting. Geneva. May 20 – 21, 2013.
 205. Invited speaker. The GRADE methodology for the development of guidelines. Biomarkers post-conference satellite meeting. Venice. May 24, 2013.
 206. Invited speaker. An introduction to the GRADE approach to rating the quality of evidence and strength of guideline recommendations. Guidelines International Network (GIN) webinar series. Hamilton, Canada. May 30, 2013.
 207. Invited speaker (keynote). Strategy around revision of the Canadian Opioid Guideline 10. National Faculty Meeting. McMaster University – National Pain Center. Hamilton, Canada. May 31, 2013.
 208. Invited speaker (grand rounds). System 1 and system 2 health care recommendations or “Do no net harm” with clinical practice guidelines. Sunnybrook HSC, Institute for Clinical Evaluative Sciences. Toronto, Canada. June 4, 2013.
 209. Invited speaker. The Health Research Methodology and the Rockefeller funded INCLEN Experience. The World Heart Federation’s Emerging Leaders Program Meeting. Population Health Research Institute. Hamilton, Canada. June 20, 2013.
 210. Invited speaker (plenary). Strengthening the Link Between Guidelines and

- Systematic Reviews. Guidelines International Network Conference, San Francisco, USA. August 19, 2013.
211. Invited panel member and speaker. The Role of Rapid Systematic Reviews for Development of Rapid Guidance in Health Care and Health Policy Settings. Guidelines International Network Conference, San Francisco, USA. August 19, 2013.
 212. Invited speaker. GRADE's Framework for Increasing Confidence in Results of Observational Studies. The Second Dave Sackett Symposium. Niagara Falls, Canada. September 28, 2013.
 213. Invited speaker. (plenary). From research to policy and back: a role for health care guidelines. 2nd Annual NHMRC Research Translation Faculty Symposium 2013, Australia. October 4, 2013.
 214. Invited speaker. Updates from GRADE, Where they are going and how EPCs can contribute. EPC conference, Washington. USA. October 29, 2013.
 215. Invited participant and reviewer of candidates at the Gairdner Medical Review Panel meeting. Toronto, Canada. November 22, 2013.
 216. Invited speaker. Clinical Guideline Development Demystified: a look under the hood. The 55th ASH Annual Meeting and Exposition. New Orleans, Louisiana. December 7, 2013
 217. Invited participant. European Network for Cancer Research in Children and Adolescents (ENCCA) General Assembly and ECRC meeting. Vienna, Austria. January 15 – 17, 2014.
 218. Invited participant and speaker. The GRADE working group. The CerQual (Certainty of Qualitative Evidence) meeting. Barcelona, Spain. January 19, 2104.
 219. Invited speaker. Rating quality of evidence with GRADE methodology (Why, How, When, What) Clinical Research Institute, National University of Columbia. Medellin. February 4, 2014.
 220. Invited speaker. The evolved model of evidence-based decision making. German Network of Evidence-based medicine. Halle, Germany. March 14, 2014
 221. Invited speaker (keynote). GRADE-DECIDE und Clinical Pathways am Beispiel des Zervikalkarzinomscreening. German Network of Evidence-based medicine. Halle, Germany. March 15, 2014
 222. Invited participant and speaker. RARE Best Practices General Assembly Meeting. Rome, Italy. March 20 – 21, 2014.
 223. Invited speaker. An Introduction to the Guideline Development Checklist. Webinar presentation for the Guidelines International Network. April 10, 2014.
 224. Invited speaker. What is a guideline? What is GRADE and how should it be used in the context of a guideline?. World Health Organization Meeting GRADE in environmental health. Geneva, Switzerland. April 14, 2014.
 225. Invited speaker GRADE approach for WHO guidelines . . World Health

- Organization Expert Group Meeting on Interim Advice for the Use of delamanid in the Treatment of Multidrug-Resistant Tuberculosis. Geneva, Switzerland. April 15– 16, 2014.
226. Invited speaker. The PICO question for provisional guidance on use of delamanid in the treatment of MDRTB. World Health Organization Expert Group Meeting on Interim Advice for the Use of delamanid in the Treatment of Multidrug-Resistant Tuberculosis Geneva, Switzerland. April 15 – 16, 2014.
227. Invited speaker (plenary) GRADE and new advances for best evidence Cochrane Canada Symposium. Ottawa, ON. April 25, 2014.
228. Invited participant. Meeting at Hannover Medical School – Implementation of a demonstrator for individualized treatment of acute leukemias. Hannover, Germany. May 2 - 3, 2014.
229. Invited speaker. Diagnostic tests, Grade and health outcome. Updates in Autoimmunity 2014 “Evidences and Outcomes Congress. Modena, Italy. May 23, 2014.
230. Invited speaker. GRADE: What does it offer to guideline producers? Developing and Evaluating Communication strategies to support Informed Decisions and practice based on Evidence (DECIDE) International Conference. Edinburgh, Scotland. June 2 – 4, 2014.
231. Invited speaker. The GRADE working group’s approach to rating the confidence in effect estimates from Network-Meta Analysis. National Institute for Health and Care Excellence. London, UK. June 5, 2014.
232. Invited speaker, GRADE, Evidence-based Medicine Workshop, McMaster University, Hamilton. June 11, 2014.
233. Invited Speaker, Checklist for Guideline Development, Webinar presentation for the World Health Organization. June 12, 2014
234. Invited speaker. 'Risk of Bias' and 'Summary of findings' tables editorial. Cochrane Collaboration Updating meeting. Hamilton, ON. June 27, 2014.
235. Invited speaker. Guidelines and the GRADE Method. Modena, Italy. September 8, 2014.
236. Invited speaker. Decision-Making in Biomedical Sciences. The International Workshop in Life Sciences, Decision-Making in Biomedical Science. Potsdam, Germany. September 12, 2014.
237. Invited speaker. Evidence-based Medicine The International Workshop in Life Sciences, Decision-Making in Biomedical Science. Potsdam, Germany. September 12, 2014
238. Invited speaker. Clinical Epidemiology. The International Workshop in Life Sciences, Decision-Making in Biomedical Science. Potsdam, Germany. September 13, 2014
239. Invited speaker, (plenary) "The author's task", framing the day. The Cochrane Tech Symposium – The Cochrane Colloquium. Hyderabad, India. September 20, 2014.
240. Invited speaker. Reporting Guideline development: latest thoughts and

- lessons from the development of Clinical Practice Guidelines EQUATOR Working meeting: Consolidating methodology for the development of reporting guidelines. Oxford, UK. November 18, 2014.
241. Invited speaker. The COMET meeting. Rome, Italy. November 19, 2014.
 242. Invited Speaker. Health -work and the evidence behind it. National clinical guidelines (NKR) - spot on implementation conference. Copenhagen. November 21, 2014.
 243. Invited member, The European Network for Cancer Research in Children and Adolescents (ENCCA) General Assembly and ECRC meeting, Brussels. January 15 – 16, 2015.
 244. Invited speaker, (keynote) .The World Allergy Organization EBM Management and Prevention of Pediatric Allergy Symposium. Rome, Italy. January 29 – 30, 2015.
 245. Invited speaker (plenary) Evidence synthesis as a driving force for guideline scope and content/how developers can anticipate the needs, perspectives and exigencies of implementation. Evidence-based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS) II conference. New York, USA. March 2, 2015.
 246. Invited Speaker (breakout session) How to make collaborative efforts work. Overcoming resource issues, proprietary obstacles. Evidence-based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS) II conference. New York, USA. March 2, 2015.
 247. Invited participant, RARE Best Practices General Assembly Rome, Italy. March 19 – 20, 2015
 248. Invited participant. Guidelines International Network mid-year meeting. Rome, Italy. March 30 -31, 2015.
 249. Invited speaker. IALS 35 years: Challenges in Science & Internationalization. IALS/BMEP Student Conference 2015. Boston, USA. April 25, 2015.
 250. Invited Speaker. (Keynote) Guidelines 2.0: a new look at an old tool. Semi-annual mtg of Canadian HIV clinical trials network Clinical Management Science Core. Toronto, Canada. April 28, 2015.
 251. Invited speaker. Session on GRADE. Cochrane mid-year meeting. Athens, Greece. May 5, 2015.
 252. Invited speaker/participant. NHF McMaster Guidelines Panel Meeting. Chicago, USA. May 11 -12, 2015.
 253. Invited speaker (Plenary). GRADE Evidence to Decision Frameworks: Use and usefulness Cochrane Canada Symposium. Calgary, Canada. May 21, 2015.
 254. Invited speaker (Keynote). GRADE evidence to decision frameworks. The 2015 Methodology Conference and Workshop of CPG&CP in TCM. Guangzhou, Guangdong Province, China May 25, 2015.
 255. Invited speaker (Keynote). The 2015 Methodology Conference and Workshop of CPG&CP in TCM. Guangzhou, Guangdong Province, China

May 26, 2015

256. Invited participant. Workshop on Increasing Robustness, Transparency and Openness of Scientific Assessments. European Food Safety Authority. Brussels, Belgium. June 29 – 30, 2015.
257. Invited Speaker/participant. The strategy for the new ARIA. The GARD (WHO Global Alliance against Chronic Respiratory Diseases) annual meeting. Lisbon, Portugal. July 1 – 2, 2015.
258. Invited speaker. The Grade Approach: assessing the quality of evidence. Cancon Workshop for the Belgian Ministry of Public Health. Brussels, Belgium. July 9 – 10, 2015
259. Invited participant. Guidelines Development Group (GDG) of the New European guidelines for breast cancer screening and diagnosis meeting. Ispra, Italy, September 7-9, 2015
260. Invited participant. Review board meeting "structural development in health care research" Berlin. September 17 – 18, 2015
261. Invited speaker (Plenary) – Guideline Development, GIN COI policy. The Guidelines International Network Conference. Amsterdam. Oct. 9, 2015
262. Invited participant. The 2nd Meeting of the STI Guideline Development Group. The World Health Organization, Geneva, 12-14 October 2015.
263. Invited speaker (Plenary) Creating trustworthy clinical practice guidelines – from asking the right questions to building a methodologically rigorous foundation. The Guideline Development Workshop Using the GRADE Approach. Orlando, USA. November 2, 2015.
264. Invited speaker (Plenary) From evidence to recommendations. The Guideline Development Workshop Using the GRADE Approach. Orlando, USA. November 3, 2015.
265. Invited participant. The expert group meeting of the TB treatment consolidated guidelines. The World Health Organization. Geneva. November 9-13, 2015.
266. Invited speaker. "Clinical Epidemiology". The HRM PhD Comprehensive Examination Seminars. McMaster University, Hamilton Canada. Nov. 19, 2015.
267. Chair. European Commission Initiative on Breast Cancer meeting. Lago Maggiore District, Italy, 9-11 December 2015.
268. Invited speaker (Plenary). Global standards for trustworthy development and implementation of health care recommendations. South African Guideline Summit. South Africa, February 24, 2016.
269. Invited presenter/advisor. GDG Meeting on consolidated policy guidance on TB DST, The World Health Organization. February 29 – March 4, 2016.
270. Invited presenter/advisor/workshop coordinator. GRADE. German Hospital, Buenos Aires, March 2016.
271. Invited speaker. Past, Present, and Future of Evidence Based Medicine: A tribute to Dr. David Sackett. The second McMaster International Review

- Course in Internal Medicine. Krakow, Poland. May 6 – 7, 2016
- 272 Invited speaker. GRADE Training Workshop. Adaption of Rheumadoid Arthritis Guidelines for the Eastern Mediterranean Region. Doha, Qatar. May 26 – 28, 2016.
 - 273 Invited speaker. What is guidelines' adaptation? When is it appropriate, when is it not? Methodology for Adapting the World Health Organization (WHO) Guidelines Meeting. Lebanon, Beirut. May 30 – 31, 2016.
 - 274 Invited speaker. Saudi Arabia Adolopment experience. Methodology for Adapting the World Health Organization (WHO) Guidelines Meeting. Lebanon, Beirut. May 30 – 31, 2016.
 - 275 Invited speaker. Database of Evidence Profiles and Database of Evidence to Decision tables. Methodology for Adapting the World Health Organization (WHO) Guidelines Meeting. Lebanon, Beirut. May 30 – 31, 2016.
 - 276 Invited participant. Meeting of the Guideline Panel for the RARE Best Practices Guideline in Sickle Cell Disease. Freiburg, Germany. June 16 – 17, 2016.
 - 277 Invited speaker. Overview of GRADE; EtD: from Evidence to Decision. GRADE-CERQual-EtD training. Ispra, Italy. June 20, 2016.
 - 278 Chiar. Meeting of the Guidelines Development Group European Commission Initiative on Breast Cancer (ECIBC). Ispra, Italy. June 21 – 23, 2016.
 - 279 Invited participant. The Guidelines Development Group on the WHO Guidelines for treatment of drug-susceptible tuberculosis and patient care & support. World Health Organization. Geneva, Switzerland. July 12 -14, 2016.
 280. Invited Chair/specialty methodologist. WHO Guideline Development Group meeting to update policy guidance on the use of Xpert MTB/RIF. Webex. August 23, 2016.
 281. Chair. Meeting of the Guidelines Development Group European Commission Initiative on Breast Cancer (ECIBC). Ispra, Italy. September 13 - 14, 2016.
 282. Invited participant/speaker. WHO Guideline Development Group Interim policy on bedaquiline meeting. Webex. September 15, 2016.
 283. Invited panelist. The Guidelines International Network conference. Transparency, Privacy, and Personal Disclosure in Guideline Development Panels. Philadelphia, USA. September 28, 2016.
 284. Invited Speaker. Integrated Evidence-based approaches to healthcare quality and safety improvement. ISQua's 33rd International Conference Tokyo, Japan. October 18, 2016.
 285. Invited Speaker. The GRADE approach for developing trustworthy guideline recommendations. ISQua's 33rd International Conference Tokyo, Japan. October 19 , 2016.
 286. Chair. Meeting of the Guidelines Development Group European

- Commission Initiative on Breast Cancer (ECIBC). Ispra, Italy. November 22 - 23. 2016.
287. Invited participant. The Final International Symposium of the RARE Best Practices. Rome, Italy. November 23 – 24, 2016.
288. Invited speaker. Presentation on American Society of Hematology (ASH) Guidelines. Hannover Medical School. Germany. December 9, 2016
289. Invited speaker. Committee to Review the Process to Update the Dietary Guidelines for Americans meeting. The National Academies of Sciences, Engineering, and Medicine. Via webex. January 10, 2017.
290. Invited participant. ROBINS-E Workshop. The National Institute of Environmental Health Sciences (NIEHS). Bristol UK. January 30 – February 1, 2017.
291. Chair. Guidelines Development Group (GDG) and the Quality Assurance Scheme Development Group (QASDG) of the European Commission Initiative on Breast Cancer (ECIBC). Ispra, Italy. February 7 – 9, 2017.
292. Invited panelist. Meeting of ASH Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer. Washington USA. March 1 – 2, 2017.
293. Invited member of the Systematic Review Team. Meeting of ASH Guideline Panel on Pediatric VTE. Washington USA. April 3 - 4, 2017.
294. Invited speaker (Plenary). From evidence to recommendations about tests. GRADE Diagnosis workshop. Minneapolis. April 12, 2017
295. Invited (Distinguished) speaker. Division of Orthopaedics Annual Academic Day. What gets me out of (or keeps me out of) bed every day. McMaster University, Hamilton ON Canada. May 10, 2017.
296. Presenter GRADE: How to go from Evidence to Decisions. Cochrane Canada Symposium. Hamilton ON. May 11, 2017
297. Presenter (Plenary) The impact and future of Cochrane evidence for consumers, practitioners, policy-makers and researchers. Cochrane Canada Symposium. Hamilton ON. May 12, 2017
298. Presenter. Summary of Methods Used to Develop Draft Guidance. GRADE for Modelled Data Workshop. Hamilton ON. May 15, 2017.
299. Invited participant. ECIB Guidelines Development Group and Communications/Inequalities and Monitoring/Evaluation Subgroups Meeting. Ispra, Italy. May 17 – 18, 2017.
300. Invited speaker. IQWIG in Dialogue. Cologne, Germany. June 16, 2017.
301. Invited speaker. Linking evidence-quality evaluations to clinical recommendations: The GRADE Methodology. Reggio, Italy. June 19, 2017.
302. Invited participant/panelist. American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) guidelines for the Eastern Mediterranean Region.(2 day expert panel meeting). Beirut. June 29 – 30, 2017.
303. Invited reviewer. Review Board meeting – Stengthening Research in

- Geriatrics and Gerontology. Berlin, Germany. July 10 – 11, 2017.
304. Invited speaker (Plenary). GRADE-Adolopment. China EBM conference. Lanzhou, China. July 21, 2017.
 305. Invited speaker. (Keynote) The “why and how” of trustworthy clinical practice guidelines. Syposium for Guidelines for Nursing in Japan. Tokyo, Japan. September 23, 2017.
 306. Invited participant/chair. Joint European Food Safety Authority (EFSA) and Evidence-based Toxicology Collaboration (EBTC) Colloquium. Lisbon, Portugal. October 25 - 26, 2017.
 307. Invited participant/panelist. Taking a step toward achieving worry free surgery in Ontario. McMaster Health Forum. (1 day Stakeholder Dialogue) Hamilton, CANADA. October 30, 2017.

Meeting and Conference Organization (selected)

1. CHAIR, Symposium “ACCP Antithrombotic Guidelines”, ACCP/Chest Conference 2004, Seattle, Washington, October 27th, 2004
2. GRADE Working Group meeting, Rome, April 2005
3. CHAIR, Evening Seminar: Patient Centered Outcomes in COPD: an evidence based approach. American Thoracic Society, International Conference, San Diego, USA, May 22 2005
4. CHAIR, Symposium “ACCP Antithrombotic Guidelines”, ACCP/Chest Conference 2004, Seattle, Washington, November 1st, 2005
5. “Effective Implementation of Appropriate Thromboprophylaxis in Hospitalized Patients”, American Thoracic Society, International Conference, San Diego, USA, May 2005
6. CHAIR, “Update in Venous Thromboembolism”, American Thoracic Society, San Diego, May 23, 2006.
7. Member, Conference Organizing Committee, International Society for Quality of Life Research, 2006
8. GRADE Workshop. COCHRANE Zentrum Workshop:, Freiburg, March 2006 & 2007
9. CHAIR and Organizer, ATS/ERS Guideline Development Conference and Workshop: COPD as a case in point, June 13 & 14, 2007 (with representatives of over 20 organizations including NIH, NICE, IQWiG and others)
10. Coordinating committee: Il Sistema GRADE. New criteria for guideline development. Italian Federation of Medical Societies. Rome, March 3, 2008
11. Member, Scientific Session, Conference Organizing Committee, Guidelines International Network, 2009
12. Chair, 2 day GRADE workshop “Evidence Profiling”, Riyadh, Saudi Arabia.

January 17 – 20, 2010

13. Chair and organizer, Grade Working Group Meeting. Rome, Italy. January 21 – 22, 2010
14. Chair, WHO Guideline Panel, “Recommendations for Isoniazid Preventative Therapy”. Geneva, Switzerland. January 25 – 27, 2010.
15. Chair, GRADE Workshop, “Grading the quality of evidence and strength of recommendations for diagnostic recommendations”, McGill University Montreal, Quebec. February 12th – 13th, 2010
16. Co-organizer, 1.5 day GRADE Workshop – Freiburg, Germany. March 19-20, 2010
17. Faculty member, GRADE, Freiburg, Germany. March 19- 20, 2010
18. Chair and organizer, 1 day workshop, GRADE, Cochrane Collaboration Evidence on Trial Symposium, Auckland, New Zealand. March 23 - 26, 2010
19. Chair and organizer of a one day workshop on GRADE
20. Chair, 1 day workshop, GRADE, “Visiting Professors Program” of National Guard Health Affairs, Riyadh, Saudi Arabia, March 26 – March 31, 2010.
21. Chair, 2 day course, Evidence-Based Medicine, “Visiting Professors Program” of National Guard Health Affairs, Riyadh, Saudi Arabia, March 26 – March 31, 2010.
22. Co-chair and organizer, 2 day workshop, “Guideline development”, to the Estonian Health Insurance Fund. Tallinn, Estonia – May 10 – 12.
23. Chair, CDC meeting, Atlanta, GA. June 21 - 23, 2010
24. Chair, WHO Expert Group Meeting on Interferon Gamma Release Assays (IGRAs). Geneva, Switzerland, 2010. July 20 - 21, 2010.
25. Chair, WHO Expert Group Meeting on Commercial serodiagnostic tests for tuberculosis – Geneva, Switzerland, 2010. July 22, 2010.
26. Chair and organizer, 3 day workshop, GRADE. Teaching Evidence and Assimilation and Collaborative Healthcare (TEACH) Workshop and Conference. New York, NY. August 11-13, 2010.
27. Chair, The WHO Guideline Panel Meeting “Automated nucleic acid amplification technology for simultaneous and rapid detection of tuberculosis and rifampicin resistance Xpert MTB/Rif system”. Geneva, Switzerland. Sept. 2, 2010
28. Co-chair, 1 day preparatory meeting of the WHO Guidelines for the programmatic management of drug-resistant tuberculosis. McMaster University, Hamilton ON. Sept. 15, 2010.
29. Chair and organizer, 2 day workshop, “Pan American Health Organization (PAHO)/WHO Guideline Development Training”. Washington, DC, USA. Sept. 16 – 17, 2010.
30. Chair, WHO Steering committee meeting on Comprehensive Cervical Cancer Control (C4-GEP). Geneva, Switzerland. September 20, 2010.

31. Chair, WHO/UNFPA Technical Consultation to Finalize the Recommendation on Cryotherapy for Cervical Precancer Treatment. Geneva, Switzerland. September 21- 23, 2010.
32. Organizer, workshop, GRADEpro. Joint Colloquium of the Cochrane & Campbell Collaborations - Keystone, Colorado. October 17, 2010.
33. Chair and organizer, 1 day workshop, "Summary of Findings & Assessment of Quality of Evidence: GRADE workshop". Joint Colloquium of the Cochrane & Campbell Collaborations - Keystone, Colorado. October 17, 2010.
34. Chair and organizer, workshop, "Grading the quality of evidence and SoF Tables for diagnostic test accuracy studies". Joint Colloquium of the Cochrane & Campbell Collaborations - Keystone, Colorado. October 20, 2010.
35. Chair and organizer, workshop, "Creating Summary of Findings Tables". Joint Colloquium of the Cochrane & Campbell Collaborations - Keystone, Colorado. October 21, 2010.
36. Organizer, "Applicability and Recommendations Methods Group Business meeting". Joint Colloquium of the Cochrane & Campbell Collaborations - Keystone, Colorado. October 19, 2010.
37. Chair, Symposium Plenary III "Framing and Presenting Evidence to Influence Practitioners and Consumers". Joint Colloquium of the Cochrane & Campbell Collaborations - Keystone, Colorado. October 21, 2010
38. Chair, 3 day Guideline Panel Meetings and lectures "WHO Guidelines for the programmatic management of drug-resistant tuberculosis". Geneva, Switzerland October 25 - 27, 2010
39. Chair and Organizer of GRADE Working Group Meeting. Geneva, Switzerland. January 13 - 14, 2011.
40. Chair of DECIDE Scientific Session 2: Strategies for Collaboration Among European Guideline Developers & HTA Geneva, Switzerland. January 10 – 12 2011
41. Chair and Organizer, 2 day workshop for WHO, GRADE approach to therapeutic interventions: an introductory workshop on guideline development. Geneva, Switzerland. February 21 – 22, 2011.
42. Organizer, 2 day workshop, "GRADE" Friburg Germany, April 7 – 8 2011.
43. Organizer, 2 day workshop "GRADE" Pan American Health Organization (PAHO). Washington. May 8 – 9, 2011.
44. Organizer, 1 day workshop on GRADE for the National Institute of Environment Health Science Research Triangle Park, NC USA. June 23, 2011.
45. Organizer and coordinator of a 2 day GRADE workshop for Cochrane Collaboration and the German Robert Koch Institute. Berlin, Germany. June 30 – July 1, 2011.
46. Organizer and coordinator a 1/2 day GRADE meeting at the G.I.N. Scientific Committee meeting , Seoul, South Korea. August 28, 2011.

47. Organizer and coordinator of a 1 day GRADE workshop - Training session on GRADE for ACIP (Advisory Committee on Immunization Practices). Atlanta, GA September 9, 2011.
48. Chair, WHO meeting of the guideline development group a(presentation) - WHO requirements for evidence-based guidelines, GRADE methodology and guidelines development process. Geneva, Switzerland. September 29 – 30.
49. Organizer and coordinator, 1 day workshop on SoF tables at the Cochrane Colloquium. Madrid, Spain. October 18, 2011.
50. Organizer and coordinator of the Applicability and Recommendations Method Group Meeting. Cochrane Colloquium. Madrid, Spain. October 19, 2011.
51. Organizer and coordinator, workshop at the Cochrane Colloquium, Create 'Summary of findings' tables. Madrid, Spain. October 20, 2011.
52. Organizer and coordinator, workshop at the Cochrane Colloquium, Grading the quality of evidence and preparing 'Summary of findings' tables for diagnostic test accuracy reviews. Madrid, Spain. October 21, 2011.
53. Organizer and coordinator, workshop at the Cochrane Colloquium, Designing a sustainable evidence-based health care in times of crisis. Madrid, Spain. October 22, 2011.
54. Organizer and coordinator, GRADE working group meeting. Cochrane Colloquium. Madrid, Spain. October 23, 2011
55. Organizer and coordinator of a 1 day GRADE workshop, sponsored by Italian Society of Clinical Biochemistry and Clinical Molecular Biology. Modena, Italy. November 8, 2011.
56. Organizer and coordinator of a 2 day GRADE diagnostics workshop. Ministry of Health (guideline development) in Chile. Santiago, Chile. November 14 – 16, 2011.
57. Chair, Organizer and coordinator, 1 day workshop on GRADE. WHO. Geneva, Switzerland. November 28, 2011.
58. Chair, Organizer and Coordinator, GRADE Working Group Meeting. Barcelona, Spain. January 12 – 13, 2012.
59. Chair, How to promote quality of guidelines on rare diseases at International level, Clinical Practice Guidelines on RARE Diseases Meeting. Rome, Italy. February 16 – 17, 2012.
60. Chair. (draft and final recommendations). WHO Policy guidance on anti-tuberculosis drug susceptibility testing and Hain MTBDRsl second-line drug molecular line probe assays Expert Group Meeting. Geneva, Switzerland. March 19 – 21, 2012.
61. Organizer and Coordinator, 2 day GRADE Workshop. Freiburg, Germany. March 23 – 24, 2012.
62. Organizer and Coordinator, 2 day GRADE Workshop (Applying GRADE to coverage decisions) Tampa, Florida. April 2 – 4, 2012.

63. Organizer and Coordinator, 1 day GRADE Workshop. Cochrane Collaboration mid-year meeting. Paris, France. April 15 – 19, 2012.
64. Chair, Comprehensive cervical cancer control: a guide to essential practice meeting. WHO. Geneva Switzerland. April 24 – 25, 2012.
65. Chair, Introduction of new drugs for treatment of TB meeting. (2 sessions) Collection of data for policy development, Development of a policy development framework. WHO. Geneva, Switzerland. April 26, 2012.
66. Organizer and Coordinator, GRADE Workshop. XI Meeting of the Iberoamerican Cochrane Network. Lima, Peru. May 23 – 25, 2012.
67. Organizer and coordinator, 1 day GRADE Workshop. 9th HTAi Annual Meeting in Bilboa, Spain. June 24, 2012.
68. Organizer coordinator and presenter of webinar, How to assess the strength of evidence: working with examples. (Agency for Healthcare Research and Quality – AHRQ) Hamilton ON CANADA. July 11, 2012.
69. Organizer and Coordinator, 1 day GRADE Workshop. Guidelines International Network Conference. Berlin, Germany. August 22, 2012.
70. Co-coordinator. Workshop. Moving from evidence to recommendations: a framework proposal for guideline developers Guidelines International Network Conference. Berlin, Germany. August 24, 2012.
71. Organizer and coordinator, workshop. The GRADE approach to assessing the quality of a body of evidence and the strength of recommendations: Diagnosis. Guidelines International Network Conference. Berlin, Germany. August 25, 2012
72. Chair, Organizer and coordinator, 3 day workshop, Guidelines and systematic reviews: an introductory workshop.. WHO, University of Tartu, Estonian Health Insurance fund. Estonia. August 28 – 30, 2012.
73. Organizer and coordinator, 2 day workshop, Train the trainer in evidence-based practice workshop. Dubai International Conference on Clinical Practice Guideline, Development, Adaptation, Implementation, and Monitoring. Dubai. September 16 – 17, 2012..
74. Organizer and coordinator, 1 day workshop, Summary of Findings and Assessment of Quality of Evidence: GRADE. Cochrane Colloquium, Auckland, NZ. September 29, 2012.
75. Organizer and coordinator, Interpreting results of Cochrane reviews, applying GRADE and creating 'Summary of Findings' tables workshop. Cochrane colloquium, Auckland NZ October 1, 2012
76. Organizer and coordinator, Using GRADEpro to create 'Summary of Findings' tables – workshop. Cochrane colloquium, Auckland, NZ. October 2, 2012
77. Organizer, Applying the GRADE criteria and presenting findings using 'Summary of Findings' tables workshop. Cochrane Colloquium, Auckland NZ. October 3, 2012..
78. Organizer and coordinator. GRADE workshop Lucerne, Switzerland. . October 30, 2012.

79. Organizer and Coordinator. GRADE workshop. Western University. London ON CANADA. November 12, 2012
80. Organizer and coordinator. 3 Day GRADE Workshop. Beijing, CHINA. November 18 – 20, 2012.
81. Organizer and coordinator, workshop Beyond the basic on the GRADE Approach for Guidelines development. The Health Technology assessment international (HTAi) LatinoAmerican Meeting. Bogota, Columbia December 4, 2012
82. Organizer and presenter. GRADE Webinar Q&A. Pan American Health Organization. Hamilton, Canada. February 6, 2013.
83. Chair and Organizer. GRADE working group meeting (1.5 days). Rome. February 25 – 26, 2013.
84. Participant. Meeting for World Allergy Organization guidelines. Milan. March 1 – 3, 2013.
85. Organizer and coordinator. GRADE Workshop. Brussels. March 11, 2013.
86. Participant. Guidelines International Network (GIN) Board Meetings. Amsterdam. March 12, 2013.
87. Organizer and coordinator. 1 day GRADE Workshop. Hamilton, Canada. April 26, 2013.
88. Organizer and coordinator of workshop. GRADE for systematic reviews, HTA and guideline developers. CADTH. St. John's NFLD. May 4 – 6, 2013.
89. Oral presentation. GRADE for Diagnosis. CADTH. St. John's NFLD. May 4 – 6, 2013
90. Participant. Scientific Board Meeting. Institute for Quality and Efficiency in Health Care (IQWiG). Cologne. May 13, 2013.
91. Participant. Clinical Guidelines Committee Meeting. American College of Physicians. Philadelphia. June 4 – 5, 2013.
92. Participant. PRECEPT Expert Meeting, Robert Koch Institute. Berlin. June 13 – 14, 2013.
93. Presenter. The Health Research Methodology and the Rockefeller-funded INCLIN experience. World Heart Federation's emerging leaders program. PHRI. Hamilton. Canada. June 20, 2013.
94. Participant. World Allergy Organization meeting (provide update for ARIA – Allergic Rhinitis and its impact on Asthma). Milan. June 23 – 24, 2013.
95. Organizer and coordinator (invited) 2 day GRADE (Guidelines development) workshop. WHO. July 4 – 5, 2013.
96. Participant. 2 day meeting: Stream three: summary of findings tables and GRADE assessments for network meta-analysis. (Cochrane). Bristol July 18 – 19, 2013.
97. Organizer and coordinator (1 day) GRADE workshop. Guidelines International Network Conference. San Francisco, USA. August 17, 2013.
98. Organizer and coordinator. Summary of Findings and Assessment of

- Quality of Evidence: GRADE - Workshop for editorial teams – Cochrane Colloquium. Quebec City, Canada. September 19, 2013.
99. Organizer and coordinator. Using the new online GRADEpro to create Summary of Findings Tables – workshop– Cochrane Colloquium. Quebec City, Canada. September 20, 2013.
 100. Organizer and coordinator. Interpreting results of Cochrane reviews and Summary of Findings Tables – workshop. Cochrane Colloquium. Quebec City, Canada. September 21, 2013.
 101. Organizer and coordinator. Grading the quality of evidence and preparing summary of findings tables for diagnostic tests– workshop. Cochrane Colloquium. Quebec City, Canada. September 23, 2013.
 102. Organizer and coordinator. (1 Day) GRADE Workshop. 2nd Annual NHMRC Research Translation Faculty Symposium 2013. Australia. October 7, 2013.
 103. Organizer and coordinator. (2 day) GRADE Workshop. The University of Freiburg. Germany. October 10- 12, 2013.
 104. Organizer and coordinator. (2 day) GRADE Workshop. Public Health Agency of Canada. November 25 – 26, 2013
 105. Organizer and coordinator (4 day) Guideline development for Saudi Arabia 4 day workshop. Saudi Center For EBHC, Ministry Of Health Saudi Arabia. December 2 – 5, 2013.
 106. Organizer and coordinator. (1 day) GRADE Diagnosis Workshop. Barcelona, Spain. December 22, 2013
 107. Organizer and coordinator. (1 day) GRADE Workshop. The Canadian Chiropractic Guideline Initiative. Toronto, Canada. January 10, 2104.
 108. Chair and Organizer. GRADE working group meeting (1.5 days). Spain. January 20 - 21, 2013.
 109. Organizer and coordinator. (1 day). GRADE methodology workshop. Clinical Research Institute, National University of Columbia. Medellin. February 3, 2014.
 110. Organizer and coordinator. GRADE/DECIDE workshop –Evidence to Decision Framework. German Network of Evidence-based medicine. Halle, Germany. March 13, 2014
 111. Chair. World Health Organization Expert Group Meeting on Interim Advice for the Use of delamanid in the Treatment of Multidrug-Resistant Tuberculosis. Geneva, Switzerland. April 14 – 15, 2014.
 112. Chair. World Health Organization meeting – Latent tuberculosis management guidelines- Meeting of the Guidelines Development Group. Geneva, Switzerland. May 14 – 15, 2014.
 113. Chair, Plenary Session 5. Developing and Evaluating Communication strategies to support Informed Decisions and practice based on Evidence (DECIDE) International Conference. Edinburgh, Scotland. June 2 – 4, 2014
 114. Organizer and coordinator. (3 day workshop) EBM and Guideline

- Development Workshop. Estonian Health Insurance Fund, Estonia. June 17 – 19, 2014.
115. Chair, Open forum: Debates in updating – Cochrane Collaboration Updating meeting. Hamilton, ON. June 27, 2014.
 116. Organizer/presenter. Grading confidence in the estimates of test accuracy and preparing 'Summary of findings' tables for diagnostic reviews. The Cochrane Colloquium, Hyderabad, India. 25 September 2014 (workshop)
 117. Organizer/presenter. Considering importance of outcomes in Cochrane reviews (workshop)
 118. Organizer/presenter. Using the new online software, GDT, to create 'Summary of findings' tables. The Cochrane Colloquium, Hyderabad, India. 26 September 2014 (workshop)
 119. Organizer/presenter. Identifying participants with missing outcome data in trials included in systematic reviews: challenges and suggested solutions. The Cochrane Colloquium, Hyderabad, India. 23 September 2014 (workshop)
 120. Organizer/presenter. Interpreting results of Cochrane Reviews and 'Summary of findings' tables The Cochrane Colloquium, Hyderabad, India. 23 September 2014 (workshop)
 121. Organizer/presenter. GRADE Workshop. Freiburg, Germany. October 9 – 11, 2014 (workshop)
 122. Organizer/presenter. GRADE Workshop. Beirut, Lebanon.. November 6 – 7, 2014 (workshop)
 123. Organizer/presenter. GRADE Workshop. BMJ Publishing Group. London, UK. January 19, 2015.
 124. Chair and Organizer. GRADE working group meeting (1.5 days). Amsterdam. March 4 – 5, 2015.
 125. Organizer and presenter. GRADE Workshop (4 days). Saudi Center For Evidence-based Health Care, (GE Health Care Partners). Riyadh, Saudi Arabia. March 14 – 18, 2015.
 126. Organizer and presenter. GRADE Workshop. Freiburg, Germany. March 27, 2015.
 127. Organizer and presenter. GRADE Workshop (2 days). Guideline Development, Using the GRADE approach. Portland, USA. April 23 – 24, 2015.
 128. Organizer and presenter. Using GRADE to assess the quality of evidence. Cochrane Canada Symposium. Calgary, Canada. May 22, 2015.
 129. Responsible for organizing and chairing approximately 20 international meetings of the GRADE working group (www.gradeworkinggroup.org)
 130. Organizer and Presenter. The Guideline Development Workshop Using the GRADE Approach.(2 day workshop) Orlando, USA. November 2-3, 2015.
 131. Organizer/presenter. (3 day workshop). Course for health care guidelines developers on treatment of rare diseases. Milan. February 10 – 12, 2016.

132. Organizer/Invited presenter. (1 day workshop). Workshop on GRADE Guidelines Developers. South African Guideline Summit. South Africa, February 23, 2016.
133. Chair. Afternoon session at The South African Guideline Summit. South Africa, February 24, 2016.
134. Organizer/presenter. (2 day workshop). GRADE workshop. Latin-American conference on evidence based decision-making in healthcare. Buenos Aires, March 17 – 18, 2016.
135. Organizer/presenter. (2 day meeting/workshop). The GRADE Working Group meeting. Washington, USA. May 2 – 4, 2016.
136. Chair. Guidelines Development Group (GDG) meeting to revise the WHO policy guidance on the use of bedaquiline and update on the WHO policy guidance on the use of delamanid in children. World Health Organization. Geneva, Switzerland. June 28 – 29, 2016.
137. Organizer/presenter. GIN Website Resources and GIN/Cochrane Task/Exchange Workshop. GIN conference. Philadelphia, USA. September 30, 2016.
138. Organizer/Chair. GRADE Working Group meeting. GIN conference. Philadelphia, USA. October 1, 2016.
139. Organizer/presenter. GRADE Guideline Workshp. ISQua's 33rd International Conference Tokyo, Japan. October 19 , 2016.
140. Organizer/Chair. GRADE Working Group meeting. The Cochrane Colloquium. Seoul. October 28, 2016.
141. Panelist. American Society of Hematology (ASH) Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer. Washington USA. November 15 – 16, 2016.
142. Chair. American Society of Hematology (ASH) Guideline Panel meeting on The Prevention of Venous Thromboembolism in Nonsurgical Patients. Washington USA. November 17 – 18, 2016.
143. Presenter/speaker. International Expert workshop on Systematic Review Methods for Chemical Risk Assessment. Lancaster Environment Centre in association with the Royal Society of Chemistry Toxicology Group. London UK. December 1 – 2, 2016
144. Organizer/presenter. GRADE Diagnosis Workshop. Minneapolis USA. April 10 – 12, 2017.
145. Coordinator/Organizer. Cochrane Canada Symposium (2 days). Hamilton, ON. Canada. May 11 – 12, 2017.
146. Coordinator/Chair. Cochrane Canada Symposium: Bringing Living Systematic Reviews to Life. Hamilton ON, Canada. May 13 – 14, 2017.
147. Coordinator/Chair. GRADE for Modelled Data Workshop. Hamilton ON. Canada. May 15 – 16, 2017.
148. Coordinator/Presenter. Cochrane GRADE Workshop (3 days). Cochrane Methods Training Event. GRADE and GRADE CERQual. Modena, Italy.

June 13- 15, 2017.

149. Organizer/Chair. GRADE Working Group meeting. The Global Evidence Summit. Cape Town, SA. September 12, 2017.
150. Technical Expert. Guideline Development Committee Meeting - updating the WHO standard guidance for the clinical management of influenza infections. Geneva, Switzerland. November 14, 2017.